




(86) Date de dépôt PCT/PCT Filing Date: 2012/12/05
(87) Date publication PCT/PCT Publication Date: 2013/06/13
(85) Entrée phase nationale/National Entry: 2014/05/09
(86) N° demande PCT/PCT Application No.: GB 2012/053022
(87) N° publication PCT/PCT Publication No.: 2013/083975
(30) Priorité/Priority: 2011/12/05 (EP11191986.6)

(51) Cl.Int./Int.Cl. *C07D 207/36* (2006.01),
A61K 31/402 (2006.01), *A61K 31/4245* (2006.01),
A61K 31/427 (2006.01), *A61K 31/4439* (2006.01),
A61P 31/04 (2006.01), *C07D 401/04* (2006.01),
C07D 401/12 (2006.01), *C07D 403/04* (2006.01),
C07D 407/04 (2006.01), *C07D 413/04* (2006.01),
C07D 417/04 (2006.01)

(71) Demandeur/Applicant:
UNIVERSITY OF LEICESTER, GB

(72) Inventeurs/Inventors:
ANDREW, PETER WILLIAM, GB;
LONNEN, RANA, GB;
...

(54) Titre : NOUVEAUX DERIVES DE PYRROLE
(54) Title: NOVEL PYRROLE DERIVATIVES



(57) Abrégé/Abstract:

There are provided inter alia compounds of formula (I) wherein R¹, R², R³, R^{4a} and R^{4b} are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.



(21) **2 855 351**

(13) **A1**

(72) **Inventeurs(suite)/Inventors(continued):** DAMASO, MAFALDA PIRES, GB; FRICKEL, FRITZ-FRIEDER, DE;
HIRST, SIMON CHRISTOPHER, GB; DAVIES, MARK WILLIAM, GB; HAMZA, DANIEL, GB

(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
13 June 2013 (13.06.2013)(10) International Publication Number
WO 2013/083975 A3

(51) International Patent Classification:

C07D 207/36 (2006.01) **C07D 413/04** (2006.01)
C07D 417/04 (2006.01) **A61K 31/402** (2006.01)
C07D 401/04 (2006.01) **A61K 31/4245** (2006.01)
C07D 401/12 (2006.01) **A61K 31/427** (2006.01)
C07D 403/04 (2006.01) **A61K 31/4439** (2006.01)
C07D 407/04 (2006.01) **A61P 31/04** (2006.01)

(21) International Application Number:

PCT/GB2012/053022

(22) International Filing Date:

5 December 2012 (05.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11191986.6 5 December 2011 (05.12.2011) EP

(71) Applicant: **UNIVERSITY OF LEICESTER** [GB/GB];
Fielding Johnson Building, University Road, Leicester LE1
7RH (GB).

(72) Inventors: **ANDREW, Peter William**; University of Leicester, Department of Infection Immunity and Inflammation, Medical Sciences Building, University Road, Leicester LE1 7RH (GB). **LONNEN, Rana**; University of Leicester, Department of Infection Immunity and Inflammation, Medical Sciences Building, University Road, Leicester LE1 7RH (GB). **DAMASO, Mafalda Pires**; University of Leicester, Department of Infection Immunity and Inflammation, Medical Sciences Building, University Road, Leicester LE1 7RH (GB). **FRICKEL, Fritz-Frieder**; Silvanerweg 7, 67146 Deidesheim (DE). **HIRST, Simon Christopher**; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF (GB). **DAVIES, Mark William**; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF (GB). **HAMZA, Daniel**; Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF (GB).


(74) Agents: **TEUTEN, Andrew** et al.; Sagittarius IP, Three Globeside, Fieldhouse Lane, Marlow, Buckinghamshire SL7 1HZ (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: NOVEL PYRROLE DERIVATIVES



(57) Abstract: There are provided inter alia compounds of formula (I) wherein R^1 , R^2 , R^3 , R^{4a} and R^{4b} are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.



WO 2013/083975 A3

WO 2013/083975 A3

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

Published:

(88) Date of publication of the international search report:
8 August 2013

— with international search report (Art. 21(3))

NOVEL PYRROLE DERIVATIVES

Field of the invention

- 5 The invention relates to compounds which are cytolysin inhibitors and their use in therapy, including in pharmaceutical combinations, especially in the treatment of bacterial, e.g. pneumococcal, infections.

Background of the invention

10

Streptococcus pneumoniae (pneumococcus) is one of the most potent human pathogens, affecting over 10 million people worldwide, of all age groups, in particular young children, the elderly and the immunocompromised. It is a leading causative agent of serious, often fatal diseases, such as pneumonia, bacteraemia and meningitis. It is also responsible of other less
15 serious, but nevertheless debilitating diseases such as otitis media and keratitis.

Even after decades of using antibiotics and steroids as adjunctive to antibiotics the mortality and morbidity from pneumococcal diseases remains very high in the developed world and alarmingly high in the developing world. Nearly 20% of hospitalised patients still die despite
20 antibiotic killing of the pneumococcus, while many survivors of pneumococcal meningitis suffer severe neurological handicaps, including cognitive impairment, vision and hearing loss, hence imposing huge distress on patients and their families and a very significant cost to healthcare systems. Today, infection with pneumococcus remains a major global public health problem that is widely recognised by leaders in the field and by health organisations, including the WHO.

25

One of the leading factors for this consistently high mortality and morbidity that is not addressed by the current standard therapy, is the toxemia resulting from the release of toxic pneumococcal products, the most important of which is the pneumococcal toxin pneumolysin. This toxin is a major player in pneumococcal virulence and is the primary direct and indirect
30 cause of toxemia.

Pneumolysin belongs to the family of cholesterol dependent cytolysins (CDCs), which bind to cholesterol containing membranes and generate large pores that have lethal and sub-lethal effects on the affected cells. In the bacterium, the toxin pneumolysin is cytoplasmic and is
35 mainly released from the pneumococcus after its lysis. Consequently, under the effect of lytic antibiotics, a large bolus of toxin is released, compounding the toxemia. Thus, even if treatment with antibiotics is successful in clearing the bacteria from the patients, the subsequent release of the toxin is detrimental and can be fatal or cause long-term handicaps.

40 This toxemia constitutes a substantial unmet medical need that is internationally recognised. Currently, corticosteroids, principally dexamethasone, are used as an adjunctive to antibiotic therapy for pneumococcal meningitis. However, even when dexamethasone is used, significant mortality and morbidity are seen and the widespread use of dexamethasone is still debated due to its non-specific effect, limited clinical impact and in some cases its detrimental effect in
45 increasing neuronal apoptosis in meningitis [Lancet (2002) 360 211-218]. Therefore, the present state of the art is not adequate for the efficient treatment of invasive pneumococcal diseases.

There is considerable evidence substantiating the validity of pneumolysin as a therapeutic target. In the laboratories of the inventors it has been demonstrated that, using a mouse pneumonia model, a mutated strain of *S. pneumoniae* (PLN-A) that does not produce
 5 pneumolysin is no longer lethal, causes substantially less bacteraemia and exhibits a significant reduction in the severity of pulmonary inflammation. Other evidence obtained in a rat meningitis model, has shown that infection with the pneumolysin-negative mutant was markedly less severe than with wild-type pneumococci, with no observed damage to the ciliated epithelium of the brain and no apoptosis of the cells surrounding the epithelium [J. Infect, (2007) 55 394-399].
 10 In pneumococcal meningitis in guinea pigs, wild-type pneumococci induced severe cochlear damage and hearing loss, while infection with PLN-A left the organ of Corti intact [Infect. Immun. (1997) 65 4411-4418]. An *ex vivo* model using cultured ciliated brain epithelial cells, enabled recreation of the *in vivo* situation, where cells lining the brain ventricles are exposed to *S. pneumoniae*. Both intact and antibiotic-killed wild-type pneumococci induced damage to the
 15 epithelial cells in culture and significantly impaired ciliary beating; effects not seen with PLN-A [Infect. Immun. (2000) 68 1557-1562]. This damaging effect of antibiotic-lysed pneumococci on the cultured ependymal cells is clearly caused by the toxin pneumolysin released from the antibiotic-lysed bacteria, as this damage was abolished in the presence of anti-pneumolysin antibodies [Infect. Immun. (2004) 72 6694-6698]. This finding supports the strategy that
 20 antibiotic-induced toxemia is prevented by combination with anti-pneumolysin agents.

Evidence for the significant involvement of pneumolysin in pneumococcal infections and the substantial improvement of the disease prognosis in the absence of pneumolysin, has led to the conclusion that pneumolysin constitutes a potential therapeutic target to develop new
 25 treatments for pneumococcal diseases. Previous research has shown the ability of cholesterol to inhibit pneumolysin [Biochem. J. (1974) 140 95-98], however, this inhibition is merely due to the fact that cholesterol is a natural cellular receptor of pneumolysin that is required for the pore formation in the target cell membrane. The topical application of cholesterol on the cornea of rabbits demonstrated a positive therapeutic effect in pneumococcal keratitis [Invest. Ophthalmol.
 30 Vis. Sci. (2007) 48 2661-2666]. This indicates the involvement of pneumolysin in pneumococcal keratitis and the therapeutic benefit obtained following its inhibition. However, cholesterol is not considered as a therapeutic agent for the treatment of pneumococcal diseases and has not been clinically used in patients. Another pneumolysin inhibitor, Allicin, a component in garlic extract, has been previously found to inhibit the haemolytic activity of
 35 pneumolysin *in vitro* [Toxicon (2011) 57 540-545]. This compound is a cysteine inhibitor that irreversibly binds to the reactive thiol group of the toxin. Compounds exhibiting such a property are unfavourable as drug candidates because of their potential unspecific binding to other cysteine-containing proteins in the body.

40 There remains a need to provide inhibitors of cytotoxins, such as pneumolysin, which are suitable for use in the treatment of bacterial infections.

The present invention provides compounds that specifically inhibit the direct toxic effect of pneumolysin and other cholesterol dependent cytotoxins that are pivotal in the virulence of their
 45 respective hosts. The compounds of the invention have no structural similarity to Allicin and do not bind covalently to the reactive thiol groups of the toxins.

Certain N-phenyl substituted pyrroles are known, however their use as pharmaceuticals in particular for the treatment of bacterial infections had not been suggested. The compounds diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (CAS 654052-34-3) and diethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate (CAS 55932-13-3) are

5 commercially available. The compounds dimethyl 3,4-dihydroxy-1-(4-bromophenyl)-1*H*-pyrrole-2,5-dicarboxylate (CAS 1087699-40-8), dimethyl 3,4-dihydroxy-1-(4-chlorophenyl)-1*H*-pyrrole-2,5-dicarboxylate (CAS 1082655-47-7), di-*tert*-butyl 3,4-dihydroxy-1-(4-nitrophenyl)-1*H*-pyrrole-2,5-dicarboxylate (CAS 110332-46-2) and dimethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (CAS 101090-98-6) are described in Justus Liebigs Annalen der
10 Chemie (1961), 639, 102-24. The compounds dimethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate (CAS 7803-73-8) and dimethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate (CAS 7342-22-5) are described in Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie (1956), 306, 49-55. The compound diethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate (CAS 55932-14-4) is disclosed in Chemische Berichte (1975), 108(2), 569-75.

15


The compounds of the present invention also prevent stimulation of host-derived toxic effects induced by pneumolysin and other cholesterol dependent cytolysins. Thus these compounds may be used as single agents or as adjunct to antibiotics, to prevent or attenuate pneumolysin-induced toxicity and its anti-host effects seen during infections caused e.g. by *S. pneumoniae*.

20

Summary of the invention

According to the invention, there is provided a compound of formula (I):

25



(I)

wherein:

30 R^1 and R^2 are independently selected from $-C(O)NR^5R^6$, $-C(O)OR^7$, CN, $-C(O)R^7$, $-C(O)NHC(O)R^7$, $-NO_2$, $-SO_3R^7$, $-SO_2R^7$, $-SOR^7$, $-SO_2NR^5R^6$, $-SO_2NH-C(O)OR^8$, $-POR^{21}R^{22}$ and optionally substituted phenyl or heteroaryl;

R^3 is optionally substituted phenyl;

35 R^{4a} and R^{4b} are independently selected from hydrogen; C_1 - C_6 alkyl which alkyl group may optionally be substituted by hydroxyl, $COOR^{12}$ or $CONR^{13}R^{14}$; aryl and $-C_1$ - C_3 alkylaryl in which said aryl groups may be optionally substituted;

R^5 and R^6 are independently selected from:

(a) hydrogen,

40 (b) C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_{10} cycloalkyl, C_5 - C_{10} cycloalkenyl, heterocyclyl, $-C_1$ - C_3 alkyl- C_3 - C_{10} cycloalkyl, $-C_1$ - C_3 alkyl- C_5 - C_{10} cycloalkenyl or $-C_1$ - C_3 alkylheterocyclyl, or R^5 and R^6 together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected

from O, S and NR⁹, in which any of the aforementioned R⁵ and R⁶ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R⁵ and R⁶ groups may be optionally substituted by one or more halogen atoms, and

(c) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;

R⁷ is selected from:

(a) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl, heterocyclyl, -C₁-C₃ alkyl-C₃-C₁₀ cycloalkyl, -C₁-C₃ alkyl-C₅-C₁₀ cycloalkenyl or -C₁-C₃ alkylheterocyclyl, in which any of the aforementioned R⁷ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R⁷ groups may be optionally substituted by one or more halogen atoms, and

(b) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;

R⁸ is C₁-C₆ alkyl;

R⁹ is hydrogen, C₁-C₆ alkyl; -C(O)R¹⁰ or -C(O)OR¹¹;

R¹⁰ is C₁-C₆ alkyl;

R¹¹ is C₁-C₆ alkyl;

R¹² is C₁-C₆ alkyl;

R¹³ is hydrogen or C₁-C₆ alkyl;

R¹⁴ is hydrogen or C₁-C₆ alkyl; and

R²¹ and R²² are independently selected from C₁-C₆ alkyl and C₁-C₆ hydroxyalkyl; or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt or solvate thereof;

provided that the compound is not:

- a) diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- 30 b) diethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate;
- c) dimethyl 3,4-dihydroxy-1-(4-bromophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- d) dimethyl 3,4-dihydroxy-1-(4-chlorophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- e) di-*tert*-butyl 3,4-dihydroxy-1-(4-nitrophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- f) dimethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- 35 g) dimethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate;
- h) diethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate; or
- i) dimethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate.

The compounds of formula (I) including the compounds which are the subject of provisos a) to i) have therapeutic activity. In a further aspect, the present invention provides a compound of formula (I) without provisos a) to i) for use as a medicament.

Brief description of the figures

Figure 1 shows the *in vitro* inhibition of pneumolysin-induced LDH release by the compound UL1-012 using A549 human lung epithelial cells.

Figure 2A shows the effect of the compound UL1-012 in inhibiting pneumolysin from damaging the ciliary function of ependymal cells in an *ex vivo* meningitis efficacy assay.

- 5 Figure 2B shows the effect of the compound UL1-012 in inhibiting a bacterial lysate from damaging the ciliary function of ependymal cells in an *ex vivo* meningitis efficacy assay.

Figure 3 shows the effect of the compound UL2-001 in inhibiting pneumolysin from damaging the ciliary function of ependymal cells in an *ex vivo* meningitis efficacy assay.

10

Figure 4 shows the experimental design for an *in vivo* mouse pneumonia model efficacy assay using the compound UL1-012.

- Figure 5 shows the survival of infected control mice and treated groups administered with 4
15 mg/kg of the compound UL1-012 in an *in vivo* mouse pneumonia model efficacy assay.

Figure 6 shows the survival of infected control mice and treated groups administered with 16 mg/kg of the compound UL1-012 in an *in vivo* mouse pneumonia model efficacy assay.

- 20 Figure 7 shows a comparison of the signs of disease between an infected/non-treated control group and an infected/ treated group that received 16 mg/kg of the compound UL1-012 in an *in vivo* mouse pneumonia model efficacy assay.

- Figure 8 shows the experimental design for an *in vivo* mouse pneumonia model efficacy assay
25 using the compound UL2-001.

Figure 9 shows the survival of infected control mice and treated groups administered with 8 mg/kg of the compound UL2-001 in an *in vivo* mouse pneumonia model efficacy assay.

30 **Detailed description of the invention**

- R¹ and R² may be independently selected from -C(O)NR⁵R⁶, -C(O)OR⁷, CN, -C(O)R⁷, -C(O)NHC(O)R⁷, -NO₂, -SO₃R⁷, -SO₂R⁷, -SOR⁷, -SO₂NR⁵R⁶, -SO₂NH-C(O)OR⁸ and optionally substituted phenyl or heteroaryl; for example R¹ and R² may be independently selected from -
35 C(O)NR⁵R⁶, -C(O)OR⁷, CN, -C(O)R⁷, -C(O)NHC(O)R⁷, -SO₃R⁷, -SO₂R⁷, -SOR⁷, -SO₂NR⁵R⁶, -SO₂NH-C(O)OR⁸ and optionally substituted phenyl or heteroaryl. R¹ and R² are preferably independently selected from -C(O)NR⁵R⁶, -C(O)OR⁷, CN, -C(O)R⁷, -C(O)NHC(O)R⁷ and -SO₂NH-C(O)OR⁸; more preferably R¹ and R² are independently selected from -C(O)NR⁵R⁶, -C(O)OR⁷ and CN; even more preferably R¹ and R² are independently selected from -C(O)NR⁵R⁶
40 and -C(O)OR⁷.

R¹ is preferably -C(O)NR⁵R⁶.

- In one embodiment R² is -C(O)NR⁵R⁶. In another embodiment R² is -C(O)OR⁷. Thus in one
45 embodiment R¹ is -C(O)NR⁵R⁶ and R² is -C(O)NR⁵R⁶ and in another embodiment R¹ is -C(O)NR⁵R⁶ and R² is -C(O)OR⁷.

When R^1 and R^2 are both $-C(O)NR^5R^6$ they may be same or different, preferably they are the same.

- 5 In an alternative embodiment R^1 and R^2 are both $-C(O)OR^7$ and they may be same or different, preferably they are the same.

R^3 is preferably substituted phenyl.

- 10 Suitable optional substituents for R^3 include 1 or more, e.g. 1, 2 or 3, substituents (e.g. 1 substituent) independently selected from halo, cyano, hydroxyl, C_1 - C_6 alkoxy, C_1 - C_6 hydroxyalkoxy, C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl; $-O-R^{15}$ wherein R^{15} is $-(CH_2)_x-$
 15 $P(O)(OR^{23})_2$ (where x is 0, 1, 2, 3 or 4 and R^{23} is independently selected from hydrogen and C_1 - C_3 alkyl), $-(CH_2)_y-S(O)_2Me$ (where y is 1, 2, 3 or 4), $-C_1$ - C_6 alkylheterocyclyl which heterocyclyl group may be optionally substituted e.g. by C_1 - C_3 alkyl, $-C_1$ - C_6 alkylphenyl which phenyl group may be optionally substituted e.g. by C_1 - C_3 alkoxy, or phenyl or 5- or 6-membered heteroaryl which phenyl or heteroaryl group may optionally be substituted by a group e.g. selected from C_1 - C_4 alkyl and halo; or $-(O(CH_2)_z)_pOR^{24}$, where each z , which may be the same or different,
 20 represents 2 or 3, p represents 1, 2, 3, 4 or 5 and R^{24} is hydrogen or C_1 - C_3 alkyl; or two adjacent carbon atoms within R^3 may be linked by $-O-CH_2-O-$.

- When R^{15} is $-C_1$ - C_6 alkylheterocyclyl, particular heterocyclyl groups which may be mentioned include 5- or 6-membered, monocyclic non-aromatic ring systems, containing up to two
 25 heteroatoms selected from N, O and S. Such rings are suitably linked to $-C_1$ - C_6 alkyl via an N atom. Examples of heterocyclic rings include morpholine, piperazine, and the like, which may be optionally substituted e.g. by C_1 - C_3 alkyl, such as methyl. Further examples of heterocyclic rings include piperidine and pyrrolidine.

- 30 A group of suitable optional substituents for R^3 which may be mentioned include 1, 2 or 3 substituents selected from halo, cyano, C_1 - C_6 alkoxy, C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl. In addition, when R^3 is substituted phenyl, said phenyl may be provided with a single substituent $-O-R^{15}$ wherein R^{15} is selected from phenyl and 5- or 6-membered heteroaryl
 35 which phenyl or heteroaryl group may optionally be substituted by a group selected from C_1 - C_4 alkyl and halo.

- Preferred optional substituents for R^3 include 1 or more, e.g. 1, 2 or 3, substituents (e.g. 1 substituent) independently selected from C_1 - C_6 alkoxy; $-O-R^{15}$ wherein R^{15} is $-(CH_2)_x-$
 40 $P(O)(OR^{23})_2$, where x is 0, 1, 2, 3 or 4 and R^{23} is independently selected from hydrogen and C_1 - C_3 alkyl or R^{15} is $-(CH_2)_y-S(O)_2Me$ where y is 1, 2, 3 or 4; and $-(O(CH_2)_z)_pOR^{24}$, where each z , which may be the same or different, represents 2 or 3, p represents 1, 2, 3, 4 or 5 and R^{24} is hydrogen or C_1 - C_3 alkyl.

- 45 Suitable optional substituents for R^3 are described in further detail below.

When R^3 is substituted phenyl, it preferably has a substituent in the meta or para position relative to the pyrrole ring, more preferably it has a substituent in the para position relative to the pyrrole ring. Alternatively, when R^3 is substituted phenyl it may have a substituent in the ortho position relative to the pyrrole ring. In one embodiment, R^3 is phenyl substituted by a single
 5 substituent. In another embodiment, R^3 is phenyl substituted by two substituents. When R^3 is substituted phenyl having 2 substituents, these may, for example, be in the meta and para positions relative to the pyrrole ring. In another embodiment, R^3 is phenyl substituted by three substituents. When R^3 is substituted phenyl having 3 substituents, these may, for example, be in the 3, 4 and 5 positions relative to the pyrrole ring.

10

For example, R^3 may represent phenyl bearing a para substituent selected from F, Cl, I, cyano, OCH_3 , OCH_2CH_3 , $OCH_2CH_2CH_3$, CF_3 , OCF_3 , $CON(CH_3)_2$, O-phenyl, methyl, ethyl, isopropyl, t-butyl, hydroxyl, $-OP(O)(OH)_2$, $-(O(CH_2)_2)_pOMe$ where p is 1, 2, 3 or 4, 3-morpholinopropoxy, 3-(4-methylpiperazin-1-yl)propoxy, 3-(diethoxyphosphoryl)propoxy, $-(O(CH_2)_3)-P(O)(OH)_2$, 3-
 15 (methylsulfonyl)propoxy, and 4-methoxybenzyloxy. In a further group of compounds that may be mentioned R^3 may represent phenyl bearing a para substituent selected from F, Cl, I, OCH_3 , OCH_2CH_3 , $OCH_2CH_2CH_3$, CF_3 , OCF_3 , $CON(CH_3)_2$, O-phenyl, methyl, ethyl, isopropyl and t-butyl. A particular R^3 group which may be mentioned is phenyl bearing a para OCH_3 substituent.

20

For example, R^3 may represent phenyl bearing an ortho substituent which is OCH_3 .

For example, R^3 may represent phenyl bearing a meta substituent which is O-phenyl or OCH_3 .

25 For example, R^3 may represent phenyl substituted in the meta position by I and in the para position by OCH_3 , or phenyl substituted in the meta position by OCH_3 and in the para position by OCH_3 , or phenyl linked in the meta and para positions by $-O-CH_2-O-$.

For example, R^3 may represent phenyl substituted in the ortho position by OCH_3 and in the para
 30 position by OCH_3 .

For example, R^3 may represent phenyl substituted in the 3, 4 and 5 positions by OCH_3 , or phenyl substituted in the 3 and 5 positions by F and in the para position by OCH_2CH_3 .

35 Hence a particularly suitable substituent for the phenyl of R^3 is OCH_3 , especially in the para position. Further particularly suitable substituents for R^3 include $-O-R^{15}$ wherein R^{15} is as defined above and $-(O(CH_2)_z)_pOR^{24}$, where z, p and R^{24} are as defined above, especially in the para position.

40 When an alkyl group or R^{4a} and/or R^{4b} is substituted by hydroxyl, $COOR^{12}$ or $CONR^{13}R^{14}$, examples of R^{4a} and/or R^{4b} groups include $-CH_2COOt$ -butyl, CH_2CONH_2 and CH_2CH_2OH .

R^{4a} and R^{4b} may be independently selected from hydrogen; C_1 - C_6 alkyl which alkyl group may optionally be substituted by hydroxyl, $COOR^{12}$ or $CONR^{13}R^{14}$; and $-C_1$ - C_3 alkylaryl in which said
 45 aryl groups may be optionally substituted. R^{4a} and R^{4b} are preferably independently selected from hydrogen, C_1 - C_6 alkyl, aryl and $-C_1$ - C_3 alkylaryl in which aryl may be optionally substituted.

For example R^{4a} and R^{4b} are preferably independently selected from hydrogen, C_1 - C_6 alkyl and C_1 - C_3 alkylaryl in which aryl may be optionally substituted. R^{4a} and R^{4b} are more preferably hydrogen or C_1 - C_3 alkylaryl, e.g. benzyl. Most preferably R^{4a} and R^{4b} are hydrogen.

- 5 R^5 and R^6 are preferably independently selected from hydrogen, C_1 - C_6 alkyl e.g. methyl, ethyl, or propyl, aryl e.g. phenyl, or C_1 - C_3 alkylaryl, e.g. benzyl in which said aryl may be optionally substituted, or R^5 and R^6 together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and NR^9 , e.g. morpholine, piperidine or piperazine (optionally N substituted with an R^9 group).

10

In one embodiment of the invention one of R^5 and R^6 is hydrogen. Preferably at least one of R^5 and R^6 is not hydrogen, more preferably both of R^5 and R^6 are not hydrogen.

- Specific- NR^5R^6 groups of interest include NMe_2 , $NHethyl$, $-N-morpholinyl$ and $N-piperidinyl$,
15 especially NMe_2 .

R^7 is preferably C_1 - C_6 alkyl e.g. methyl, ethyl, propyl or butyl, such as *iso*-propyl or *tert*-butyl.

R^8 is preferably methyl.

- 20 R^9 is preferably hydrogen, methyl, $COCH_3$ or $-CO-t-butyl$.

R^{10} is preferably methyl.

R^{11} is preferably methyl.

R^{12} is preferably methyl.

R^{13} is preferably H or methyl.

- 25 R^{14} is preferably H or methyl.

In an embodiment R^{15} is $-(CH_2)_x-P(O)(OR^{23})_2$ or $-(CH_2)_y-S(O)_2Me$.

In an embodiment R^{15} group is optionally substituted phenyl, e.g. unsubstituted phenyl.

In an embodiment R^{15} is C_1 - C_6 alkylheterocyclyl which heterocyclyl group may be optionally substituted e.g. by C_1 - C_3 alkyl.

- 30 R^{21} and R^{22} are preferably independently selected from C_1 - C_6 alkyl, e.g. methyl.

R^{23} is preferably hydrogen, methyl or ethyl.

R^{24} is preferably C_1 - C_3 alkyl, e.g. methyl.

x is preferably 0, 1, 2, 3 or 4.

y is preferably 1, 2 or 3.

- 35 z is preferably 2.

p is preferably 2, 3, 4 or 5.

- Prodrug derivatives of compounds of the invention will break down after administration to a subject to form an active compound of formula (I) *in vivo*. Prodrug derivatives of compounds of
40 the invention may have some intrinsic biological activity (e.g. as pneumolysin inhibitors) however typically they have little or no such intrinsic activity.

- Prodrug derivatives of the compounds of formula (I) include ester prodrug derivatives. Ester prodrug derivatives include carboxylate ester, sulfamate ester, phosphate ester and carbamate
45 ester derivatives, preferably carboxylate ester, sulfamate ester or phosphate ester derivatives, more preferably carboxylate ester or phosphate ester derivatives, even more preferably

carboxylate ester derivatives. Examples of ester prodrug derivatives thus include compounds of formula (I) wherein one or both of R^{4a} and R^{4b} are independently selected from $-C(O)R^{16}$, $-SO_2NH_2$, $-PO(OR^{19})(OR^{20})$, $-CHR^{26}-OPO(OR^{19})(OR^{20})$ (where R^{26} is hydrogen or C_1-C_6 alkyl), and $-C(O)NR^{17}R^{18}$, wherein R^{16} , R^{17} , R^{18} , R^{19} and R^{20} are independently selected from:

- 5 (a) C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, heterocyclyl, $-C_1-C_3$ alkyl- C_3-C_{10} cycloalkyl, $-C_1-C_3$ alkyl- C_5-C_{10} cycloalkenyl or $-C_1-C_3$ alkylheterocyclyl, or R^{17} and R^{18} together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and $NR^{25a}R^{25b}$ where R^{25a} is hydrogen, C_1-C_6 alkyl, $-CH_2-OPO(OR^{19})(OR^{20})$ or
10 a 5- or 6-membered heterocyclic ring, and R^{25b} is absent or C_1-C_6 alkyl; and in which any of the aforementioned R^{16} , R^{17} or R^{18} groups may be optionally substituted by one or more groups, e.g. one group, selected from cyano, $-OPO(OR^{19})(OR^{20})$, $-(O(CH_2)_z)_rOR^{24}$ (wherein each z, which may be the same or different, represents 2 or 3, r represents an integer selected from 1 to 20, e.g. 7 to 12, and R^{24} is hydrogen, C_1-C_3 alkyl or $-$
15 $PO(OR^{19})(OR^{20})$), C_1-C_6 alkoxy, C_1-C_6 fluoroalkoxy, C_1-C_6 alkyl, C_1-C_6 fluoroalkyl and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1-C_6 alkyl, and any of the aforementioned R^{16} , R^{17} or R^{18} groups may be optionally substituted by one or more halogen atoms; and
(b) aryl, heteroaryl, C_1-C_3 alkylaryl and $-C_1-C_3$ alkylheteroaryl, said aryl and heteroaryl
20 groups being optionally substituted;
or R^{18} , R^{19} and R^{20} may independently represent hydrogen.

Optional substituents for phenyl, aryl and heteroaryl groups within the definitions of R^1 , R^2 , R^3 , R^{4a} , R^{4b} , R^5 , R^6 , R^7 , R^{16} , R^{17} , R^{18} , R^{19} and R^{20} are suitably selected from hydroxyl, halo, cyano, $-(CHR^{26})_q-OPO(OR^{19})(OR^{20})$ wherein q represents 0 or 1 (said group not being substituted by
25 another R^{19} or R^{20} containing group), C_1-C_6 alkoxy or C_1-C_6 fluoroalkoxy, e.g. C_1-C_3 alkoxy or C_1-C_3 fluoroalkoxy such as methoxy, ethoxy or trifluoromethoxy, C_1-C_6 alkyl or C_1-C_6 fluoroalkyl, e.g. C_1-C_3 alkyl or C_1-C_3 fluoroalkyl such as methyl or trifluoromethyl, and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1-C_6 alkyl e.g. C_1-C_3 alkyl such as
30 methyl; and also when two adjacent hydroxyl substituents are present they may optionally be connected by a methylene group to form an acetal. Another possible optional substituent is $-SF_5$. Said aryl and heteroaryl groups, if substituted, may be substituted by 1, 2 or 3, preferably 1 or 2, more preferably 1 substituent.

35 Optional substituents for the C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_5-C_{10} cycloalkenyl, heterocyclyl, $-C_1-C_3$ alkyl- C_3-C_{10} cycloalkyl, $-C_1-C_3$ alkyl- C_5-C_{10} cycloalkenyl, $-C_1-C_3$ alkylheterocyclyl or heterocyclic ring groups of R^5 , R^6 , R^7 , R^{16} , R^{17} , R^{18} , R^{19} and R^{20} include substituents selected from cyano, $-OPO(OR^{19})(OR^{20})$ (said group not being substituted by
another R^{19} or R^{20} containing group), C_1-C_6 alkoxy or C_1-C_6 fluoroalkoxy, e.g. C_1-C_3 alkoxy or
40 C_1-C_3 fluoroalkoxy such as methoxy, ethoxy or trifluoromethoxy, C_1-C_6 alkyl or C_1-C_6 fluoroalkyl, e.g. C_1-C_3 alkyl or C_1-C_3 fluoroalkyl such as methyl or trifluoromethyl, and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1-C_6 alkyl e.g. C_1-C_3 alkyl such as methyl. Optional substituents for the groups R^5 , R^6 and R^7 also include one or more (e.g. 1, 2, or 3) halogen atoms e.g. F or Cl atoms (especially F atoms).

45

R¹⁶ preferably represents C₁-C₆ alkyl or C₃-C₁₀ cycloalkyl in which either of the aforementioned groups may be optionally substituted (and is preferably substituted) by a group selected from -OPO(OR¹⁹)(OR²⁰) and -(O(CH₂)_z)_rOR²⁴, where each z, which may be the same or different, represents 2 or 3, r represents an integer selected from 1 to 20, e.g. 7 to 12, and R²⁴ is
 5 hydrogen, C₁-C₃ alkyl or -PO(OR¹⁹)(OR²⁰).

Alternatively, R¹⁶ preferably represents phenyl optionally substituted (and is preferably substituted) by -(CHR²⁶)_q-OPO(OR¹⁹)(OR²⁰) wherein q represents 0 or 1.

R¹⁷ preferably represents C₁-C₆ alkyl e.g. methyl. R¹⁸ preferably represents C₁-C₆ alkyl e.g. methyl. Alternatively, R¹⁷ and R¹⁸ together with the N to which they are attached may form a 5-
 10 or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and NR^{25a} where R^{25a} is hydrogen, C₁-C₆ alkyl, -CH₂-OPO(OR¹⁹)(OR²⁰) or a 5- or 6-membered heterocyclic ring.

R¹⁹ is preferably hydrogen, methyl or ethyl, especially hydrogen.

15 R²⁰ is preferably hydrogen, methyl or ethyl, especially hydrogen.

R^{25a} is preferably hydrogen or methyl.

R^{25b} is preferably absent.

R²⁶ is preferably hydrogen or methyl, more preferably methyl.

In one embodiment q represents 0. In another embodiment q represents 1.

20

In one embodiment one of R^{4a} and R^{4b} represents a prodrug derivative group as defined above. In another embodiment both of R^{4a} and R^{4b} represent a prodrug group as defined above. When only one of R^{4a} and R^{4b} represents a prodrug derivative group as defined above the other of R^{4a} and R^{4b} is preferably hydrogen.

25

In one embodiment both of R^{4a} and R^{4b} are independently selected from -C(O)R¹⁶, -SO₂NH₂, -PO(OR¹⁹)(OR²⁰), -CHR²⁶-OPO(OR¹⁹)(OR²⁰) where R²⁶ is hydrogen or C₁-C₆ alkyl, and -C(O)NR¹⁷R¹⁸. In a further embodiment one of R^{4a} and R^{4b} is selected from -C(O)R¹⁶, -SO₂NH₂, -PO(OR¹⁹)(OR²⁰), -CHR²⁶-OPO(OR¹⁹)(OR²⁰) where R²⁶ is hydrogen or C₁-C₆ alkyl, and -
 30 C(O)NR¹⁷R¹⁸; and the other of R^{4a} and R^{4b} is hydrogen.

One or both of R^{4a} and R^{4b} are preferably independently selected from -C(O)R¹⁶.

When the prodrug is a carboxylate ester prodrug, e.g. wherein one or both of R^{4a} and R^{4b} are -C(O)R¹⁶, the carbon atom adjacent to the C(O) moiety is preferably a tertiary or quaternary carbon atom.
 35

Specific examples of prodrug derivatives include compounds of formula (I) wherein one or both of R^{4a} and R^{4b} are independently selected from -SO₂NH₂, -PO(OH)₂, -CH₂-PO(OH)₂, -PO(OEt)₂,
 40 -CON-(4-N-piperidiny-piperidine), -COt-butyl, -COisopropyl, -CON-(N-methyl)piperazine, -CON-piperazine, -CON(CH₃)₂, COCH₃, -CO-(CH₂)₂-OMe, -CO(CH₂)₂-(O(CH₂)₂)_pOMe where p is 1 to 12, -CO-CMe₂-CH₂-(O(CH₂)₃)_pOMe where p is 1 to 12, -CO-CMe₂-CH₂-(O(CH₂)₂)_pO-PO(OH)₂ where p is 1 to 12, -CO-CMe₂-CH₂-(O(CH₂)₂)_pO-PO(OH)₂ where p is 1 to 12, -CO-(4-phosphonoxymethylbenzene) and -CO-(4-phosphonoxymethylcyclohexane); wherein when only
 45 one of R^{4a} and R^{4b} represents a prodrug derivative group as defined above the other of R^{4a} and R^{4b} is hydrogen. A group of specific examples of prodrug derivatives include compounds of

formula (I) wherein R^{4a} and R^{4b} are independently selected from -SO₂NH₂, -PO(OH)₂, -CON-(4-N-piperidinyl-piperidine), -COt-butyl, -COisopropyl, -CON-(N-methyl)piperazine, -CON(CH₃)₂ and COCH₃.

- 5 While the preferred groups for each variable have generally been listed above separately for each variable, preferred compounds of this invention include those in which several or each variable in formula (I) is selected from the preferred, more preferred or particularly listed groups for each variable. Therefore, this invention is intended to include all combinations of preferred, more preferred and particularly listed groups.

10

The molecular weight of the compounds of the invention is preferably less than 2000, more preferably less than 1000, even more preferably less than 800, for example less than 600.

Particular compounds of the invention include the following:

- 15 *N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-ethoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
3,4-dihydroxy-1-(4-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
20 (1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-dimethyl-*N*²,*N*⁵-diphenyl-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
di-*tert*-butyl 4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate);
25 1,1'-(4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-diisopropyl-*N*²,*N*⁵-dimethyl-1*H*-pyrrole-2,5-
30 dicarboxamide;
*N*²,*N*⁵-dibenzyl-1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
di-*tert*-butyl 4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate);
(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperazin-1-ylmethanone);
35 1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetraisopropyl-1*H*-pyrrole-2,5-dicarboxamide;
(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
3,4-dihydroxy-1-(2-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
(3,4-dihydroxy-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
1-(4-ethoxyphenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
40 (1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
(3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
*N*²-ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(piperidine-1-carbonyl)-1*H*-pyrrole-2-carboxamide;
45 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxamide;

- 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxamide;
- 3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxamide;
- 5 1-(4-(dimethylcarbamoyl)phenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
- tert*-butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonylcarbamate;
- 5-cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide;
- 10 ethyl 5-(dimethylcarbamoyl)-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;
- 1,1'-(4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
- 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile;
- isopropyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
- 15 *tert*-butyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
- ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxylate;
- ethyl 5-(dibutylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
- ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;
- 20 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxylate;
- ethyl 5-(diethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
- ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-iodophenyl)-1*H*-pyrrole-2-carboxylate;
- ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
- 25 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-1*H*-pyrrole-2,5-dicarboxamide;
- 3,4-bis(benzyloxy)-*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
- 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
- di-*tert*-butyl 4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate);
- 30 (3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
- 3,4-bis(benzyloxy)-1-(2-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
- (3,4-bis(benzyloxy)-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
- 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
- (3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
- 35 3,4-bis(benzyloxy)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxamide;
- 3,4-bis(benzyloxy)-*N*²-ethyl-1-(4-methoxyphenyl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
- 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxamide;
- 40 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(piperidine-1-carbonyl)-1*H*-pyrrole-2-carboxamide;
- 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxamide;
- 1,1'-(4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
- 45 ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate;

- 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide;
ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-iodophenyl)-1*H*-pyrrole-2-carboxylate;
3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
5 3,4-bis(benzyloxy)-*N*²,*N*⁵-diethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-ethoxyphenyl)-*N*²,*N*⁵-diethyl-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
10 ethyl 3,4-bis(benzyloxy)-5-carbamoyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
ethyl 5-carbamoyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
ethyl 3,4-bis(benzyloxy)-5-(2-methoxyphenyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate;
ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate;
15 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-4-yl)-1*H*-pyrrole-2-carboxylate;
ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-3-yl)-1*H*-pyrrole-2-carboxylate;
ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-pyrrole-2-
carboxylate;
20 ethyl 3,4-bis(benzyloxy)-5-(5-ethyl-1,3,4-oxadiazol-2-yl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-
carboxylate;
ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2*H*-tetrazol-5-yl)-1*H*-pyrrole-2-carboxylate;
ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2*H*-tetrazol-5-yl)-1*H*-pyrrole-2-carboxylate;
diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (this compound is not
25 novel per se);
diethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate (this compound is not novel per se);
diethyl 1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(3-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(4-(trifluoromethoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
30 diethyl 3,4-dihydroxy-1-(4-isopropylphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(4-phenoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 1-(4-ethylphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(*p*-tolyl)-1*H*-pyrrole-2,5-dicarboxylate;
35 diethyl 1-(3,4-dimethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 1-(4-chlorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(3,4,5-trimethoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 1-(2,4-dimethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
40 diethyl 3,4-dihydroxy-1-(4-propoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 1-(4-ethoxy-3,5-difluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 3,4-dihydroxy-1-(3-phenoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
diethyl 1-(benzo[d][1,3]dioxol-5-yl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
diisopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
45 2-ethyl 5-isopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
di-*tert*-butyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;

- diethyl 3,4-dihydroxy-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-cyanophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-fluorophenyl)-3-hydroxy-4-(2-hydroxyethoxy)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-hydroxy-4-(2-hydroxyethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 5 diethyl 3-(2-(tert-butoxy)-2-oxoethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-
 dicarboxylate;
 diethyl 3-(benzyloxy)-4-(2-(tert-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 dicarboxylate;
 diethyl 3-(2-amino-2-oxoethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 10 diethyl 3-(2-(tert-butoxy)-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 dicarboxylate;
 diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-(tert-butyl)phenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate; and
 diethyl 3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 15 or a pharmaceutically acceptable prodrug derivative of any one thereof, or a pharmaceutically
 acceptable salt or solvate of any one thereof.

Further particular compounds of the invention include the following:

- 5-acetyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide;
 20 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(2-methoxyethoxy)phenyl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 3-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-
 pyrrole-2-carboxylate;
 ethyl 1-(4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)-5-(dimethylcarbamoyl)-3,4-dihydroxy-1*H*-
 25 pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(methylcarbamoyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(phosphonooxy)phenyl)-1*H*-pyrrole-2-
 carboxylate;
 30 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1*H*-
 pyrrole-2-carboxylate;
 ethyl 1-(4-(3-(diethoxyphosphoryl)propoxy)phenyl)-5-(dimethylcarbamoyl)-3,4-dihydroxy-1*H*-
 35 pyrrole-2-carboxylate;
 (3-(4-(2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-3,4-dihydroxy-1*H*-pyrrol-1-
 yl)phenoxy)propyl)phosphonic acid;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1*H*-pyrrole-
 2-carboxylate;
 40 neopentyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 2,6-dimethylcyclohexyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-
 carboxylate;
 cyclopentyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-
 carboxylate;
 45 5-(dimethylphosphoryl)-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-
 carboxamide;

diethyl 3,4-dihydroxy-1-(4-(2-methoxyethoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-1*H*-pyrrole-2,5-
 dicarboxylate;
 diethyl 1-(4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-
 5 dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate; and
 diethyl 3,4-dihydroxy-1-(4-((4-methoxybenzyl)oxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 or a pharmaceutically acceptable prodrug derivative of any one thereof, or a pharmaceutically
 acceptable salt or solvate of any one thereof.

10

Particular prodrug derivatives of the compounds of the invention include the following:

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl diacetate;
 ethyl 5-(dimethylcarbamoyl)-3,4-bis((dimethylcarbamoyl)oxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-
 2-carboxylate;

15 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-
 methylpiperazine-1-carboxylate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis([1,4'-
 bipiperidine]-1'-carboxylate);

ethyl 5-(dimethylcarbamoyl)-4-((dimethylcarbamoyl)oxy)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-
 20 pyrrole-2-carboxylate;

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2-
 methylpropanoate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-
 dimethylpropanoate);

25 ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(sulfamoyloxy)-1*H*-pyrrole-2-
 carboxylate;

ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonooxy)-1*H*-pyrrole-2-
 carboxylate; and

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl [1,4'-
 30 bipiperidine]-1'-carboxylate;

or a pharmaceutically acceptable salt or solvate of any one thereof.

Further particular prodrug derivatives of the compounds of the invention include the following:

ethyl 3,4-bis((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-
 35 2-carboxylate;

ethyl 3-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-
 pyrrole-2-carboxylate;

ethyl 4-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-
 pyrrole-2-carboxylate;

40 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-
 1*H*-pyrrole-3,4-diyl bis(2-methylpropanoate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-
 methoxypropanoate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-
 45 methoxyethoxy)propanoate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)-2,2-dimethylpropanoate);

ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate;

5 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-methoxyethoxy)ethoxy)-2,2-dimethylpropanoate);

2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2-methylpropanoate);
ethyl 5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-3-((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate;

10 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(3-(phosphonooxy)propoxy)propanoate);

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate);

15 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate);

2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate);

20 2-(dimethylcarbamoyl)-5-(isopropoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate);

2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(piperidine-4-carboxylate);

2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-

25 ((phosphonooxy)methyl)benzoate); and

(1*R*,1'*R*,4*R*,4'*R*)-2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)cyclohexanecarboxylate);

or a pharmaceutically acceptable salt or solvate of any one thereof.

30 Particular compound of the invention and prodrugs which may be mentioned include those designated as compounds UL1-004, UL1-005, UL1-012, UL1-024, UL1-028, UL1-035, UL1-049, UL1-070, UL1-089, UL1-098, UL1-106, UL1-109, UL1-111, UL1-114, UL1-115, UL1-116, UL1-117, UL1-118, UL1-120, UL1-121, UL1-122, UL1-124, UL1-126 and UL2-001, in Table 1 below.

35

Alkyl as used herein refers to straight chain or branched chain alkyl, such as, without limitation, methyl, ethyl, propyl, *iso*-propyl, butyl, and *tert*-butyl. In one embodiment alkyl refers to straight chain alkyl in another embodiment alkyl refers to branched chain alkyl. Alkenyl and alkynyl should be interpreted accordingly.

40

Fluoroalkyl groups are as described above for alkyl, but may have one or more hydrogen atoms replaced by fluoro. Examples of fluoroalkyl groups include -CH₂F, -CHF₂ and -CF₃.

Cycloalkyl as used herein refers to a cyclic alkyl group, containing 3-10 carbon atoms, optionally

45 branched, for example cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. A branched example is 2-methylcyclopentyl. Cycloalkenyl refers to a cyclic alkenyl group containing typically 5-10 carbon

atoms, for example cyclopentyl, cyclohexenyl or cycloheptenyl. Cycloalkyl and cycloalkenyl groups may for example be monocyclic or bicyclic (including spirocyclic) but are suitably monocyclic.

Alkoxy as used herein refers to straight or branched chain alkoxy, for example methoxy, ethoxy, propoxy, butoxy. Alkoxy as used herein also extends to embodiments in which the oxygen atom is located within the alkyl chain, for example $-\text{CH}_2\text{OCH}_3$. In one embodiment the alkoxy is linked through oxygen to the remainder of the molecule. In one embodiment the disclosure relates to straight chain alkoxy.

10 Halo includes fluoro, chloro, bromo or iodo, in particular fluoro, chloro or bromo, especially fluoro or chloro.

Heterocyclyl as used herein includes 4- to 10-membered mono or bicyclic non-aromatic ring systems, e.g. 4- to 7-membered monocyclic saturated rings, containing up to three heteroatoms selected from N, O and S. Examples of heterocyclic rings include oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, tetrahydrothiophene, tetrahydrothiopyran, thiopane, thiocane, azetidine, pyrrolidine, piperidine, azepane, azocane, [1,4]dioxane, oxazolidine, piperazine, and the like a further example is morpholine. Other examples of heterocyclic rings include the oxidised forms of the sulfur-containing rings. Thus, tetrahydrothiophene-1-oxide, tetrahydrothiophene-1,1-dioxide, tetrahydrothiopyran-1-oxide and tetrahydrothiopyran-1,1-dioxide are also considered to be heterocyclic rings.

Aryl as used herein includes C_6 - C_{14} mono or bicyclic groups having 1 or 2 rings wherein at least one ring is aromatic, including phenyl, naphthyl, 5,6,7,8-tetrahydronaphthyl and the like, such as phenyl and naphthyl particularly phenyl.

Heteroaryl as used herein includes 5- to 10-membered aromatic mono or bicyclic ring systems comprising one or more, (for example 1, 2, 3 or 4) heteroatoms independently selected from O, N and S. Examples of heteroaryl groups include pyrrole, furan, thiophene, oxazole, thiazole, isothiazole, oxadiazole, tetrazole, imidazole, pyrazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine, benzothiophene, benzofuran, 1, 2, 3-triazole and 1, 2, 4-triazole. In a bicyclic ring system the definition of heteroaryl will be satisfied if at least one ring contains a heteroatom and at least one ring is aromatic. The heteroaryl may be linked to the remainder of the molecule through a carbocyclic ring or a ring comprising a heteroatom.

Examples of salts of the compounds of formula (I) include all pharmaceutically acceptable salts prepared from pharmaceutically acceptable non-toxic bases or acids. Salts derived from bases include, for example, potassium and sodium salts and the like. Salts derived from acids, include those derived from inorganic and organic acids such as, for example, hydrochloric, methanesulfonic, sulfuric and p-toluenesulfonic acid and the like.

Examples of solvates include hydrates.

The compounds described herein may include one or more chiral centers, and the disclosure extends to include racemates, enantiomers and stereoisomers resulting therefrom. In one

embodiment one enantiomeric form is present in a substantially purified form that is substantially free of the corresponding enantiomeric form.

The invention also extends to all polymorphic forms of the compounds of formula (I).

5


The invention also extends to isotopically-labelled compounds of formula (I) in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, 10 fluorine, such as ^2H , ^3H , ^{11}C , ^{14}C and ^{18}F . Isotopically labelled compounds of formula (I) may be prepared by carrying out the synthetic methods described below and substituting an isotopically labelled reagent or intermediate for a non-isotopically labelled reagent or intermediate.

The invention extends to all tautomeric forms of the compounds illustrated herein (particularly 15 enol-keto tautomers). For example whereas formula (I) illustrates in some embodiments (e.g. when R^{4a} and/or R^{4b} represents H) an enol form, the corresponding keto form is also embraced as part of the invention. The same applies to other structures herein which illustrate enol or keto forms of compounds. Similarly, the disclaimed compounds are disclaimed in all their tautomeric forms.

20

Compounds of the invention may be prepared by the following methods or by methods analogous thereto or by using conventional methods known to a skilled person:


A general method for preparing compounds of formula (I) in which R^{4a} and R^{4b} represent 25 hydrogen is shown below in **Scheme A**:



Scheme A

In the third step shown in Scheme A, R^x typically represents C_1 - C_6 alkyl such as methyl or ethyl. 30


A method for preparing certain compounds of formula (I) in which R^1 is $-\text{C}(\text{O})\text{NR}^5\text{R}^6$, R^2 is $-\text{C}(\text{O})\text{OR}^7$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme B**:



Scheme B


In the second step shown in Scheme B, R^x typically represents C_1 - C_6 alkyl such as methyl or ethyl.

An alternative method for preparing certain compounds of formula (I) in which R^1 is - $C(O)NR^5R^6$, R^2 is $-C(O)OR^7$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme C**:




Scheme C

A method for preparing certain compounds of formula (I) in which R^1 is $-C(O)NHR^6$, R^2 is $C(O)NR^5R^6$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme D**:



Scheme D


A method for preparing certain compounds of formula (I) in which R^1 is $-C(O)NR^5R^6$, R^2 is $C(O)NR^5R^6$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme E**:



5

Scheme E

A method for preparing certain compounds of formula (I) in which R^1 is $-CN$, R^2 is $C(O)NR^5R^6$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme F**:




10


Scheme F

A method for preparing certain compounds of formula (I) in which R^1 is $-C(O)OR^7$, R^2 is CN and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme G**:

15

**Scheme G**


A method for preparing certain compounds of formula (I) in which R^1 is $-\text{SO}_2\text{NH}-\text{C}(\text{O})\text{OR}^8$, R^2 is $\text{C}(\text{O})\text{NR}^5\text{R}^6$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme H**:



Scheme H

5


A method for preparing certain compounds of formula (I) in which R^1 is $-\text{CN}$, R^2 is $-\text{CN}$ and R^{4a} and R^{4b} represent hydrogen is shown below in **Scheme I**:



Scheme I

10

A method for preparing certain compounds of formula (I) in which R^{4a} and R^{4b} represent groups other than hydrogen is shown below in **Scheme J**:



Scheme J


15

Scheme J may be adapted to convert one or both hydroxyl groups to OR^{4a} and/or OR^{4b} depending on the molar excess of reagent(s) employed. When R^{4a} and R^{4b} are different, it may

20


be necessary to employ a protection strategy to incorporate one and then the other group. This process is also suitable for preparing prodrug derivatives of compounds of formula (I).

A method for preparing certain compounds of formula (I) where R^2 is $-C(O)R^7$ and R^{4a} and R^{4b} represent H is shown below in **Scheme K**:



Scheme K


A method for preparing certain compounds of formula (I) where R^2 is aryl/heteroaryl is shown below in **Scheme L**:



Scheme L


Compounds where R^2 is $-POR^{21}R^{22}$ may be prepared by reaction of a compound of formula (XVII) shown above with a compound of formula $POR^{21}R^{22}Cl$, followed by deprotection.

A method for preparing certain compounds of formula (I) where R^1 is $-C(O)OR^7$ and R^2 is a thiazole containing group and R^{4a} and R^{4b} represent H is shown below in **Scheme M**:



Scheme M


A method for preparing certain compounds of formula (I) where R^1 is $-C(O)OR^7$, R^2 is tetrazole and R^{4a} and R^{4b} represent H is shown below in **Scheme N**:



Scheme N

5

A method for preparing certain compounds of formula (I) where R^1 is $-C(O)OR^7$ and R^2 is a oxadiazole containing group and R^{4a} and R^{4b} represent H is shown below in **Scheme O**:



Scheme O

10

In the above Schemes A to O the general conditions for performing the reactions specified will be well known to a skilled person.

Compounds of formula (I) may be converted to different compounds of formula (I) by the above methods and/or by conventional methods.

For example the skilled person will be familiar with standard procedures for converting carboxylic acids to esters, amides, carbamates and ureas and for converting amines to amides and sulphonamides.


20

Thus compounds of formula (I) in which R^1 and/or R^2 represents $-C(O)NHC(O)R^7$ may be prepared by reaction of a compound of formula (I) in which R^1 and/or R^2 represents $-C(O)NH_2$ with a compound of formula $R^7C(O)L$ wherein L represents a leaving group, such as halogen.

Protecting groups may be required to protect chemically sensitive groups during one or more of the reactions described above, to ensure that the process is efficient. Thus if desired or necessary, intermediate compounds may be protected by the use of conventional protecting groups. Protecting groups and means for their removal are described in "Protective Groups in Organic Synthesis", by Theodora W. Greene and Peter G.M. Wuts, published by John Wiley & Sons Inc; 4th Rev Ed., 2006, ISBN-10: 0471697540.

Any novel intermediates, such as those defined above, may be of use in the synthesis of compounds of formula (I) and are therefore also included within the scope of the invention.

5 Thus according to a further aspect of the invention there is provided a compound of formula (II):



(II)


- wherein R¹ and R² are as defined above for the compounds of formula (I), and R³ is phenyl substituted by 1 or more, e.g. 1, 2 or 3, substituents (e.g. 1 substituent) independently selected from halo, cyano, hydroxyl, C₁-C₆ alkoxy, C₁-C₆ hydroxyalkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl; -O-R¹⁵ wherein R¹⁵ is -(CH₂)_x-P(O)(OR²³)₂, where x is 0, 1, 2, 3 or 4 and R²³ is independently selected from hydrogen and C₁-C₃ alkyl, -(CH₂)_y-S(O)₂Me where y is 1, 2, 3 or 4, -C₁-C₆ alkylheterocyclyl which heterocyclyl group may be optionally substituted by C₁-C₃ alkyl, -C₁-C₆ alkylphenyl which phenyl group may be optionally substituted by C₁-C₃ alkoxy, or phenyl or 5- or 6-membered heteroaryl which phenyl or heteroaryl group may optionally be substituted by a group selected from C₁-C₄ alkyl and halo; or -(O(CH₂)_z)_pOR²⁴, where each z, which may be the same or different, represents 2 or 3, p represents 1, 2, 3, 4 or 5 and R²⁴ is hydrogen or C₁-C₃ alkyl; or two adjacent carbon atoms within R³ may be linked by -O-CH₂-O-, or a salt or protected derivative thereof;
- provided that when R⁵ or R⁶ is optionally substituted aryl, said aryl is optionally substituted by 1, 2 or 3 groups selected from hydroxyl, halo, cyano, C₁-C₆ alkoxy or C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl or C₁-C₆ fluoroalkyl, and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl; or when two adjacent hydroxyl substituents are present they may optionally be connected by a methylene group to form an acetal; and provided that the compound is not:
- methyl 2-((2-oxo-2-(phenylamino)ethyl)(phenyl)amino)acetate;
 - methyl 2-((4-methoxyphenyl)(2-oxo-2-(phenylamino)ethyl)amino)acetate;
 - ethyl 2-(phenyl(tosylmethyl)amino)acetate;
 - ethyl 2-((cyanomethyl)(3,4-dichlorophenyl)amino)acetate;
 - methyl 2-((cyanomethyl)(p-tolyl)amino)acetate;
 - ethyl 2-(mesityl(2-oxopropyl)amino)acetate;
 - dimethyl 2,2'-((3-bromophenyl)azanediyl)diacetate; or
 - dimethyl 2,2'-((4-iodophenyl)azanediyl)diacetate.

The specific compounds disclaimed from the definition of formula (II) above are found in CAS as follows: methyl 2-((2-oxo-2-(phenylamino)ethyl)(phenyl)amino)acetate (CAS 862699-62-5), methyl 2-((4-methoxyphenyl)(2-oxo-2-(phenylamino)ethyl)amino)acetate (CAS 862699-57-8), ethyl 2-(phenyl(tosylmethyl)amino)acetate (CAS 1129284-66-7), ethyl 2-((cyanomethyl)(3,4-dichlorophenyl)amino)acetate (CAS 1003878-20-3), methyl 2-((cyanomethyl)(p-tolyl)amino)acetate (CAS 100134-88-1) and ethyl 2-(mesityl(2-oxopropyl)amino)acetate (CAS 935758-17-1); or otherwise as follows: dimethyl 2,2'-((3-bromophenyl)azanediyl)diacetate and

dimethyl 2,2'-((4-iodophenyl)azanediyl)diacetate (International Patent Application WO2006/020004).

- Compounds of formula (II) which may be mentioned in particular are those in which R^1 is -
 5 $C(O)NR^5R^6$ and R^2 is $-C(O)NR^5R^6$ or wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)OR^7$.

According to a further aspect of the invention there is provided a compound of formula (II):



(II)

- 10 wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)NR^5R^6$ or wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)OR^7$, and R^3 , R^5 and R^6 are as defined above for the compounds of formula (I), or a salt or protected derivative thereof;
 provided that when R^5 or R^6 is optionally substituted aryl, said aryl is optionally substituted by 1, 2 or 3 groups selected from hydroxyl, halo, cyano, C_1 - C_6 alkoxy or C_1 - C_6 fluoroalkoxy, C_1 - C_6
 15 alkyl or C_1 - C_6 fluoroalkyl, and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl; or when two adjacent hydroxyl substituents are present they may optionally be connected by a methylene group to form an acetal;
 and provided that the compound is not:
 a) methyl 2-((2-oxo-2-(phenylamino)ethyl)(phenyl)amino)acetate; or
 20 b) methyl 2-((4-methoxyphenyl)(2-oxo-2-(phenylamino)ethyl)amino)acetate.

Any preferences or examples of specific groups for R^1 , R^2 , R^3 , R^5 , R^6 , R^a and R^b as described above for the compounds of formula (I) also apply to the definitions of R^1 , R^2 , R^3 , R^5 , R^6 , R^a and R^b in the compounds of formula (II).

25

Particular compounds of formula (II) include those mentioned in the examples.

- There is also provided a process for preparing compounds of formula (I) in which R^{4a} and R^{4b} represent H which comprises reacting a compound of formula (II) with a compound of formula
 30 $R^xOCOCOR^x$ in which R^x represents C_1 - C_6 alkyl. This process is typically performed in a polar protic solvent such as ethanol in the presence of a strong base such as sodium ethoxide.

Compounds of formula (I) without provisos a) to i) are referred to below as "compounds of the invention".

35

As indicated above the compounds of the invention are useful for treatment of bacterial infections caused by bacteria producing pore-forming toxins, such as cholesterol dependent cytolysins.

- 40 In particular the compounds of the invention are useful for the treatment of toxemia associated with bacterial infections.

For such use the compounds of the invention will generally be administered in the form of a pharmaceutical composition.

Further, the present invention provides a pharmaceutical composition comprising a compound of formula (I) without provisos a) to i) optionally in combination with one or more pharmaceutically acceptable diluents or carriers.

5

Diluents and carriers may include those suitable for parenteral, oral, topical, mucosal and rectal administration.

As mentioned above, such compositions may be prepared e.g. for parenteral, subcutaneous, intramuscular, intravenous, intra-articular or peri-articular administration, particularly in the form of liquid solutions or suspensions; for oral administration, particularly in the form of tablets or capsules; for topical e.g. intravitreal, pulmonary or intranasal administration, particularly in the form of eye drops, powders, nasal drops or aerosols and transdermal administration; for mucosal administration e.g. to buccal, sublingual or vaginal mucosa, and for rectal administration e.g. in the form of a suppository.

The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., (1985). Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray. For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate, pregelatinated starch, and the like.

Compositions suitable for oral administration may comprise one or more physiologically compatible carriers and/or excipients and may be in solid or liquid form. Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or poly-vinylpyrrolidone; fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulfate. Liquid compositions may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats; emulsifying agents such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). Liquid compositions may be encapsulated in, for example, gelatin to provide a unit dosage form.

Solid oral dosage forms include tablets, two-piece hard shell capsules and soft elastic gelatin (SEG) capsules.

A dry shell formulation typically comprises of about 40% to 60% concentration of gelatin, about a 20% to 30% concentration of plasticizer (such as glycerin, sorbitol or propylene glycol) and about a 30% to 40% concentration of water. Other materials such as preservatives, dyes, opacifiers and flavours also may be present. The liquid fill material comprises a solid drug that

has been dissolved, solubilized or dispersed (with suspending agents such as beeswax, hydrogenated castor oil or polyethylene glycol 4000) or a liquid drug in vehicles or combinations of vehicles such as mineral oil, vegetable oils, triglycerides, glycols, polyols and surface-active agents.

5

Pharmaceutical compositions of the invention may optionally include one or more anti-oxidants (e.g. ascorbic acid or metabisulfate and salts thereof).

The compounds of the invention are inhibitors of the cholesterol-dependent cytolysin, pneumolysin, produced by the bacterium *Streptococcus pneumoniae*. They also inhibit Streptolysin O (SLO) produced by Group A Streptococci and Perfringolysin O (PFO) produced by *Clostridium perfringens*. They are also expected to inhibit other members of the closely related cholesterol-dependent cytolysins, examples of which include, but are not limited to, Listeriolysin O (LLO) produced by *Listeria monocytogenes*, Anthrolysin O (ALO) produced by
15 *Bacillus anthracis* and Suilyisin (SLY) produced by *Streptococcus suis*.

The compounds of the invention are useful for the treatment of bacterial infections, e.g. pneumococcal infections including the associated toxemia where the pneumolysin toxin has been demonstrated to play a pivotal role in the diseases produced. Such diseases include, but
20 are not limited to, pneumococcal pneumonia, pneumococcal meningitis, pneumococcal septicaemia/bacteraemia, pneumococcal keratitis and pneumococcal otitis media. The compounds of the invention are also useful for the treatment of pneumococcal infections associated with other conditions. Such conditions include (without limitation) cystic fibrosis and chronic obstructive pulmonary disease (COPD). For example, *S pneumoniae* has been
25 isolated from patients with COPD and is believed to be an exacerbatory factor in this disease.

The compounds of the invention are useful for the treatment of infections caused by group A Streptococci (GAS), including but not limited to, invasive group A Streptococcal diseases, where the toxin Streptolysin O (SLO) has been demonstrated to play a crucial role in the pathogenesis
30 of systemic GAS diseases.

The compounds of the invention are useful for the treatment of infections caused by *Clostridium perfringens* including, but not limited to, gas gangrene, characterized by myonecrosis, septic shock and death, where the toxin Perfringolysin O has been demonstrated to be a major
35 virulence factor in the pathogenesis of this disease.

The compounds of the invention are useful for the treatment of infections caused by *Bacillus anthracis*, where the cholesterol dependent cytolysin Anthrolysin O (ALO) plays an essential role in gastrointestinal (GI) anthrax, and contributes to the pathogenesis of inhalational anthrax.
40

The compounds of the invention are useful for the treatment of other diseases caused by Gram positive bacteria, producing cholesterol-dependent cytolysins, examples of which include, but are not limited to:

Porcine meningitis, septicaemia/bacteraemia and septic shock caused by *Streptococcus suis* which produces a cholesterol dependent cytolysin, Suilysin, involved in the pathogenesis of diseases by *S. suis*.

- 5 Encephalitis, enteritis, meningitis, septicaemia/bacteraemia and pneumonia caused by *Listeria monocytogenes* where the cholesterol dependent cytolysin, listeriolysin O (LLO), plays an important role in the pathogenesis of the above diseases.

10 The compounds of the invention may well also be useful for the inhibition of other bacterial pore-forming toxins, such as the RTX family of toxins, which are essential in the virulence of their host. Examples include, but are not limited to, pneumonia and septicaemia/bacteraemia caused by *Staphylococcus aureus*, which produces the pore-forming toxin staphylococcal α -hemolysin and peritonitis caused by pathogenic *Escherichia coli* which produces the pore forming toxin α -hemolysin.

15

Thus the invention provides:

-A compound of the invention for use in the treatment of bacterial infections caused by bacteria producing pore-forming toxins, wherein the bacterial infection is caused by *Streptococcus* spp. (e.g. *Streptococcus pneumoniae*, Group A Streptococci or *Streptococcus* 20 *suis*), *Clostridium* spp. (e.g. *Clostridium perfringens*), *Listeria* spp. (e.g. *Listeria monocytogenes*) or *Bacillus* spp. (e.g. *Bacillus anthracis*);

-A compound of the invention for the treatment of bacterial infection which is caused by *Streptococcus pneumoniae*;

25 -A compound of the invention for use in the treatment of pneumococcal pneumonia, pneumococcal meningitis, pneumococcal septicaemia/bacteraemia, pneumococcal keratitis or pneumococcal otitis media; and

30 -A compound of the invention for the treatment of conditions selected from gas gangrene, gastrointestinal anthrax, inhalational anthrax, porcine meningitis, encephalitis, septicaemia/bacteraemia and pneumonia which are caused by bacteria other than pneumococcus.

35 The compounds of the invention may be used to treat either humans or animals, such as domestic animals or livestock, e.g. pigs, cows, sheep, horses etc, and references to pharmaceutical compositions should be interpreted to cover compositions suitable for either human or animal use.

Thus, in a further aspect, the present invention provides a compound of formula (I) without provisos a) to i) for use in the treatment of the above mentioned conditions.

40 In a further aspect, the present invention provides a compound of formula (I) without provisos a) to i) for the manufacture of a medicament for the treatment of the above mentioned conditions.

45 In a further aspect, the present invention provides a method of treatment of the above mentioned conditions which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) without provisos a) to i) or a pharmaceutical composition thereof.

The word "treatment" is intended to embrace prophylaxis as well as therapeutic treatment.

The compounds of the invention may be used either alone or in combination with further
5 therapeutically active ingredients. Thus compounds of the invention may be administered in
combination, simultaneously, sequentially or separately, with further therapeutically active
ingredients either together in the same formulation or in separate formulations and either via the
same route or via a different route of administration. The compounds of the invention may thus
be administered in combination with one or more other active ingredients suitable for treating
10 the above mentioned conditions. For example, possible combinations for treatment include
combinations with antimicrobial agents, e.g. antibiotic agents, including natural, synthetic and
semisynthetic antimicrobial agents. Examples of antibiotic agents include β -lactams including,
but not limited to, penicillin, benzylpenicillin, amoxicillin and all generations thereof; β -lactams in
combination with β -lactamase inhibitors including, but not limited to, clavulanic acid and
15 sulbactam; cephalosporins including, but not limited to, cefuroxime, cefotaxime and ceftriaxone;
fluoroquinolones including, but not limited to, levofloxacin and moxifloxacin; tetracyclines
including, but not limited to, doxycycline; macrolides including, but not limited to, erythromycin
and clarithromycin; lipopeptide antibiotics including, but not limited to, daptomycin;
aminoglycosides including, but not limited to, kanamycin and gentamicin; glycopeptide
20 antibiotics, including but not limited to, vancomycin; lincosamides including, but not limited to,
clindamycin and lincomycin; rifamycins including, but not limited to, rifampicin; and
chloramphenicol.

Further combinations include combinations with immunomodulatory agents, such as anti-
25 inflammatory agents.

Immunomodulatory agents can include for example, agents which act on the immune system,
directly or indirectly, by stimulating or suppressing a cellular activity of a cell in the immune
system, for example, T-cells, B-cells, macrophages, or antigen presenting cells, or by acting
30 upon components outside the immune system which, in turn, stimulate, suppress, or modulate
the immune system, for example, hormones, receptor agonists or antagonists and
neurotransmitters, other immunomodulatory agents can include immunosuppressants or
immunostimulants. Anti-inflammatory agents include, for example, agents which treat
inflammatory responses, tissue reaction to injury, agents which treat the immune, vascular or
35 lymphatic systems or combinations thereof. Examples of anti-inflammatory and
immunomodulatory agents include, but are not limited to, interferon derivatives such as
betaseron, β -interferon, prostane derivatives such as iloprost and cicaprost, corticosteroids such
as prednisolone, methylprednisolone, dexamethasone and fluticasone, COX2 inhibitors,
immunosuppressive agents such as cyclosporine A, FK-506, methoxsalene, thalidomide,
40 sulfasalazine, azathioprine and methotrexate, lipoxigenase inhibitors, leukotriene antagonists,
peptide derivatives such as ACTH and analogs, soluble TNF (tumor necrosis factor) -receptors,
TNF-antibodies, soluble receptors of interleukines, other cytokines and T-cell-proteins,
antibodies against receptors of interleukins, other cytokines and T-cell-proteins. Further anti-
inflammatory agents include non-steroidal anti-inflammatory drugs (NSAID's). Examples of
45 NSAID's include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors
e.g. theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors, leukotriene antagonists,

inhibitors of leukotriene synthesis such as montelukast, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists such as adenosine 2a agonists, cytokine antagonists e.g. chemokine antagonists, such as CCR3 antagonists, or inhibitors of cytokine synthesis, and 5-lipoxygenase inhibitors.

5

Thus an aspect of the invention provides a compound of formula (I) without provisos a) to i) in combination with one or more further active ingredients, for example one or more of the active ingredients described above.

10 Another aspect of the invention provides a pharmaceutical composition comprising a compound of formula (I) without provisos a) to i) optionally in combination with one or more pharmaceutically acceptable adjuvants, diluents or carriers and comprising one or more other therapeutically active ingredients.

15 Similarly, another aspect of the invention provides a combination product comprising:
 (A) a compound of formula (I) without provisos a) to i); and
 (B) another therapeutic agent,
 wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

20

In this aspect of the invention, the combination product may be either a single (combination) pharmaceutical formulation or a kit-of-parts.

Thus, this aspect of the invention encompasses a pharmaceutical formulation including a
 25 compound of the present invention and another therapeutic agent, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier (which formulation is hereinafter referred to as a "combined preparation").

It also encompasses a kit of parts comprising components:

30 (i) a pharmaceutical formulation including a compound of formula (I) without provisos a) to i) in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and
 (ii) a pharmaceutical formulation including another therapeutic agent, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier;
 which components (i) and (ii) are each provided in a form that is suitable for administration in
 35 conjunction with the other.

Component (i) of the kit of parts is thus component (A) above in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier. Similarly, component (ii) is component (B) above in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

40

The other therapeutic agent (i.e. component (B) above) may be, for example, any of the agents e.g. antimicrobial or immunomodulatory agents mentioned above.

The combination product (either a combined preparation or kit-of-parts) of this aspect of the
 45 invention may be used in the treatment or prevention of any of the conditions mentioned above.

The compounds of formula (I) without provisos a) to i) may also be provided for use, e.g. with instructions for use, in combination with one or more further active ingredients.

Thus a further aspect of the invention provides a compound of formula (I) without provisos a) to i) for use in combination with one or more further active ingredients, for example one or more of the active ingredients described above.

The compound of formula (I) without provisos a) to i) for use in this aspect of the invention may be used in the treatment or prevention of any of the conditions mentioned above.

The invention will now be described by reference to the following examples which are for illustrative purposes and are not to be construed as a limitation of the scope of the present invention.

15 Examples

Abbreviations

	AcOH	glacial acetic acid
20	aq.	aqueous
	Bn	benzyl
	br	broad
	Boc	<i>tert</i> -butoxycarbonyl
	COPD	chronic obstructive pulmonary disease
25	d	doublet
	DCM	dichloromethane
	DIPEA	<i>N,N</i> -diisopropylethylamine
	DMAP	4-dimethylaminopyridine
	DMF	<i>N,N</i> -dimethylformamide
30	DMSO	dimethylsulfoxide
	EtOAc	ethyl acetate
	h	hour(s)
	HATU	<i>N,N,N',N'</i> -tetramethyl- <i>O</i> -(7-azabenzotriazol-1-yl)uronium PF ₆
	HPLC	high performance liquid chromatography
35	m	multiplet
	MeCN	acetonitrile
	MeOH	methanol
	min	minute(s)
	NMR	nuclear magnetic resonance
40	quin.	quintet
	RT	room temperature
	s	singlet
	sat.	saturated
	SAX	solid supported strong cation exchange resin
45	sept.	septet
	sext.	sextet

t	triplet
TFAA	trifluoroacetic acid anhydride
THF	tetrahydrofuran

5 General Procedures

All starting materials and solvents were obtained from commercial sources or prepared according to literature conditions.

- 10 Hydrogenations were performed either on a Thales H-cube flow reactor or with a suspension of the catalyst under a balloon of hydrogen.

Column chromatography was performed on pre-packed silica (230-400 mesh, 40-63 μ M) cartridges.

15

Analytical Methods

Reverse Phase High Performance Liquid Chromatography:

- 20 Agilent Zorbax Extend RRHT column 1.8 μ m (4.6x30 mm) flow rate 2.5 mL/min eluting with a H₂O-MeCN gradient containing 0.1% v/v formic acid employing UV detection at 215 and 254 nm.

¹H NMR Spectroscopy:

- 25 NMR spectra were recorded using a Bruker Avance III 400 MHz instrument, using either residual non-deuterated solvent or tetra-methylsilane as reference.

Chemical Synthesis:


The compounds of formula (I) were prepared using the following general methods:

30

Example A: *N*²,*N*²,*N*⁵,*N*⁵-Tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide (**UL1-003**)

WO 2013/083975

PCT/GB2012/053022



Step (i): 3,4-Bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylic acid (**2**)

- 5 A mixture of diethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**1**) (2.8 g, 5.29 mmol), 2M NaOH (aq.) (26.4 mL, 52.9 mmol), in ethanol (12 mL) and THF (20 mL) was stirred at 60°C for 72 h. After cooling to RT, the mixture was acidified with 6M HCl (aq.) and the resulting precipitate was collected by filtration, washed with water (5 mL), and Et₂O (5 mL) to afford 4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylic acid (**2**) (1.94 g, 67 %)
- 10 % as an off-white solid: *m/z* 474 (*M*+*H*)⁺ (*ES*⁺); 472 (*M*-*H*)⁻ (*ES*⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.61 (s, 2H), 7.46-7.40 (m, 4H), 7.39-7.29 (m, 6H), 7.16-7.07 (m, 2H), 6.92-6.84 (m, 2H), 5.07 (s, 4H), 3.78 (s, 3H).

Step (ii): 3,4-Bis(benzyloxy)-*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide (**UL-046**)


15

- To a solution of 4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylic acid (**2**) (400 mg, 0.85 mmol) and DIPEA (386 μL, 2.11 mmol) in DMF (4 mL) was added HATU (803 mg, 2.11 mmol) followed by diethylamine (219 μL, 2.11 mmol). The reaction mixture was stirred at
- 20 RT for 1h and then partitioned between Et₂O (50 mL) and sat. NaOAc (aq.) (30 mL). The organic phase was washed successively with sat. NaOAc (aq.) (20 mL), sat. NaHCO₃ (aq.) (20 mL) and brine (2 x 20 mL), dried (MgSO₄), filtered and concentrated *in vacuo* to afford the crude product. The residue was purified by silica gel chromatography (12 g, 30% EtOAc/isohexane) to afford 3,4-bis(benzyloxy)-*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
- 25 dicarboxamide (**UL1-046**) (201 mg, 41 %) as a yellow solid: *m/z* 584 (*M*+*H*)⁺ (*ES*⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.47-7.22 (m, 10H), 7.09-6.99 (m, 2H), 6.94-6.76 (m, 2H), 4.97 (s, 4H), 3.74 (s, 3H), 3.29-3.03 (m, 8H), 0.98-0.71 (m, 12H).

Step (iii): *N*²,*N*²,*N*⁵,*N*⁵-Tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide (**UL1-003**)

A solution of 3,4-bis(benzyloxy)-*N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide **UL1-046** (50 mg, 0.086 mmol) in methanol/DCM (4 mL/4 mL) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1 mL/min at 25°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford *N*²,*N*²,*N*⁵,*N*⁵-tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide (**UL1-003**) (32 mg, 93 %) as a light yellow solid: *m/z* 404 (M+H)⁺ (ES⁺); 402 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.26 (s, 2H), 6.96-6.88 (m, 2H), 6.87-6.81 (m, 2H), 3.72 (s, 3H), 3.27 (q, *J* = 7.1 Hz, 8H), 0.96 (t, *J* = 7.0 Hz, 12H).

Example B: Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**)



Step (i): Diethyl 2,2'-((4-methoxyphenyl)azanediyl)diacetate (**4**)

Ethyl 2-bromoacetate (146 mL, 1.3 mol) was added dropwise to a stirred solution of 4-methoxyaniline (**3**) (75 g, 0.61 mol) and DIPEA (265 mL, 1.5 mol) in MeCN (300 mL). The

reaction mixture was stirred at 60°C for 16h and then partitioned between 2 M HCl (aq.) (500 mL), and EtOAc (300 mL), the aqueous phase was extracted with EtOAc (300 mL) and the combined organics were washed succesively with 2 M HCl (aq.) (2 x 300 mL), water (500 mL), and brine (500 mL), dried (MgSO₄), filtered and solvents removed *in vacuo* to give diethyl 2,2'-((4-methoxyphenyl)azanediyl)diacetate (4) (180 g, 100 %) as a purple oil: m/z 296 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ 6.82-6.78 (m, 2H), 6.64-6.59 (m, 2H), 4.19 (q, J = 7.1 Hz, 4H), 4.10 (s, 4H), 3.74 (s, 3H), 1.27 (t, J = 7.1 Hz, 6H).

Step (ii): Diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-001**)

Diethyl oxalate (83 ml, 0.61 mol) was added dropwise to a stirred solution of diethyl 2,2'-((4-methoxyphenyl)azanediyl)diacetate (4) (180 g, 0.61 mol) in NaOEt (21% by wt in EtOH) (506 ml, 1.3 mol), the mixture was stirred at 100°C for 1h. The reaction was quenched with acetic acid (210 ml, 3.7 mol) and the resulting suspension was poured into iced water (1 L), the resulting off-white solid collected by vacuum filtration. The crude product was recrystallised from hot EtOH (3.5 L) to give diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-001**) (152 g, 71 %) as a white solid: m/z 350 (M+H)⁺ (ES⁺); 348 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.64 (s, 2H), 7.13-7.01 (m, 2H), 6.92-6.81 (m, 2H), 3.99 (q, J = 7.1 Hz, 4H), 3.78 (s, 3H), 0.99 (t, J = 7.1 Hz, 6H).

Step (iii): Diethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (1)

Benzyl bromide (42.6 ml, 358 mmol) was added dropwise to a stirred suspension of 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-001**) (50 g, 143 mmol) and K₂CO₃ (49.5 g, 358 mmol) in DMF (1 L), the reaction mixture was stirred at 60°C for 4h. After cooling to RT the reaction mixture was poured into ether (500 mL) and washed with brine (3 x 250 mL), dried (MgSO₄), filtered and concentrated *in vacuo* to afford a bright yellow solid. The crude product was triturated with isohexane to give diethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (1) (64.8 g, 85 %) as a white solid: m/z 530 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.48-7.29 (m, 10H), 7.17-7.09 (m, 2H), 6.95-6.87 (m, 2H), 5.09 (s, 4H), 3.99 (q, J = 7.1 Hz, 4H), 3.80 (s, 3H), 0.99 (t, J = 7.1 Hz, 6H).

Step (iv): Triethylammonium 3,4-bis(benzyloxy)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (5)

To a solution of diethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (1) (39.6 g, 74.8 mmol) in THF/EtOH (300/50 mL) was added NaOH (3.07 g, 77 mmol) as a solution in water (20 mL). The reaction was stirred at 50°C for 16h. Triethylamine was added (30 mL, 215 mmol) and the volatiles were removed *in vacuo*. The residue was purified by silica gel chromatography (50% isohexane:DCM (+2% Et₃N), then 20% MeOH/EtOAc (+2% Et₃N)) to afford triethylammonium 3,4-bis(benzyloxy)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (5) (39.3 g, 83 %) as a yellow oil: m/z 502 (M+H)⁺ (ES⁺); 500 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.51-7.26 (m, 10H), 7.11-7.05 (m, 2H), 6.92-6.83 (m, 2H), 5.09 (s, 2H), 5.06 (s, 2H), 3.95 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 2.85-2.62 (m, 6H), 1.08-0.92 (m, 12H).


Step (v): Ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (6)

To a solution of triethylammonium 3,4-bis(benzyloxy)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (5) (10.84 g, 17.99 mmol) in DMF (150 mL), at 0°C was added HATU (10.26 g, 27.0 mmol), dimethylamine hydrochloride (2.93 g, 36.0 mmol) and DIPEA (18.8 mL, 108 mmol). The reaction mixture was stirred at RT for 16h and partitioned between EtOAc (500 mL) and 1M HCl (aq.) (250 mL). The organic phase was washed successively with 1M HCl (aq.) (250 mL), sat. NaHCO₃ (aq.) (2 x 250 mL), and brine (2 x 250 mL), dried (MgSO₄), filtered and concentrated *in vacuo* to afford ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (6) (7.62 g, 79 %) as a light yellow oil, that solidified on standing: *m/z* 529 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.51-7.21 (m, 10H), 7.14-7.03 (m, 2H), 6.94-6.84 (m, 2H), 5.12 (s, 2H), 4.96 (s, 2H), 4.00 (q, *J* = 7.1 Hz, 2H), 3.77 (s, 3H), 2.70 (s, 6H), 1.00 (t, *J* = 7.1 Hz, 6H).

Step (vi): Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-012)

Ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (6) (1.03 g, 1.94 mmol) was dissolved in EtOH and then treated with 10% Pd/C (37 mg). The reaction mixture was purged with N₂ for 5 min then Hydrogen gas was bubbled through the mixture with stirring at RT for 1.5h. The mixture was filtered through Celite and concentrated *in vacuo*. The residual yellow solid was triturated with Et₂O to afford ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-012) (602 mg, 89 %) as a white solid: *m/z* 349 (M+H)⁺ (ES⁺), 347 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.60 (s, 1H), 8.46 (s, 1H), 7.08-7.01 (m, 2H), 6.90-6.82 (m, 2H), 4.00 (q, *J* = 7.0 Hz, 2H), 3.76 (s, 3H), 2.83 (br s, 6H), 0.99 (t, *J* = 7.1 Hz, 6H).

Example C: *N*²-Ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide (UL1-024)



Step (i): 3,4-Bis(benzyloxy)-*N*²-ethyl-1-(4-methoxyphenyl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide (UL1-055)

To a stirred suspension of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (6) (200 mg, 0.38 mmol) and ethylamine hydrochloride (61.7 mg, 0.75


mmol) in THF (2 mL) was added isopropylmagnesium chloride (2 M in THF) (757 μ L, 1.51 mmol) and the reaction stirred at RT for 2h, further portions of ethylamine hydrochloride (120 mg, 1.5 mmol) and isopropylmagnesium chloride (2 M in THF) (1.5 mL, 3.0 mmol) were added and the reaction stirred for 16h at RT. The reaction mixture was partitioned between sat. NH_4Cl solution (aq.) (5 mL) and EtOAc (20 mL) the aqueous was further acidified with 1 M HCl (5 mL).
 5 The organic layer was separated and washed with brine (25 mL), dried (MgSO_4), filtered and concentrated *in vacuo* to afford crude product. The residue was purified by silica gel chromatography (25 g, 30-80% EtOAc in isohexane) to afford 3,4-bis(benzyloxy)- N^2 -ethyl-1-(4-methoxyphenyl)- N^5 , N^5 -dimethyl-1*H*-pyrrole-2,5-dicarboxamide (**UL1-055**) (192 mg, 95 %) as a
 10 yellow oil: m/z 528 ($\text{M}+\text{H}^+$) (ES^+). ^1H NMR (400 MHz, CDCl_3) δ : 7.44-7.30 (m, 10H), 7.20-7.09 (m, 2H), 7.06-6.97 (m, 1H), 6.89-6.80 (m, 2H), 5.20 (s, 2H), 5.07 (s, 2H), 3.79 (s, 3H), 3.25-3.14 (m, 2H), 2.79 (s, 3H), 2.72 (s, 3H), 0.97 (t, $J = 7.3$ Hz, 3H).

Step (ii) N^2 -Ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)- N^5 , N^5 -dimethyl-1*H*-pyrrole-2,5-dicarboxamide (**UL1-024**)
 15

A solution of 3,4-bis(benzyloxy)- N^2 -ethyl-1-(4-methoxyphenyl)- N^5 , N^5 -dimethyl-1*H*-pyrrole-2,5-dicarboxamide (**UL1-055**) (118 mg, 0.22 mmol) in methanol (4.5 mL) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1 mL/min at 30°C under H_2 (full H_2 mode).
 20 The output was concentrated *in vacuo* to afford N^2 -ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)- N^5 , N^5 -dimethyl-1*H*-pyrrole-2,5-dicarboxamide (**UL1-024**) (66 mg, 82 %) as a brown solid: m/z 348 ($\text{M}+\text{H}^+$) (ES^+); 346 ($\text{M}-\text{H}^-$) (ES^-). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 9.44 (s, 1H), 8.42 (s, 1H), 7.10-7.03 (m, 1H), 7.02-6.97 (m, 2H), 6.86-6.77 (m, 2H), 3.75 (s, 3H), 3.14-3.06 (m, 2H), 2.81 (br s, 6H), 0.97 (t, $J = 7.2$ Hz, 3H).

25

Example D: isopropyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-035**)



30

Step (i): Isopropyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**8**)


To a stirred suspension of triethylammonium 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**7**) [prepared as example B-step (iv) using ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**6**) as starting material] (360 mg, 0.60 mmol) and Cs_2CO_3 (429 mg, 1.32 mmol) in DMF (3 mL) was added 2-bromopropane (197 μ L, 2.10 mmol) and the reaction stirred at 40°C for 2h then
 35

partitioned between EtOAc (50 mL) and water (20 mL). The organic was separated and washed with water (2 x 50 mL), brine (2 x 50 mL), dried (MgSO₄), filtered and concentrated *in vacuo* to afford a yellow oil. The residue was purified by silica gel chromatography (40 g, 20-60% EtOAc in isohexane) to afford isopropyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (8) (108 mg, 33 %) as a yellow oil: ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.51-7.43 (m, 2H), 7.43-7.28 (m, 8H), 7.19-7.05 (m, 2H), 6.96-6.84 (m, 2H), 5.13 (s, 2H), 4.96 (s, 2H), 4.85 (sept., J = 6.2 Hz, 1H), 3.78 (s, 3H), 2.72 (s, 3H), 2.71 (s, 3H), 1.10 (d, J = 6.2 Hz, 6H).

10 Step (ii): Isopropyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-035)

A solution of isopropyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (8) (130 mg, 0.240 mmol) in methanol (5 mL) was passed through a
 15 Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1 mL/min at 30°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford isopropyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-035) (69 mg, 79 %) as a white solid: m/z 363 (M+H)⁺ (ES⁺); 361 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.60 (s, 1H), 8.42 (s, 1H), 7.10-6.99 (m, 2H), 6.91-6.82 (m, 2H), 4.83 (sept., J = 6.2 Hz, 1H), 3.77 (s, 3H), 2.83 (br s, 6H),
 20 0.96 (d, J = 6.2 Hz, 6H).

Example E: *tert*-Butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonylcarbamate (UL1-030)



25

Step (i): 3,4-Bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (9)

A solution of triethylammonium 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (7) (3.5 g, 6.70 mmol) in acetic acid (100 mL) was stirred at RT for 4h and then 110°C for 1h. The volatiles were removed *in vacuo* and the crude material partitioned between EtOAc (100 mL) and 1M NaOH (aq.) (20 mL)/brine (50 mL), the organic layer was then
 5 dried (MgSO₄), filtered and concentrated *in vacuo* to afford 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (9) (3.05 g, 100 %) as a yellow oil: m/z 457 (M+H)⁺ (ES⁺).

Step (ii): *tert*-Butyl (3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonylcarbamate (10)
 10

To a solution of chlorosulfonyl isocyanate (70.9 µL, 0.82 mmol) at -5°C in anhydrous DCM (4 mL) was added *tert*-butanol (solution in 0.5 mL anhydrous DCM) (81 µL, 0.85 mmol) dropwise over 5 min and the reaction stirred at -5°C for 15 min. After this time, DIPEA (296 µL, 1.70
 15 mmol) was added dropwise. After 15 min a solution of 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (9) (310 mg, 0.68 mmol) in DCM (1 mL) was added and the reaction was allowed to warm to RT and stirred for 16h. The reaction was partitioned between water (10 mL) and DCM (20 mL) and the organic washed with 1 M HCl (aq.) (2 x 20 mL), and brine (10 mL), dried (MgSO₄), filtered and solvent removed *in vacuo* to afford crude
 20 product. The residue was purified by silica gel chromatography (40 g, 0-4% MeOH in DCM) to afford *tert*-butyl (3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonylcarbamate (10) (166 mg, 35 %) as a colourless oil: m/z 636 (M+H)⁺ (ES⁺); 634 (M-H)⁻ (ES⁻).


25 Step (iii): *tert*-Butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonylcarbamate (UL1-030)

tert-Butyl (3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonyl carbamate (10) (166 mg, 0.26 mmol) in methanol (2.5 mL) was passed through a
 30 Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1 mL/min at 30°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford *tert*-butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-2-yl)sulfonylcarbamate (UL1-030) (65 mg, 52 %) as a yellow solid: m/z 456 (M+H)⁺ (ES⁺); 454 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 11.04 (s, 1H), 8.75 (s, 1H), 8.35 (s, 1H), 7.07-7.00 (m, 2H), 6.92-6.86 (m, 2H), 3.77 (s, 3H), 2.80 (br s, 6H),
 35 1.35 (s, 9H).

Example F: 5-Cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (UL1-031)

WO 2013/083975

PCT/GB2012/053022



Step (i): 3,4-Bis(benzyloxy)-1-(4-methoxyphenyl)-N²,N²-dimethyl-1H-pyrrole-2,5-dicarboxamide (11)

- 5 3,4-Bis(benzyloxy)-1-(4-methoxyphenyl)-N²,N²-dimethyl-1H-pyrrole-2,5-dicarboxamide (11) was prepared using the same procedure as Example B step (iv) except using triethylammonium 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (7) (570 mg, 0.76 mmol) and ammonium chloride (405 mg, 7.58 mmol) to afford 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-N²,N²-dimethyl-1H-pyrrole-2,5-dicarboxamide (11) as yellow oil: m/z 500 (M+H)⁺ (ES⁺).

Step (ii): 3,4-Bis(benzyloxy)-5-cyano-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (12)


- 15 Trifluoroacetic anhydride (27.0 μ L, 0.19 mmol) was added dropwise to a stirred solution of 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-N²,N²-dimethyl-1H-pyrrole-2,5-dicarboxamide (11) (88 mg, 0.18 mmol) and triethylamine (74.3 μ L, 0.53 mmol) in DCM (4 mL) at 0°C. The reaction mixture was stirred for 1h before and trifluoroacetic anhydride (27.0 μ L, 0.19 mmol) was added and the mixture allowed to warm to RT. The reaction was partitioned between sat. NaHCO₃ (aq.) (5 mL) and DCM (5 mL) the organic layer was separated and volatiles removed *in vacuo* to afford 4-bis(benzyloxy)-5-cyano-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (12) (85 mg, 100 %), as a yellow oil: m/z 482 (M+H)⁺ (ES⁺).

Step (iii): 5-Cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (UL1-031)

- 4-Bis(benzyloxy)-5-cyano-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (12) (85 mg, 0.17 mmol) in methanol (2 mL) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1.5 mL/min at 25°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford 5-cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-

carboxamide (**UL1-031**) (11 mg, 21 %) as a yellow solid: m/z 302 ($M+H$)⁺ (ES^+); 300 ($M-H$)⁻ (ES^-). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 9.80 (s, 1H), 8.80 (s, 1H), 7.21-7.11 (m, 2H), 7.03-6.93 (m, 2H), 3.79 (s, 3H), 2.88 (br s, 6H).

5 Example G: 3,4-Dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile (**UL1-034**)



Step (i): 3,4-Bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile (14)

10 To a stirred solution of 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide (13) [*prepared using the same procedure as Example A step (ii) using ammonium chloride*] (267 mg, 0.57 mmol) and triethylamine (710 μ L, 5.10 mmol) in DCM (8 mL) at 0°C was added trifluoroacetic anhydride (240 μ L, 1.70 mmol) and the reaction allowed to warm to RT over 30 min. The reaction mixture was partitioned between DCM (50 mL) and 1 M HCl (aq.) (30 mL), the organic was washed with 1 M HCl (aq.) (20 mL), sat. NaHCO₃ (aq.) (30 mL), and brine (20 mL), dried (MgSO₄), filtered and volatiles removed *in vacuo* to afford a yellow solid. The crude residue was purified by silica gel chromatography (40 g, 0-50% EtOAc in isohexane) to afford 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile (14) (240 mg, 97 %) as a pale yellow solid: ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.47-7.27 (m, 10H), 7.30-7.20 (m, 2H), 7.05-6.91 (m, 2H), 5.26 (s, 4H), 3.79 (s, 3H).

Step (ii): 3,4-Dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile (**UL1-034**)


25 3,4-Bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile (14) (70 mg, 0.16 mmol) in THF (5 mL) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1.5 mL/min at 25°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford the crude product. The compound was purified by preparative HPLC (C-18 column, 21.2 mm i.d. x 100 mm, 5 micron particle size, gradient 5-95 % MeCN in 0.1 % aqueous formic acid over 16 min) to afford 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile (**UL1-034**) (6 mg, 14%) as a yellow powder: m/z 254 ($M-H$)⁻ (ES^-). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.44-7.36 (m, 2H), 7.14-7.05 (m, 2H).

Example H: Ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate (**UL1-039**)

35

WO 2013/083975

PCT/GB2012/053022



Step (i): Ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate (**UL1-060**)

5


To a stirred solution of ethyl 3,4-bis(benzyloxy)-5-carbamoyl-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate (**15**) (1.1 g, 2.25 mmol) [*prepared using the same procedure as Example B step (v) using triethylammonium 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-fluorophenyl)-1H-pyrrole-2-carboxylate and ammonium chloride*] and triethylamine (1.26 mL, 9.0 mmol) in DCM (60 mL) at 0°C was added trifluoroacetic anhydride (0.48 mL 3.38 mmol). The reaction mixture was allowed to warm to RT and partitioned between 1M HCl (aq.) (25 mL) and DCM (50 mL) the organic layer was washed with 1M HCl (aq.), and sat. NaHCO₃ (aq.) (25 mL), dried (MgSO₄), filtered and the volatiles removed *in vacuo* to afford the crude product. The crude residue was purified by silica gel chromatography (40 g, 0-20% EtOAc in isohexane) to afford ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate (**UL1-060**) (1.01 g, 94 %) as yellow solid: *m/z* 471 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.57-7.27 (m, 14H), 5.27 (s, 2H), 5.11 (s, 2H), 4.05 (q, *J* = 7.1 Hz, 2H), 1.00 (t, *J* = 7.1 Hz, 3H).

Step (ii): Ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate (**UL1-039**)

20


Ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate (**UL1-060**) (102 mg, 0.22 mmol) in THF (5 mL) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1.5 mL/min at 20°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford the crude product. The crude residue was purified by silica gel chromatography (4 g, 0-35% EtOAc in isohexane) to afford ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate (**UL1-039**) (18 mg, 29 % yield) as a white solid: *m/z* 291 (M+H)⁺ (ES⁺); 289 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.14 (s, 1H), 8.99 (s, 1H), 7.44-7.36 (m, 2H), 7.35-7.26 (m, 2H), 4.05 (q, *J* = 7.1 Hz, 2H), 1.01 (t, *J* = 7.1 Hz, 3H).

Example I: *tert*-Butyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-036**)




To a solution of *tert*-butyl 2-((2-(dimethylamino)-2-oxoethyl)(4-methoxyphenyl)amino)acetate (16) (1.98 g, 6.14 mmol) and di-*tert*-butyl oxalate (1.37 g, 6.76 mmol) in anhydrous *tert*-butanol (6 mL) was added potassium *tert*-butoxide (20 wt. % in THF) (10.77 mL, 15.35 mmol) and the reaction was stirred at 100°C for 1.5 h, di-*tert*-butyl oxalate (300 mg, 1.5 mmol), potassium *tert*-butoxide (20 wt. % in THF) (4 mL, 5.71 mmol), THF (10 mL), and *tert*-butanol (4 mL) were added and the mixture stirred for a further 1h. The mixture was allowed to cool to RT and acetic acid (4 mL, 69.9 mmol) added, the mixture was poured on to ice-cold water (50 mL) and the resulting precipitate was collected by vacuum filtration and recrystallised from hot ethanol to afford *tert*-butyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-036) (890 mg, 37 %) as a white powder: *m/z* 377 (*M*+*H*)⁺ (ES⁺); 375 (*M*-*H*)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.62 (s, 1H), 8.45 (s, 1H), 7.12-6.99 (m, 2H), 6.94-6.81 (m, 2H), 3.76 (s, 3H), 2.83 (br s, 6H), 1.17 (s, 9H).

Example J: 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl diacetate (UL1-044)



To a suspension of ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-012) (120 mg, 0.35 mmol) in acetic anhydride (1 mL, 10.6 mmol) was added NaOAc (90 mg, 1.06 mmol), the suspension was stirred at 100°C for 2h. The reaction mixture was partitioned between DCM (25 mL) and iced water (25 mL), dried (MgSO₄), filtered and volatiles removed *in vacuo* to afford a colourless oil. Trituration of the colourless oil from Et₂O gave 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl diacetate (UL1-044) (80 mg, 52 %) as a white solid: *m/z* 433 (*M*+*H*)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.27-7.11 (2H, m), 7.00-6.88 (2H, m), 4.00 (q, *J* = 7.1 Hz, 2H), 3.79 (s, 3H), 2.79 (s, 3H), 2.71 (s, 3H), 2.26 (s, 6H) 1.05 (t, *J* = 7.1 Hz, 3H).

Example K: Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**)



5

Step (i): Ethyl 2-((4-methoxyphenyl)amino)acetate (**17**)

To a solution of sodium iodide (122 g, 0.81 mol) and sodium acetate trihydrate (221 g, 1.62 mol) in water (200 mL) was added 4-methoxyaniline (**3**) (100 g, 0.81 mol) followed by ethyl 2-bromoacetate (90 mL, 812 mmol) the reaction was stirred at 90°C for 3h. The reaction mixture was cooled to RT and partitioned with EtOAc (1 L), the organic phase was separated, washed with water (400 mL), 1 M HCl (aq.) (3 x 500 mL), and the organic phase discarded. The combined acidic extracts were cooled to 0°C and solid NaOH was added to pH 14 and the aqueous phase was extracted with EtOAc (3 x 400 mL). The combined organics were washed with brine (250 mL), dried (MgSO₄), filtered and solvents removed *in vacuo* to give ethyl 2-((4-methoxyphenyl)amino)acetate (**17**) (128 g, 75 %) as a purple oil that crystallised on standing: *m/z* 210 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 6.75-6.69 (m, 2H), 6.55-6.46 (m, 2H), 3.99 (t, *J* = 6.5 Hz, 1H), 4.10 (q, *J* = 7.1 Hz, 2H), 3.82 (d, *J* = 6.5 Hz, 2H), 3.63 (s, 3H), 1.19 (t, *J* = 7.1 Hz, 3H).

20

Step (ii): 2-((4-Methoxyphenyl)amino)acetic acid (**18**)

2M NaOH (aq.) (149 mL, 0.30 mol) was added dropwise to a stirred solution of ethyl 2-((4-methoxyphenyl)amino)acetate (**17**) (59.2 g, 0.28 mol) in EtOH/THF (300 mL/80 mL). The reaction was stirred at 40°C for 3h. The mixture was diluted with water (100 mL) and phosphoric acid (85 % wt in water) (35.9 g, 0.31 mol) was added to pH 3. The resulting brown precipitate was collected by filtration and washed with water (100 mL) and dried under vacuum to give 2-((4-methoxyphenyl)amino)acetic acid (**18**) (45.5 g, 84 %) as a brown solid: *m/z* 182 (M+H)⁺ (ES⁺); 180 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 6.78-6.64 (m, 2H), 6.55-6.44 (m, 2H), 3.74 (s, 2H), 3.64 (s, 3H).

30

Step (iii): 2-((4-Methoxyphenyl)amino)-*N,N*-dimethylacetamide (**19**)

To a stirred suspension of 2-((4-methoxyphenyl)amino)acetic acid (18) (45 g, 0.25 mol) and dimethylamine hydrochloride (40.5 g, 0.5 mol) in acetonitrile (1 L) at 0°C, was added DIPEA (174 ml, 0.99 mol) followed by HATU (99 g, 0.26 mol). The reaction mixture was stirred at RT for 1 h, and then partitioned between EtOAc (1 L) and 5% NaH₂PO₄ (aq.) (250 mL), the organic layer was washed with sat. NaHCO₃ (aq.) (3 x 300 mL), and 3M HCl (aq.) (4 x 250 mL). The combined acidic extracts were cooled to 0°C and solid NaOH was added to pH 14 and the aqueous phase was extracted with EtOAc (3 x 400 mL), the combined organics were washed with brine (500 mL) dried (MgSO₄), filtered and solvents removed *in vacuo* to give 2-((4-methoxyphenyl)amino)-*N,N*-dimethylacetamide (19) (37.1g, 71 %) as a brown solid: m/z 209 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 6.74-6.70 (m, 2H), 6.65-6.59 (m, 2H), 5.10 (br s, 1H), 3.81 (s, 2H), 3.64 (s, 3H), 3.01 (s, 3H), 2.87 (s, 3H).


Step (iv): Ethyl 2-((2-(dimethylamino)-2-oxoethyl)(4-methoxyphenyl)amino)acetate (20)

To a stirred solution of 2-(4-methoxyphenylamino)-*N,N*-dimethylacetamide (19) (10.7 g, 51.2 mmol) in MeCN (80 mL) and DIPEA (13.4 ml, 77 mmol) was added ethyl bromoacetate (6.84 ml, 61.4 mmol) the reaction was stirred at 60°C for 16h. The volatiles were removed *in vacuo*, and the crude mixture was dissolved in EtOAc (150 mL), washed with 1M HCl (aq.) (150 mL), brine (150 mL), dried (MgSO₄), filtered and solvents removed *in vacuo* to afford a purple oil. The residue was purified by silica gel chromatography (120 g, 60-100% EtOAc in isohexane) to afford ethyl 2-((2-(dimethylamino)-2-oxoethyl)(4-methoxyphenyl)amino)acetate (X) (12.9 g, 85 %) as a purple oil: m/z 295.4 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 6.81-6.71 (m, 2H), 6.60-6.47 (m, 2H), 4.24-3.96 (m, 6H), 3.66 (s, 3H), 2.99 (br s, 3H), 2.83 (br s, 3H), 1.19 (t, J = 7.1 Hz, 3H).

Step (v): Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**)

Diethyl oxalate (2.54 ml, 18.6 mmol) was added dropwise to a stirred solution of ethyl 2-((2-(dimethylamino)-2-oxoethyl)(4-methoxyphenyl)amino)acetate (20) (5.21 g, 17.7 mmol) in NaOEt (21% by wt in EtOH) (27.8 ml, 74.3 mmol), the mixture was stirred at 85°C for 1.5h. The reaction was quenched with acetic acid (10.1 ml, 177 mmol) and the resulting suspension was poured into iced water (200 mL), and extracted with EtOAc (3 x 100 mL), combined organics were washed with brine (200 mL), dried (MgSO₄), filtered and solvents removed *in vacuo* to afford a brown oil. The residue was purified by silica gel chromatography (80 g, 0-10% MeOH (+1% NH₃) in DCM) to afford ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**) (3.64 g, 53 %) as a white solid: m/z 349 (M+H)⁺ (ES⁺), 347 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.60 (s, 1H), 8.46 (s, 1H), 7.08-7.01 (m, 2H), 6.90-6.82 (m, 2H), 4.00 (q, J = 7.0 Hz, 2H), 3.76 (s, 3H), 2.83 (br s, 6H), 0.99 (t, J = 7.1 Hz, 6H).


Example L: Diisopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-020**) and 2-ethyl 5-isopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-021**)



Lithium isopropoxide (2M in THF) (10.4 mL, 20.8 mmol) was added to a mixture of diisopropyl 2,2'-((4-methoxyphenyl)azanediyl)diacetate (21) (2.69 g, 8.32 mmol) [prepared using the same procedure as Example B step (i) using isopropyl 2-bromoacetate] and diethyl oxalate (1.13 mL, 8.32 mmol), the mixture was stirred at 65°C for 16h. A further portion of lithium isopropoxide (2M in THF) (5.2 mL, 10.4 mmol) was added and the reaction stirred at 65°C for 3h. The reaction was quenched with acetic acid (5 mL) and the volatiles removed *in vacuo*, the crude product was taken up in EtOAc (100 mL) and partitioned with water (100 mL), the aqueous was washed with EtOAc (2 x 100 mL) combined organics were washed with brine (150 mL), dried (MgSO₄), filtered and solvents removed *in vacuo* to afford a brown oil. The crude product was recrystallised from hot *i*-PrOH (50 mL), to provide a white solid. The solid was purified by silica gel chromatography (12 g, 0-50% EtOAc in isohexane) to afford diisopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (**UL2-020**) (21 mg, 1 %) as a white solid: *m/z* 378 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.62 (s, 2H), 7.12-7.01 (m, 2H), 6.93-6.84 (m, 2H), 4.80 (sept., *J* = 6.3 Hz, 2H), 3.78 (s, 3H), 0.95 (d, *J* = 6.2 Hz, 12H).

Impure fractions were combined and purified by preparative HPLC (C-18, 5 μm, 21.2x50 mm column, 5-95% MeCN in Water 0.1% Formic Acid) to afford 2-ethyl 5-isopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (**UL2-021**) (22 mg, 1%) as a white solid: *m/z* 364 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.66 (s, 1H), 8.62 (s, 1H), 7.09-7.03 (m, 2H), 6.90-6.85 (m, 2H), 4.80 (sept., *J* = 6.2 Hz, 1H), 3.98 (q, *J* = 7.1 Hz, 2H), 3.77 (s, 3H), 1.00 (t, *J* = 7.1 Hz, 3H), 0.93 (d, *J* = 6.2 Hz, 6H).

Example M: Diethyl 3-(2-(benzyloxy)ethoxy)-1-(4-fluorophenyl)-4-hydroxy-1H-pyrrole-2,5-dicarboxylate (**UL2-025**)




Step (i) Diethyl 3-(2-(benzyloxy)ethoxy)-1-(4-fluorophenyl)-4-hydroxy-1H-pyrrole-2,5-dicarboxylate (22)

Diisopropyl azodicarboxylate (317 μ L, 1.63 mmol) was added to a solution of diethyl 1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate (**UL2-003**) (500 mg, 1.48 mmol), 2-(benzyloxy)ethanol (232 μ L, 1.63 mmol) and triphenylphosphine (428 mg, 1.63 mmol) in DCM (5 ml), at 0°C. The reaction mixture was allowed to warm to RT and stirred for 1h. The reaction was washed with water (5 mL) and the phases separated using a phase separation cartridge, the organic was concentrated *in vacuo* to afford a yellow oil. The residue was purified by silica gel chromatography (80 g, 0-25% EtOAc in isohexane) to afford diethyl 3-(2-(benzyloxy)ethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-dicarboxylate (**22**) (122 mg, 17 %) as a yellow oil: m/z 472 (M+H)⁺ (ES⁺); 470 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.70 (s, 1H), 7.38-7.26 (m, 5H), 7.24-7.12 (m, 4H), 4.54 (s, 2H), 4.27-4.16 (m, 2H), 4.09-3.89 (m, 4H), 3.78-3.71 (m, 2H), 1.01-0.94 (m, 6H).

Step (ii) Diethyl 1-(4-fluorophenyl)-3-hydroxy-4-(2-hydroxyethoxy)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-025**)

A solution of diethyl 3-(2-(benzyloxy)ethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-dicarboxylate (**22**) (122 mg, 0.26 mmol) in MeOH (120 ml) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1 mL/min at 30°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford diethyl 3-(2-(benzyloxy)ethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-dicarboxylate (**UL2-025**) (122 mg, 85 %) as a pale yellow oil: m/z 382 (M+H)⁺ (ES⁺), 380 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.94 (br s, 1H), 7.29-7.22 (m, 2H), 7.21-7.14 (m, 2H), 5.01 (br s, 1H), 4.08-3.97 (m, 6H), 3.73-3.65 (m, 2H), 1.02 (t, J = 7.1 Hz, 3H), 0.99 (t, J = 7.1 Hz, 3H).

Example N: Diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-031**)



Step (i): Diethyl 3-(benzyloxy)-4-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (23)

- 5 Benzyl bromide (2.13 ml, 17.9 mmol) was added dropwise to a suspension of DIPEA (3.12 mL, 17.9 mmol) and diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (UL2-001) (5 g, 14.3 mmol) in EtOH (200 mL). The reaction mixture was stirred at 50°C for 18h. Additional benzyl bromide (0.85 mL, 7.20 mmol) and DIPEA (1.25 mL, 7.20 mmol) were added and the reaction stirred at 60°C for 24h, after which further portions of benzyl bromide (0.85 ml, 7.20 mmol) and DIPEA (1.25 mL, 7.20 mmol) were added and the reaction mixture stirred at 60°C for 24h. The reaction mixture was allowed to cool to RT, and partitioned between EtOAc (200 mL) and sat. NaHCO₃ (aq.) (200 mL), the organic layer was separated and washed with sat. NaHCO₃ (aq.) (2 x 200 mL) dried (MgSO₄), filtered and solvents removed *in vacuo* to give an orange oil. The residue was purified by silica gel chromatography (80 g, 0-100% EtOAc in isohexane) to afford a yellow solid. The product was recrystallised from EtOH (100 mL) to afford diethyl 3-(benzyloxy)-4-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (23) (2.89 g, 37 %) as a pale yellow solid: *m/z* 440 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.82 (s, 1H), 7.52-7.30 (m, 5H), 7.16-7.03 (m, 2H), 6.94-6.83 (m, 2H), 5.09 (s, 2H), 4.10-3.91 (m, 4H), 3.79 (s, 3H), 1.02-0.92 (m, 6H).

Step (ii): Diethyl 3-(benzyloxy)-4-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (UL2-028)

- tert*-Butyl 2-bromoacetate (0.55 ml, 3.41 mmol) was added dropwise to a stirred solution of diethyl 3-(benzyloxy)-4-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate (23) (1.0 g,

2.28 mmol) and K_2CO_3 (0.63 g, 4.55 mmol) in DMF (20 mL). The reaction mixture was stirred at RT for 18h, and partitioned between EtOAc (200 mL) and sat. $NaHCO_3$ (aq.) (200 mL), the organic layer was separated and washed with sat. $NaHCO_3$ (aq.) (2 x 200 mL), dried ($MgSO_4$), filtered and solvents removed *in vacuo* to give a yellow oil. The residue was purified by silica gel chromatography (120 g, 0-20% EtOAc in isohexane) to afford diethyl 3-(benzyloxy)-4-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-028**) (912 mg, 72 %) as a pale yellow oil: m/z 554 ($M+H$)⁺ (ES^+). ¹H NMR (400 MHz, $DMSO-d_6$) δ : 7.49-7.44 (m, 2H), 7.43-7.31 (m, 3H), 7.15-7.08 (m, 2H), 6.94-6.88 (m, 2H), 5.12 (s, 2H), 4.59 (s, 2H), 4.02-3.94 (m, 4H), 3.79 (s, 3H), 1.40 (s, 9H), 1.02 (t, $J = 7.1$ Hz, 3H), 0.97 (t, $J = 7.1$ Hz, 3H).

Step (iii): 2-((4-(benzyloxy)-2,5-Bis(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl)oxy)acetic acid (24)

Diethyl 3-(benzyloxy)-4-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-028**) (250 mg, 0.45 mmol) was dissolved in 4 M HCl in dioxane (2.5 mL, 10.0 mmol), and the reaction mixture was stirred at RT for 2h, volatiles were removed *in vacuo* and the product was azeotroped with toluene (2 x 5 mL) to afford 2-((4-(benzyloxy)-2,5-bis(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl)oxy)acetic acid (24) (216 mg, 87 %) as a yellow oil: m/z 498 ($M+H$)⁺ (ES^+); 496 ($M-H$)⁻ (ES^-).

Step (iv): Diethyl 3-(2-amino-2-oxoethoxy)-4-(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (25)


HATU (153 mg, 0.40 mmol) was added to a stirred solution 2-((4-(benzyloxy)-2,5-bis(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl)oxy)acetic acid (24) (100 mg, 0.20 mmol), DIPEA (176 μ L, 1.00 mmol), and NH_4Cl (53.8 mg, 1.00 mmol) in THF (2 mL) at 0°C. The reaction mixture was stirred at 0°C for 20 min and then at RT for 2h volatiles were removed *in vacuo*, dissolved in EtOAc (30 mL) and washed with 1 M HCl (3 x 30 mL), sat. $NaHCO_3$ (aq.) (3 x 30 mL) and brine (30 mL), dried ($MgSO_4$), filtered and solvents removed *in vacuo* to give a yellow oil. The product was purified by silica gel chromatography (12 g, 0-100% EtOAc in isohexane) to afford diethyl 3-(2-amino-2-oxoethoxy)-4-(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (25) (66 mg, 66 %) as a white solid: m/z 497 ($M+H$)⁺ (ES^+). ¹H NMR (400 MHz, $DMSO-d_6$) δ : 7.58 (br s, 1H), 7.51 (br s, 1H), 7.49-7.44 (m, 2H), 7.43-7.33 (m, 3H), 7.17-7.09 (m, 2H), 6.95-6.86 (m, 2H), 5.10 (s, 2H), 4.46 (s, 2H), 4.00 (q, $J = 7.1$ Hz, 2H), 3.98 (q, $J = 7.1$ Hz, 2H), 3.79 (s, 3H), 0.97 (t, $J = 7.1$ Hz, 3H), 0.96 (t, $J = 7.1$ Hz, 3H).

Step (v): Diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-031**).

Diethyl 3-(2-amino-2-oxoethoxy)-4-(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (25) (66 mg, 0.133 mmol) in MeOH (66 mL) was passed through a Thales 'H-cube' cartridge (10% Pd/C) at a flow rate of 1 mL/min at 20°C under H_2 (full H_2 mode). The output was concentrated *in vacuo* to afford a yellow oil. The residue was purified by silica gel chromatography (4 g, 0-100% EtOAc in isohexane) to afford diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate (**UL2-031**) (25 mg, 46 %) as a white solid: m/z 407 ($M+H$)⁺ (ES^+); 405 ($M-H$)⁻ (ES^-). ¹H NMR (400 MHz, $DMSO-d_6$) δ : 9.61 (s, 1H),


7.82-7.63 (m, 2H), 7.10-7.06 (m, 2H), 6.93-6.84 (m, 2H), 4.49 (s, 2H), 4.03-3.93 (m, 4H), 3.79 (s, 3H), 1.05-0.94 (m, 6H).

Example O: Ethyl 5-(dimethylcarbamoyl)-3,4-bis((dimethylcarbamoyl)oxy)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**UL1-063**)



Dimethylcarbamic chloride (160 μ L, 1.74 mmol) was added dropwise to a stirred suspension of ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**UL1-012**) (202 mg, 0.58 mmol) and K_2CO_3 (240 mg, 1.74 mmol) in MeCN (4 mL). The resulting mixture was stirred at 80°C for 16h then partitioned between sat. $NaHCO_3$ (aq.) (10 mL) and Et_2O (10 mL) the aqueous layer was extracted with Et_2O (2 x 10 mL), the combined organics were washed with 10% $NaOH$ (aq.) (2 x 10 mL), water (2 x 10 mL) and brine (2 x 10 mL), dried ($MgSO_4$), filtered and solvents removed *in vacuo* to give an orange oil. Trituration of the oil with isohexane provided ethyl 5-(dimethylcarbamoyl)-3,4-bis((dimethylcarbamoyl)oxy)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**UL1-063**) (40 mg, 14 %) as a cream solid: m/z 491 ($M+H$)⁺ (ES^+). ^1H NMR (400 MHz, $DMSO-d_6$) δ : 7.21-7.11 (m, 2H), 6.98-6.88 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.01 (s, 3H), 2.96 (s, 3H), 2.90 (s, 3H), 2.88 (s, 3H), 2.80 (s, 3H), 2.70 (s, 3H), 1.05 (t, J = 7.1 Hz, 3H).


Example P: Ethyl 5-(dimethylcarbamoyl)-4-((dimethylcarbamoyl)oxy)-3-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**UL1-066**)



Dimethylcarbamic chloride (163 μ L, 1.77 mmol) was added dropwise to a stirred suspension of


ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**) (494 mg, 1.42 mmol) and K₂CO₃ (255 mg, 1.85 mmol) in MeCN (8 mL). The resulting mixture was stirred at RT for 24h then partitioned between water (30 mL) and DCM (20 mL) the aqueous layer was extracted with DCM (2 x 20 mL), the combined organics were dried (MgSO₄), filtered and solvents removed *in vacuo* to give an orange oil. The residue was purified by silica gel chromatography (12 g, 0-10% MeOH (+1% NH₃) in DCM) to afford ethyl 5-(dimethylcarbamoyl)-4-((dimethylcarbamoyl)oxy)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-066**) (35 mg, 6 %) as a white solid: *m/z* 420 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.85 (s, 1H), 7.16-7.06 (m, 2H), 6.95-6.86 (m, 2H), 4.00 (q, *J* = 7.1 Hz, 2H), 3.77 (s, 3H), 2.98 (s, 3H), 2.88 (s, 3H), 2.78 (s, 3H), 2.69 (s, 3H), 1.00 (t, *J* = 7.1 Hz, 3H).

Example Q: Ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(sulfamoyloxy)-1*H*-pyrrole-2-carboxylate (**UL1-068**)



Formic acid (165 μL, 4.31 mmol) was added dropwise to neat sulfurisocyanatidic chloride (374 μL, 4.31 mmol) at 0°C with stirring. The reaction mixture allowed to warm to RT and stirred for 2h, after which a solution of ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**) (0.5 g, 1.44 mmol) in NMP (3 mL) was added dropwise. The reaction mixture was stirred at 0°C for 30 min and allowed to warm to RT and stirred for a further 2h. The reaction mixture was partitioned with brine (30 mL) and EtOAc (25 mL), the aqueous layer was extracted with EtOAc (2 x 25 mL) the combined organics were dried (MgSO₄), filtered and solvents removed *in vacuo* to give a yellow oil. The compound was purified by preparative HPLC (C-18 column, 21.2 mm i.d. x 100 mm, 5 micron particle size, gradient 5-95 % MeCN in 0.1 % aqueous formic acid over 16 min) to afford ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(sulfamoyloxy)-1*H*-pyrrole-2-carboxylate (**UL1-068**) (76 mg, 12 %) as a white solid: *m/z* 428 (M+H)⁺ (ES⁺); 426 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.87 (s, 1H), 7.92 (s, 2H), 7.16-7.08 (m, 2H), 6.96-6.88 (m, 2H), 4.03 (q, *J* = 7.1 Hz, 2H), 3.79 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H), 1.02 (t, *J* = 7.1 Hz, 3H).

Example R: Ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonooxy)-1*H*-pyrrole-2-carboxylate (**UL1-070**)



Step (i): Ethyl 4-((bis(benzyloxy)phosphoryl)oxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**26**)

5

Perbromomethane (286 mg, 0.86 mmol) and *N*-ethyl-*N*-isopropylpropan-2-amine (376 μ L, 2.15 mmol) were added successively to a solution of *N,N*-dimethylpyridin-4-amine (8.8 mg, 0.07 mmol) and ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**UL1-012**) (250 mg, 0.72 mmol) in MeCN (3 mL) at -10°C . The reaction mixture was allowed to stir for 30 min and bis(phenoxyethyl)phosphine oxide (166 μ L, 0.75 mmol) was added, the reaction was allowed to slowly warm to 0°C and stirred for 1h. The reaction was quenched with 5 % NaH_2PO_4 (aq.) (20 mL) and extracted with EtOAc (3 x 25 mL). The combined organics were washed with brine (50 mL), dried (MgSO_4), filtered and solvents removed *in vacuo*. The crude residue was purified by silica gel chromatography (40 g, 0-4 % MeOH in DCM) to afford an orange oil. The compound was purified by preparative HPLC (C-18 column, 21.2 mm i.d. x 100 mm, 5 micron particle size, gradient 5-95 % MeCN in 0.1 % aqueous formic acid over 16 min) to afford ethyl 4-((bis(benzyloxy)phosphoryl)oxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**26**) (228 mg, 51 %) as a pale yellow solid: m/z 609 ($\text{M}+\text{H}^+$) (ES^+); 607 ($\text{M}-\text{H}^-$) (ES^-).


20

Step (ii): Ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonooxy)-1H-pyrrole-2-carboxylate (**UL1-070**)

A solution of ethyl 4-((bis(benzyloxy)phosphoryl)oxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**26**) (225 mg, 0.37 mmol) in MeOH (10 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 30°C under H_2 (full H_2 mode). The output was concentrated *in vacuo* to afford ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonooxy)-1H-pyrrole-2-carboxylate (**UL1-070**) (151 mg, 94 %) as a pale yellow solid: m/z 429 ($\text{M}+\text{H}^+$) (ES^+); 427 ($\text{M}-\text{H}^-$) (ES^-). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.11-7.03 (m, 2H), 6.93-6.85 (m, 2H), 3.99 (q, $J = 7.1$ Hz, 2H), 3.77 (s, 3H), 2.82 (s, 3H), 2.71 (s, 3H), 1.02 (t, $J = 7.1$ Hz, 3H).

35

Example S: Ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate (**UL1-083**)



Step (i): Ethyl 3,4-bis(benzyloxy)-5-iodo-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (28)

- 5 *N*-Iodosuccinimide (1.77g, 7.57 mmol) was added to a solution of ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (27) [prepared using the same procedure as Example E step (i) using (5) as starting material] (3.0 g, 6.56 mmol) in DMF (60 mL) and stirred at 0°C for 10 min. The mixture was partitioned between sat. Na₂S₂O₃ (aq.) (100 mL) and Et₂O (250 mL), the organic layer was separated and washed with sat. Na₂S₂O₃ (aq.) (100 mL), brine (100 mL)
- 10 dried (MgSO₄), filtered and solvents removed *in vacuo*. The crude residue was purified by silica gel chromatography (120 g, 0-40 % Et₂O in isohexane) to afford ethyl 3,4-bis(benzyloxy)-5-iodo-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (28) (2.92 g, 76 %) as a white solid: m/z 584 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.51-7.29 (m, 10 H), 7.14-7.05 (m, 2H), 7.03-6.92 (m, 2H), 5.12 (s, 2H), 5.00 (s, 2H), 3.97 (q, J = 7.1 Hz, 2H) 3.82 (s, 3H), 0.99 (t, J =
- 15 7.1 Hz, 3H).

Step (ii): Ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate (UL1-082)

- 20 To a solution of ethyl 3,4-bis(benzyloxy)-5-iodo-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (28) (300 mg, 0.51 mmol) in DMF (5 mL) was added 2-(tributylstannyl)pyridine (280 μL, 0.87 mmol), copper(I) iodide (19.6 mg, 0.10 mmol) and dichlorobis(triphenylphosphine)palladium(II) (36.1 mg, 0.05 mmol). The mixture was heated in a microwave at 140°C for 30 min, AcOH (2 mL) was added and the crude product was loaded onto a column of SCX (5 g). The column was
- 25 washed with MeOH and then the product was eluted with 1 % NH₃ in MeOH. The resultant mixture was concentrated *in vacuo* and the residue was purified by silica gel chromatography (12 g, 20-100 % EtOAc in isohexane) to afford ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate (UL1-082) (231 mg, 83 %) as a pale yellow oil: m/z 535


(M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.47-8.40 (m, 1H), 7.71-7.63 (m, 1H), 7.54-7.47 (m, 2H), 7.45-7.16 (m, 10H), 7.12-7.03 (m, 2H), 6.83-6.76 (m, 2H), 5.18 (s, 2H), 4.96 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.72 (s, 3H), 1.03 (t, J = 7.1 Hz, 3H).

5 Step (iii): Ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate (**UL1-083**)

A solution of ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate (**UL1-082**) (146 mg, 0.273 mmol) in MeOH/THF (9:1; 20 mL) was passed through a
 10 Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 30°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* and the resulting oil was purified by silica gel chromatography (12 g, 0-2 % MeOH in DCM) to afford ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate (**UL1-083**) (86 mg, 89 %) as a pale orange solid: m/z 355 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.84 (s, 1H), 8.62 (s, 1H), 8.56-8.47 (m, 1H), 7.67-7.55 (m, 1H), 7.26-7.12 (m, 3H), 7.01-6.89 (m, 2H), 6.62-6.49 (m, 1H), 4.01 (q, J = 7.1 Hz, 2H), 3.80 (s, 3H), 1.02 (t, J = 7.1 Hz, 3H).

Example T: Ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-086**)

20



Step (i): Ethyl 3,4-bis(benzyloxy)-5-(4-ethylthiazol-2-yl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (30)

25

A solution of 1-bromobutan-2-one (24 μL, 0.21 mmol) and ethyl 3,4-bis(benzyloxy)-5-carbamothioyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (29) [*prepared under standard conditions from UL1-079 and Lawesson reagent*] (100 mg, 0.19 mmol) in EtOH (4 mL) was heated at 80°C for 45 min. The volatiles were removed *in vacuo* and the product was purified by
 30 silica gel chromatography (12 g cartridge, 0-25 % EtOAc in isohexane) to afford ethyl 3,4-bis(benzyloxy)-5-(4-ethylthiazol-2-yl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (30) (82 mg, 75 %) as a yellow oil: m/z 569 (M+H)⁺ (ES⁺).


Step (ii) Ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-086**)

35

A solution of ethyl 3,4-bis(benzyloxy)-5-(4-ethylthiazol-2-yl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (30) (70 mg, 0.12 mmol) in MeOH/THF (3:1; 5 mL) was passed through a Thales

'H-cube' cartridge (10 Pd/C) at a flow rate of 1 mL/min at 40°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* and the resulting oil was purified by silica gel chromatography (12 g, 0-20 % EtOAc in isohexane) to afford ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-086**) (30 mg, 63 %) as an off-white solid: *m/z* 389 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.82 (s, 1H), 8.68 (s, 1H), 7.28-7.19 (m, 2H), 7.06-7.03 (m, 1H), 7.03-6.97 (m, 2H), 4.00 (q, *J* = 7.1 Hz, 2H), 3.82 (s, 3H), 2.67 (q, *J* = 7.5 Hz, 2H), 1.16 (t, *J* = 7.5 Hz, 3H), 0.99 (t, *J* = 7.1 Hz, 3H).

Example U: Ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-pyrrole-2-carboxylate (**UL1-087**)



Step (i): Ethyl 5-(2-acetylhydrazinecarbonyl)-3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (31)


HATU (739 mg, 1.94 mmol) was added to a solution of triethylammonium 3,4-bis(benzyloxy)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (5) (325 mg, 0.65 mmol), DIPEA (566 μL, 3.24 mmol) and acetylhydrazide (53 mg, 0.71 mmol) in DMF (5 mL) at 0°C. The mixture was stirred for 30 min and allowed to warm to RT. The reaction was partitioned between water (10 mL) and Et₂O (30 mL) and NH₄OAc (aq.) (20 mL) was added, the organic layer was separated and washed with sat. NaHCO₃ (aq.) (20 mL), brine (20 mL), dried (MgSO₄), filtered and solvents removed *in vacuo*. The product was purified by silica gel chromatography (40 g, 0-80 % EtOAc in isohexane) to afford ethyl 5-(2-acetylhydrazinecarbonyl)-3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (31) (196 mg, 100 %) as a colourless oil: *m/z* 558 (M+H)⁺ (ES⁺).

Step (ii): Ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-pyrrole-2-carboxylate (**UL1-087**)

A solution of ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2-acetylhydrazinecarbonyl)-1*H*-pyrrole-2-carboxylate (31) (155 mg, 0.56 mmol) and Burgess reagent (132 mg, 0.56 mmol) were dissolved in THF (2 mL). The mixture was heated in a microwave at 100°C for 30 min and the volatiles removed *in vacuo*. The crude product was purified by silica gel chromatography (12 g, 0-30 % EtOAc in isohexane) to afford ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-pyrrole-2-carboxylate (**UL1-087**) (115 mg, 77 %) as a colourless oil: *m/z* 540 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.51-7.46 (m, 2H), 7.43-7.31 (m, 8H),

7.18-7.12 (m, 2H), 6.93-6.87 (m, 2H), 5.17 (s, 2H), 5.07 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.35 (s, 3H), 1.01 (t, J = 7.1 Hz, 3H).

Example V: Ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2H-tetrazol-5-yl)-1H-pyrrole-2-carboxylate (**UL1-089**)



Step (i): Ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2H-tetrazol-5-yl)-1H-pyrrole-2-carboxylate (**UL1-090**)


A solution of ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**32**) [prepared using the same procedure as Example H step(i) using **UL1-079** as starting material] (400 mg, 0.83 mmol), NH_4Cl (222 mg, 4.14 mmol) and sodium azide (269 mg, 4.14 mmol) were dissolved in DMF (4 mL). The reaction mixture was heated in a microwave at 120°C for 2h, partitioned between EtOAc (15 mL) and water (15 mL). The organic layer was separated and washed with water (3 x 15 mL), dried (MgSO_4), filtered and solvents removed *in vacuo*. The product was purified by silica gel chromatography (40 g, 0-40 % MeOH in DCM/2.5 % Et_3N) to afford the triethylammonium salt of (**UL1-090**). The salt was dissolved in DCM (10 mL) and the organic layer was washed with 1M HCl (aq.) (10 mL), brine (10 mL), sat. NaHCO_3 (aq.) (10 mL), brine (10 mL), dried (MgSO_4), filtered and solvents removed *in vacuo* to afford ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2H-tetrazol-5-yl)-1H-pyrrole-2-carboxylate (**UL1-090**) (150 mg, 34 %) as a white solid: m/z 526 ($\text{M}+\text{H}^+$) (ES^+); 524 ($\text{M}-\text{H}^-$) (ES^-). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.51-7.45 (m, 2H), 7.42-7.25 (m, 8H), 7.10-7.03 (m, 2H), 6.83-6.76 (m, 2H), 5.15 (s, 2H), 4.95 (s, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.74 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H).

Step (ii): Ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2H-tetrazol-5-yl)-1H-pyrrole-2-carboxylate (**UL1-089**)

A solution of ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2H-tetrazol-5-yl)-1H-pyrrole-2-carboxylate (**UL1-090**) (85 mg, 0.16 mmol) in MeOH (6 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 40°C under H_2 (full H_2 mode). The output was concentrated *in vacuo*. The crude material was dissolved in DCM (5 mL) and washed with 1M HCl (aq.), brine (5 mL), sat. NaHCO_3 (aq.) (5 mL), the basic aqueous layer was acidified with 1M HCl (aq.) (5 mL) and washed with DCM (2 x 5 mL), the combined organics were dried (MgSO_4), filtered and solvents removed *in vacuo* to afford ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2H-tetrazol-5-yl)-1H-pyrrole-2-carboxylate (**UL1-089**) (45 mg, 79 %) as a white solid: m/z 346 ($\text{M}+\text{H}^+$) (ES^+); 344 ($\text{M}-\text{H}^-$) (ES^-). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 9.30 (br s,

1H), 8.67 (s, 1H), 7.10-7.05 (m, 2H), 6.87-6.81 (m, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 0.99 (t, J = 7.1 Hz, 3H).

Example W: 5-Acetyl-3,4-dihydroxy-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (**UL1-091**)



Step (i): 3,4-Bis(benzyloxy)-N²-methoxy-1-(4-methoxyphenyl)-N²,N⁵,N⁵-trimethyl-1H-pyrrole-2,5-dicarboxamide (33)

10

(COCl)₂ (560 μ L, 6.39 mmol) was added dropwise to a stirred solution of 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylic acid (7) (1.6 g, 3.20 mmol) in DCM (20 mL) at 0°C, followed by 2 drops of DMF. The reaction mixture was stirred at RT for 5h, concentrated *in vacuo* and the resulting residue was dissolved in DCM (15 mL). N,O-

15

dimethylhydroxylamine was added (215 mg, 3.52 mmol) followed by pyridine (620 μ L, 7.67 mmol), and the reaction allowed to stir at RT for 18h. The mixture was diluted with DCM (25 mL) and water (50 mL), the organic layer was separated and washed with water (2 x 25 mL), brine (25 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The product was purified by silica gel chromatography (40 g, 0-80 % EtOAc in isohexane) to afford 3,4-bis(benzyloxy)-N²-

20

methoxy-1-(4-methoxyphenyl)-N²,N⁵,N⁵-trimethyl-1H-pyrrole-2,5-dicarboxamide (33) (505 mg, 22 %) as a colourless oil. m/z 544 (M+H)⁺ (ES⁺).

Step (ii): 5-Acetyl-3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide (34)

25

Methylmagnesium bromide (3 M in Et₂O) (294 μ L, 0.88 mmol) was added dropwise to a stirred solution of 3,4-bis(benzyloxy)-N²-methoxy-1-(4-methoxyphenyl)-N²,N⁵,N⁵-trimethyl-1H-pyrrole-2,5-dicarboxamide (33) (320 mg, 0.59 mmol) in THF (1 mL) at 0°C. The reaction mixture was allowed to warm to RT and stirred for 20h. The reaction mixture was cooled to -10°C and 1 M


HCl (aq.) (10 mL) was added. The aqueous layer was extracted with DCM (3 x 10 mL). The combined organic phases were washed with water (20 mL), brine (20 mL), dried (MgSO₄), filtered and concentrated *in vacuo* to give a yellow oil.

The product was purified by silica gel chromatography (40 g, 0-100 % EtOAc in isohexane) to afford 5-acetyl-3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (34) (110 mg, 38 %) as a yellow oil: *m/z* 499 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.46-7.33 (m, 10H), 7.05-7.03 (m, 2H), 6.88-6.86 (m, 2H), 5.25 (s, 2H), 5.01 (s, 2H), 3.77 (s, 3H), 2.71 (s, 6H), 2.26 (s, 3H).

10 Step (iii): 5-Acetyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (UL1-091)

A solution of 5-acetyl-3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (34) (100 mg, 0.20 mmol) in MeOH (5 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 20°C under H₂ (full H₂ mode). The output was concentrated *in vacuo*. The crude compound was purified by preparative HPLC (C-18 column, 21.2 mm i.d. x 100 mm, 5 micron particle size, gradient 5-95 % MeCN in 0.1 % aq. formic acid over 16 min) to afford 5-acetyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (UL1-091) (45 mg, 70 %) as a pale yellow solid: *m/z* 319 (M+H)⁺ (ES⁺), 317 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.77 (s, 1H), 8.57 (s, 1H), 7.09-7.07 (m, 2H), 6.88-6.86 (m, 2H), 3.77 (s, 3H), 2.81 (br s, 6H), 2.05 (s, 3H).


Example X: Ethyl 3,4-bis((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-092)



Perbromomethane (207 mg, 0.62 mmol) and DIPEA (131 μL, 0.75 mmol) were added successively to a solution of DMAP (3.05 mg, 0.03 mmol) and ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-012) (87 mg, 0.25 mmol) in MeCN (3 mL) at -10°C. The reaction mixture was allowed to stir for 30 min and diethyl phosphite (166 μL, 0.75 mmol) added, the reaction was allowed to warm slowly to RT and stirred for 3h. The reaction was quenched with 5 % NaH₂PO₄ (aq.) (20 mL) and extracted with EtOAc (3 x 25 mL). The combined organics were washed with brine (50 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (40 g, 0-4 % MeOH in DCM) to afford an orange oil. The compound was further purified by preparative HPLC (C-18 column, 21.2 mm i.d. x 100 mm, 5 micron particle size, gradient 5-95 % MeCN in

0.1 % aq. formic acid over 16 min) to afford ethyl 3,4-bis((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-092**) (35 mg, 22 %) as a yellow oil: m/z 621 ($M+H$)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.18-7.15 (m, 2H), 6.97-6.94 (m, 2H), 4.22-4.02 (m, 10H), 3.79 (s, 3H), 2.75 (s, 3H), 2.71 (s, 3H), 1.31-1.24 (m, 12H), 1.07 (t, J = 7.2 Hz, 3H).

Example Y: Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-100**)



Step (i): Ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate (**36**)

A solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-((4-methoxybenzyl)oxy)phenyl)-1*H*-pyrrole-2-carboxylate (**35**) [*prepared using the same procedure as Example B except 4-((4-methoxybenzyl)oxy)aniline used in step (i)*] (46 mg, 0.07 mmol) in AcOH (5 mL) was stirred at 105°C for 18h. The volatiles were removed *in vacuo* and the residue was purified by silica gel chromatography (4 g, 0-10 % MeOH in DCM) to afford ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate (**36**) (35 mg, 91 %) as a yellow solid: m/z 515 ($M+H$)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 9.63 (1H, s), 7.47-7.42 (m, 2H), 7.41-7.29 (m, 8H), 6.99-6.91 (m, 2H), 6.73-6.66 (m, 2H), 5.10 (s, 2H), 4.95 (s, 2H), 3.99 (q, J = 7.1 Hz, 2H), 2.69 (s, 3H), 2.67 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H).


Step (ii): Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-100**)

A solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate (**36**) (30 mg, 0.06 mmol) in MeOH (2 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 25°C under H₂ (full H₂ mode). The output was concentrated *in vacuo*, and a solid was collected by filtration after trituration with isohexane to afford ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-100**) (11 mg, 56 %) as a yellow solid: m/z 335 ($M+H$)⁺ (ES⁺), 333 ($M-H$)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 9.50 (s, 1H), 8.54 (s, 1H), 8.42 (s, 1H), 6.94-6.86 (m, 2H), 6.69-6.62 (m, 2H), 3.99 (q, J = 7.0 Hz, 2H), 2.81 (br s, 6H), 0.98 (t, J = 7.0 Hz, 3H).

Example Z: Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1*H*-pyrrole-2-carboxylate (**UL1-102**)

WO 2013/083975

PCT/GB2012/053022




Step (i): Ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-morpholinopropoxy)phenyl)-1H-pyrrole-2-carboxylate (37)

- 5 A solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-hydroxyphenyl)-1H-pyrrole-2-carboxylate (36) (45 mg, 0.09 mmol), 4-(3-chloropropyl)morpholine hydrochloride (19 mg, 0.10 mmol) and K₂CO₃ (25 mg, 0.18 mmol) in DMF (1 mL) was stirred at 60°C for 18h. The reaction mixture was partitioned between EtOAc (10 mL) and water (5 mL), the organic layer was separated and washed with brine (5 mL), dried (MgSO₄), filtered and concentrated *in vacuo*.
- 10 The residue was dissolved in MeOH (2 mL) and loaded onto a column of SCX (5 g). The column was washed with MeOH and then the product was eluted with 1 % NH₃ in MeOH, removal of the solvents *in vacuo* afforded ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-morpholinopropoxy)phenyl)-1H-pyrrole-2-carboxylate (37) (32 mg, 57 %) as a yellow oil: m/z 642 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.47-7.42 (m, 2H), 7.41-7.30 (m, 8H), 7.10-7.05 (m, 2H), 6.99-6.91 (m, 2H), 5.11 (s, 2H), 4.96 (s, 2H), 4.04-3.95 (m, 4H), 3.59-3.52 (m, 5H), 2.72-2.67 (m, 6H), 2.44-2.38 (m, 3H), 2.37-2.32 (m, 5H), 1.92-1.81 (m, 2H), 1.00 (t, J = 7.0 Hz, 3H).

Step (ii): Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1H-pyrrole-2-carboxylate (UL1-102)


- A solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-morpholinopropoxy)phenyl)-1H-pyrrole-2-carboxylate (37) (105 mg, 0.16 mmol) in MeOH (4 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 25°C
- 25 under H₂ (full H₂ mode). The output was concentrated *in vacuo*, and a solid was collected by filtration after trituration with isohexane to afford ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1H-pyrrole-2-carboxylate (UL1-102) (20 mg, 25 %) as a yellow solid: m/z 462 (M+H)⁺ (ES⁺), 460 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.58 (s, 1H), 8.44 (s, 1H), 7.05-6.99 (m, 2H), 6.86-6.82 (m, 2H), 4.03-3.95 (m, 4H), 3.61-3.53 (m, 4H), 2.82
- 30 (br s, 6H), 2.45-2.34 (m, 6H), 1.93-1.81 (m, 2H), 0.98 (t, J = 7.0 Hz, 3H).

Example A1: 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(3-methoxypropanoate) (UL1-104)



Isobutyl chloroformate (410 μ L, 3.16 mmol) was added dropwise to a stirred solution of 3-methoxypropanoic acid (297 μ L, 3.16 mmol) and 4-methylmorpholine (790 μ L, 7.18 mmol) in DCM (20 mL) at -15°C and the reaction mixture was allowed to stir for 20 min. A solution of ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate (**UL1-012**) (0.5 g, 1.44 mmol) in DCM (20 mL) was added, and the reaction allowed to warm to RT and stirred for 18h. The solvents were removed *in vacuo*, and the mixture was partitioned between DCM (30 mL) and 1 M HCl (aq.) (10 mL), the organic layer was separated and washed with sat. NaHCO_3 (aq.) (10 mL), dried (MgSO_4), filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (40 g, 50-70 % EtOAc in isohexane) to afford 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(3-methoxypropanoate) (**UL1-104**) (300 mg, 39 %) as a yellow oil: m/z 521 ($\text{M}+\text{H}^+$) (ES^+). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 7.24-7.15 (m, 2H), 6.98-6.89 (m, 2H), 4.00 (q, $J = 7.1$ Hz, 2H), 3.79 (s, 3H), 3.65-3.59 (m, 4H), 3.27 (s, 3H), 3.25 (s, 3H), 2.82 (s, 3H), 2.78 (t, $J = 6.0$ Hz, 4H), 2.71 (s, 3H), 1.05 (t, $J = 7.1$ Hz, 3H).

Example B1: 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)-2,2-dimethylpropanoate) (**UL1-108**)



Step (i): Methyl 3-(2-methoxyethoxy)-2,2-dimethylpropanoate (39)

Sodium hydride (60 % wt in oil) (3.14 g, 78 mmol) was added to a stirred solution of methyl 3-hydroxy-2,2-dimethylpropanoate (5 mL, 39.2 mmol) in DMF (5.6 mL) at 0°C, after 5 min 1-bromo-2-methoxyethane (7.4 mL, 78 mmol) was added dropwise, and the reaction mixture was allowed to stir for 3h. The reaction was quenched with sat. NH_4Cl (aq.) (30 mL) and the aqueous layer was extracted with DCM (2 x 50 mL), the combined organic layers were dried (MgSO_4), filtered and concentrated *in vacuo*. The crude oil was dissolved in EtOAc (125 mL) and washed with water (3 x 40 mL), dried (MgSO_4), filtered and concentrated *in vacuo*. The material was purified by vacuum distillation (68-69°C, 4.4 mbar) to afford methyl 3-(2-methoxyethoxy)-2,2-dimethylpropanoate (39) (1.83 g, 25 %) as a colourless oil: ^1H NMR (400 MHz, CDCl_3) δ : 3.68 (s, 3H), 3.60-3.58 (m, 2H), 3.52-3.50 (m, 2H), 3.49 (s, 2H), 3.37 (s, 3H), 1.19 (s, 6H).

Step (ii): 3-(2-Methoxyethoxy)-2,2-dimethylpropanoic acid (40)

A suspension of methyl 3-(2-methoxyethoxy)-2,2-dimethylpropanoate (39) (1.83 g, 9.62 mmol) and KOH (2.16 g, 38.5 mmol) in water (20 mL) was stirred at RT for 3 days. The aqueous layer was washed with DCM (3 x 20 mL) and acidified to pH 1-2 with 6 M HCl (aq.) and extracted with DCM (3 x 20 mL). The combined organics were dried (MgSO_4), filtered and concentrated *in vacuo* to afford 3-(2-methoxyethoxy)-2,2-dimethylpropanoic acid (40) (1.62 g, 96 %) as colourless oil: ^1H NMR (400 MHz, CDCl_3) δ : 3.67-3.65 (m, 2H), 3.56-3.54 (m, 2H), 3.51 (s, 2H), 3.38 (s, 3H), 1.23 (s, 6H).


Step (iii): 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)-2,2-dimethylpropanoate) (UL1-108)

DMF (2.2 μL , 0.03 mmol) was added to a stirred solution of 3-(2-methoxyethoxy)-2,2-dimethylpropanoic acid (40) (500 mg, 2.84 mmol) followed by a solution of $(\text{COCl})_2$ (0.25 mL, 2.85 mmol) in DCM (11.4 mL), the reaction mixture was allowed to stir for 1h. To this mixture

was added ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**) (450 mg, 1.29 mmol), followed by Et₃N (900 μ L, 6.45 mmol) and the reaction allowed to stir for 45 min. The reaction was then filtered, and the filtrate concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (40 g, 0-3 % MeOH in DCM) to afford 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)-2,2-dimethylpropanoate) (**UL1-108**) (447 mg, 52 %) as a light yellow oil: *m/z* 665 (M+H)⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.23-7.15 (m, 2H), 6.98-6.89 (m, 2H), 4.02 (q, *J* = 7.2 Hz, 2H), 3.79 (s, 3H), 3.58-3.39 (m, 12 H), 3.24 (s, 3H), 3.23 (s, 3H), 2.81 (s, 3H), 2.70 (s, 3H), 1.25 (s, 6H), 1.19 (s, 6H), 1.05 (t, *J* = 7.2 Hz, 3H).

10

Example C1: Ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate (**UL1-109**)



15

Step (i): Ethyl 3-(benzyloxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (41)

Benzyl bromide (3.94 mL, 33.2 mmol) was added to a stirred suspension of ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**) (10.5 g, 30.1 mmol), potassium iodide (5.50 g, 33.2 mmol) and K₂CO₃ (4.58 g, 33.2 mmol) in DMF (100 mL). The reaction was allowed to stir at 80°C for 24h. The reaction mixture was poured into water (200 mL), washed with Et₂O (2 x 200 mL), and the combined organic layers were washed with 1M HCl (aq.) (400 mL), brine (2 x 400 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was purified by silica gel chromatography (330 g, 0-

50 % EtOAc in toluene) to afford ethyl 3-(benzyloxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (41) (4.36 g, 33 %) as a pale yellow solid: *m/z* 439 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.82 (s, 1H), 7.53-7.47 (m, 2H), 7.42-7.29 (m, 3H), 7.08-7.01 (m, 2H), 6.90-6.84 (m, 2H), 5.09 (s, 2H), 3.96 (q, *J* = 7.0 Hz, 2H), 3.76 (s, 3H), 2.82 (br s, 6H), 0.97 (t, *J* = 7.0 Hz, 3H).

Step (ii): Ethyl 3-(benzyloxy)-4-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (42)

- 10 A solution of dibenzyl (chloromethyl) phosphate (0.23 g, 0.70 mmol) in DMF (1 mL) was added dropwise to a stirred suspension of ethyl 3-(benzyloxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (41) (0.26 g, 0.58 mmol) and K₂CO₃ (80 mg, 0.58 mmol) in DMF (4 mL) at 0°C, the reaction was stirred at for 1h, then allowed to warm to RT over 16 h. A solution of dibenzyl (chloromethyl) phosphate (0.23 g, 0.70 mmol) in DMF (1 mL) and
- 15 K₂CO₃ (80 mg, 0.58 mmol) were added and the reaction was stirred for a further 24h. A further solution of dibenzyl (chloromethyl) phosphate (0.11 g, 0.35 mmol) in DMF (1 mL) and K₂CO₃ (40 mg, 0.29 mmol) were added and the reaction was stirred for a further 4h. The reaction mixture was poured into water (20 mL) and extracted with Et₂O (2 x 20 mL). The combined organic layers were washed with brine (3 x 100 mL), dried (MgSO₄), filtered and concentrated *in vacuo*.
- 20 The crude product was purified by silica gel chromatography (12 g, 0-50 % EtOAc in toluene) to afford ethyl 3-(benzyloxy)-4-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (42) (0.10 g, 23 %) as a colourless gum: *m/z* 729 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.36-7.30 (m, 13H), 7.09-7.05 (m, 2H), 6.88-6.92 (m, 2H), 5.49 (d, *J* = 11.1 Hz, 2H), 5.11 (s, 2H), 5.06-4.96 (m, 2H), 4.96-5.05 (m, 4H), 4.00 (q, *J*
- 25 = 7.1 Hz, 2H), 3.77 (s, 3H), 2.72 (s, 3H), 2.65 (s, 3H), 0.99 (t, *J* = 7.0 Hz, 3H).

Step (iii): Ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate (UL1-109)


- 30 A solution of ethyl 3-(benzyloxy)-4-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (42) (2.17 g, 2.99 mmol) in MeOH (20 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 40°C under H₂ (full H₂ mode). The output was concentrated *in vacuo*, the residue was taken up in water (50 mL) and washed with EtOAc (50 mL), the organic layer was washed with
- 35 water (2 x 50 mL) and the combined aqueous layers were freeze-dried to afford ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate (UL1-109) (720 mg, 52 %) as a white solid: *m/z* 459 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.14-7.05 (m, 2H), 6.93-6.85 (m, 2H), 5.35-5.23 (br m, 2H), 3.99 (q, *J* = 7.2 Hz, 2H), 3.77 (s, 3H), 2.73 (s, 3H), 2.70 (s, 3H), 1.02 (t, *J* = 7.2 Hz, 3H).

40

Example D1: Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1*H*-pyrrole-2-carboxylate (UL1-110)

WO 2013/083975

PCT/GB2012/053022



Step (i): Ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-(methylthio)propoxy)phenyl)-1H-pyrrole-2-carboxylate (43)

5

To a stirred solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-hydroxyphenyl)-1H-pyrrole-2-carboxylate (36) (350 mg, 0.68 mmol) in THF (2 mL) at 0°C was added 3-(methylthio)propan-1-ol (84 µL, 0.82 mmol), triphenylphosphine (214 mg, 0.82 mmol), and DIAD (159 µL, 0.82 mmol). After 2h further portions of 3-(methylthio)propan-1-ol (84 µL, 0.82 mmol), triphenylphosphine (214 mg, 0.82 mmol) and DIAD (159 µL, 0.82 mmol) were added, and the reaction mixture was allowed to stir at RT for 4 days. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 x 20 mL), the combined organics were washed with brine (30 mL), dried (MgSO₄) filtered and concentrated *in vacuo*. The crude product was purified by silica gel chromatography (12 g, 0-100 % EtOAc in isohexane) to afford ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-(methylthio)propoxy)phenyl)-1H-pyrrole-2-carboxylate (43) (389 mg, 85 %) as a clear yellow oil: m/z 603 (M+H)⁺ (ES⁺).

Step (ii): Ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1H-pyrrole-2-carboxylate (44)

20

To a stirred solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-(methylthio)propoxy)phenyl)-1H-pyrrole-2-carboxylate (43) (389 mg, 0.65 mmol) in DCM (8 mL) at 0°C was added m-CPBA (445 mg, 2.58 mmol) the mixture was allowed to warm up to RT and stirred for 1h, the reaction was quenched with sat. Na₂CO₃ (aq.) (20 mL) and extracted with DCM (3 x 10 mL) the combined organics were washed with brine (40 mL), passed through a phase separator, and the volatiles removed *in vacuo*. The crude product was purified by silica gel chromatography (12 g, 0-2 % MeOH(1 % NH₃) in DCM) to afford ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1H-pyrrole-2-carboxylate (44) (96 mg, 23 %) as a brown oil: m/z 635 (M+H)⁺ (ES⁺).


30

Step (iii): Ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1H-pyrrole-2-carboxylate (UL1-110)

1*H*-pyrrole-2-carboxylate (UL1-110)

A solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1*H*-pyrrole-2-carboxylate (44) (95 mg, 0.15 mmol) in MeOH (4 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 40°C under H₂ (full H₂ mode). The output was concentrated *in vacuo*, and the compound was purified by preparative HPLC (C-18 column, 21.2 mm i.d. x 100 mm, 5 micron particle size, gradient 15-40 % MeCN in 0.1 % aq. formic acid over 16 min) to afford ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1*H*-pyrrole-2-carboxylate (UL1-110) (40 mg, 58 %) as a yellow solid: *m/z* 455 (M+H)⁺ (ES⁺); 453 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.58 (s, 1H), 8.45 (s, 1H), 7.07-7.02 (m, 2H), 6.89-6.84 (m, 2H), 4.08 (t, *J* = 7.2 Hz, 2H), 3.99 (q, *J* = 7.1 Hz, 2H), 3.29-3.25 (m, 2H), 3.02 (s, 3H), 2.92-2.71 (br s, 6H), 2.21-2.07 (m, 2H), 0.99 (t, *J* = 7.1 Hz, 3H).

15 Example E1: 2,6-Dimethylcyclohexyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-113)



20 Step (i): 2,6-Dimethylcyclohexyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (45)


Sodium hydride (60 wt % in oil) (78 mg, 1.95 mmol) was added to a stirred solution of 2,6-dimethylcyclohexanol (250 mg, 1.95 mmol) in DMF (1.95 mL). The mixture was heated at 60°C for 10 min and then ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (6) (206 mg, 0.39 mmol) was added in one portion. The reaction was allowed to stir at 70°C for 16h. The cooled reaction mixture was filtered through Celite, and the filtrate diluted with EtOAc (20 mL) and washed with water (3 x 10 mL), the organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was purified by silica gel

chromatography (12 g, 0.5 % MeOH (1 % NH₃) in DCM) to afford 2,6-dimethylcyclohexyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (45) (73 mg, 20 %) as a brown oil. *m/z* 611 (M+H)⁺ (ES⁺)

5 Step (ii): 2,6-Dimethylcyclohexyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-113**)

A solution of 2,6-dimethylcyclohexyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (45) (73 mg, 0.12 mmol) in MeOH (6 mL) was passed
10 through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 26°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* and the crude product was purified by preparative HPLC (Waters, Acidic (0.1 % formic acid), Waters X-Select Prep-C18, 5 μm, 19x50 mm column, 5-95 % MeCN in Water) to afford 2,6-dimethylcyclohexyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-113**)
15 (15 mg, 29 %) as a yellow solid: *m/z* 431 (M+H)⁺ (ES⁺); 429 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 8.67-8.40 (m, 2H), 7.15-7.05 (m, 2H), 6.91-6.85 (m, 2H), 5.05 (br s, 1H), 3.76-3.75 (m, 3H), 2.82 (br s, 6H), 1.64-0.94 (m, 6H), 0.74-0.57 (m, 6H), 0.57-0.40 (m, 2H).

Example F1: 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (**UL1-117**)



Step (i): 2-(2-(Benzyloxy)ethoxy)ethyl methanesulfonate (47)

MsCl (15.8 mL, 204 mmol) was added to a solution of 2-(2-(benzyloxy)ethoxy)ethanol (46) (25 g, 127 mmol) and Et₃N (36 mL, 255 mmol) in DCM (180 mL) at 0°C, the reaction mixture was
 5 allowed to warm up to RT and stirred for 16h. The reaction mixture was diluted with DCM (50 mL) and washed with water (2 x 50 mL), 1M HCl (aq.) (2 x 50 mL), the organic layer was dried (MgSO₄), filtered and concentrated *in vacuo* to afford 2-(2-(benzyloxy)ethoxy)ethyl
 methanesulfonate (47) (35 g, 100 %) as an orange oil: m/z 275 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 7.37-7.27 (m, 5H), 4.55 (s, 2H), 4.40-4.37 (m, 2H), 3.78-3.76 (m, 2H), 3.71-3.68
 10 (m, 2H), 3.64-3.62 (m, 2H), 3.02 (s, 3H).

Step (ii): *tert*-Butyl 3-(2-(2-(benzyloxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (48)

To a solution of *tert*-butyl 3-hydroxy-2,2-dimethylpropanoate (353 mg, 2.03 mmol) and 2-(2-(benzyloxy)ethoxy)ethyl methanesulfonate (47) (500 mg, 1.82 mmol) in DMF (6 mL) at 0°C was
 15 added NaH (60 wt % in oil) (109 mg, 2.73 mmol), and the reaction mixture was allowed to stir at RT for 30 min. The reaction mixture was quenched with sat. NH₄Cl (aq.) (1 mL) diluted with water (20 mL) and washed with EtOAc (4 x 20 mL). The combined organic layers were dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was purified by silica gel
 20 chromatography (12 g, 0-40 % Et₂O in isohexane) to afford *tert*-butyl 3-(2-(2-(benzyloxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (48) (619 mg, 96 %) as a colourless oil: m/z 375 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 7.32-7.25 (m, 5H), 4.54 (s, 2H), 3.66-3.56 (m, 8H), 3.41 (s, 2H), 1.40 (s, 8H), 1.10 (s, 6H).

25 Step (iii): *tert*-Butyl 3-(2-(2-hydroxyethoxy)ethoxy)-2,2-dimethylpropanoate (49)

A suspension of *tert*-butyl 3-(2-(2-(benzyloxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (48) (13 g, 37 mmol) and 10 % Pd/C (1.3g) in EtOH (92 mL) were placed under 5 bar of H₂ pressure (isolated system), and stirred for 16h. The mixture was filtered through celite and the filtrate
 30 concentrated *in vacuo* to afford *tert*-butyl 3-(2-(2-hydroxyethoxy)ethoxy)-2,2-dimethylpropanoate (49) (8.2 g, 85 %) as a colourless oil: m/z 285 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 3.73-3.69 (m, 2H), 3.66-3.58 (m, 6H), 3.44 (s, 2H), 2.37 (t, J = 6.2 Hz, 1H), 1.43 (s, 9H), 1.14 (s, 6H).

35 Step (iv): *tert*-Butyl 3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (50)

A mixture of *tert*-butyl 3-(2-(2-hydroxyethoxy)ethoxy)-2,2-dimethylpropanoate (49) (6.87 g, 26.2 mmol), 5-methyl-1*H*-tetrazole (4.40 g, 52.4 mmol), and dibenzyl diethylphosphoramidite (12.47 g, 39.3 mmol) in THF (66 mL) was allowed to stir at RT for 1.5h. The solution was cooled to 0°C and *m*-CPBA (10.85 g, 47.1 mmol) was slowly added, the mixture was allowed to stir at RT for 16h. The reaction was diluted with DCM (200 mL) and washed with sat. NaHCO₃ (aq.) (4 x 100 mL), the organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. The crude
 40 product was purified by silica gel chromatography (220 g, 0-40 % EtOAc in isohexane) to afford *tert*-butyl 3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (50) (12.2 g, 89 %) as a colourless oil: m/z 545 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ: 7.35-

7.31 (m, 10H), 5.09-5.00 (m, 4H), 4.13-4.09 (m, 2H), 3.65-3.63 (m, 2H), 3.59-3.52 (m, 4H), 3.39 (s, 2H), 1.41 (s, 9H), 1.11 (s, 6H).

Step (v): 3-(2-(2-((Bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoic acid
5 (51)

TFA (6.63 mL, 86 mmol) was added dropwise to a stirred solution of *tert*-butyl 3-(2-(2-
((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (50) (4.5 g, 8.61 mmol)
in DCM (43 mL) and the reaction mixture was allowed to stir at RT for 16h then concentrated *in*
10 *vacuo*. The crude product was dissolved in EtOAc (150 mL) and washed with 1M HCl (aq.) (50
mL), water (2 x 50 mL), and brine (50 mL) the organic layer was dried (MgSO₄), filtered and
concentrated *in vacuo* to afford 3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-
dimethylpropanoic acid (51) (3.98 g, 99 %) as a colourless oil: m/z 467 (M+H)⁺ (ES⁺); 465 (M-
H)⁻ (ES⁻). ¹H NMR (400 MHz, CDCl₃) δ: 7.36-7.31 (m, 10H), 5.12-5.03 (m, 4H), 4.14-4.09 (m,
15 2H), 3.69-3.64 (m, 2H), 3.60 (s, 4H), 3.47 (s, 2H), 1.20 (s, 6H).

Step (vi): 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl
bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (52)


DMF (0.2 μL, 2.14 μmol) was added to a stirred solution of 3-(2-(2-
((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoic acid (51) (100 mg, 0.21
mmol), followed by a solution of (COCl)₂ (19 μL, 0.22 mmol) in DCM (860 μL), the reaction
mixture was allowed to stir for 45 min. To this mixture was added ethyl 5-(dimethylcarbamoyl)-
3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-012) (30 mg, 0.09 mmol),
25 the reaction mixture was cooled to 0°C and Et₃N (60 μL, 0.43 mmol) was added, the resulting
mixture was allowed to stir for 45 min. The volatiles were concentrated *in vacuo*, the crude was
suspended in Et₂O (5 mL) filtered, concentrated *in vacuo* and the residue purified by silica gel
chromatography (4 g, 0-2 % MeOH in DCM) to afford a yellow oil. The compound was further
purified by preparative HPLC (C-18 column, 19 mm i.d. x 50 mm, 5 micron particle size,
30 gradient 5-95 % MeCN in 0.1 % aq. formic acid over 16 min) to afford 2-(dimethylcarbamoyl)-5-
(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-
((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (52) (11 mg, 10 %) as
a colourless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.30 (m, 20H), 7.25-7.10 (m, 2H), 3.87-6.85
(m, 2H), 5.09-4.99 (m, 8H), 4.14-4.05 (m, 6H), 3.81 (s, 3H), 3.65-3.48 (m, 16H), 2.80 (s, 3H),
35 2.75 (s, 3H), 1.32 (s, 6H), 1.23 (s, 6H). 1.06 (t, J = 7.2 Hz, 3H).

Step (vii): 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl
bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (UL1-117)

A solution of methyl 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-
3,4-diyl bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate (52)
(10 mg, 8.03 μmol) in MeOH (4 mL) was passed through a Thales 'H-cube' cartridge (10 %
Pd/C) at a flow rate of 1 mL/min at 25°C under H₂ (10 bar). The output was concentrated *in*
vacuo to afford 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-
45 diyl bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (UL1-
117) (5 mg, 70 %) as a white solid: m/z 885 (M+H)⁺ (ES⁺); 883 (M-H)⁻ (ES⁻). ¹H NMR (CDCl₃) δ:

7.25-7.15 (m, 2H), 6.91-6.86 (m, 2H), 4.20-4.02 (m, 6H), 3.82 (s, 3H), 3.75-3.50 (m, 16H), 2.83 (s, 3H), 2.77 (s, 3H), 2.69 (br s, 4H), 1.35 (s, 6H), 1.28 (s, 6H), 1.08 (t, J = 7.1 Hz, 3H).

Example G1: 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(3-(phosphonooxy)propoxy)propanoate) (**UL1-118**)



Step (i): *tert*-Butyl 3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoate (54)

- 10 DIAD (1.36 mL, 6.97 mmol) was added dropwise to a stirred solution of PPh₃ (76 mg, 0.30 mmol), dibenzyl phosphite (1.94 g, 6.97 mmol) and *tert*-butyl 3-(3-hydroxypropoxy)-2,2-dimethylpropanoate (53) (1.08 g, 4.65 mmol) [*prepared using the same procedure as Example F1 steps (ii)-(iii) using 3-(benzyloxy)propyl 4-methylbenzenesulfonate in step (ii)*] in THF (100 mL) at 0°C. The reaction was allowed to warm to RT and stirred for 16h, and the volatiles were
- 15 removed *in vacuo*. The crude product was purified by silica gel chromatography (120 g, 0-60 % EtOAc in isohexane) to afford *tert*-butyl 3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoate (54) (1.76 g, 54 %) as a clear colourless oil: m/z 515 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.40-7.35 (m, 10H), 5.07-4.96 (m, 4H), 4.04-3.92 (m, 2H), 3.39 (t, J = 6.2 Hz, 2H), 3.28 (s, 2H), 1.77 (quin, J = 6.2 Hz, 2H), 1.35 (s, 9H), 1.02 (s, 6H).

20

Step (ii): 3-(3-((Bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoic acid (55)

- To a stirred solution of *tert*-butyl 3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoate (54) (1.76 g, 3.57 mmol) in DCM (30 mL) was added TFA (1.38 mL, 17.9
- 25 mmol), and the reaction was allowed to stir at RT for 4h. The volatiles were removed *in vacuo* and the crude product was purified by silica gel chromatography (40 g, 0-30 % EtOAc in isohexane (+1 % AcOH)) to afford 3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoic acid (55) (1.03 g, 58 %) as a colourless oil: m/z 437 (M+H)⁺ (ES⁺); 435 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.49-7.26 (m, 10H), 5.08-4.95 (m, 4H), 4.03-3.96 (m, 2H), 3.42-3.35 (m, 2H), 3.31 (s, 2H), 1.77 (quin, J = 6.2 Hz, 2H), 1.05 (s, 6H).
- 30


Step (iii): 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoate) (56)

(COCl)₂ (28 µL, 0.32 mmol) was added dropwise to a stirred solution of 3-(3-
 5 ((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoic acid (55) (0.14 g, 0.32 mmol) at 0°C, followed by a solution DMF (0.25 µL, 3.2 µmol) in DCM (0.1 mL), the reaction was allowed to warm to RT and left to stir for 2.5h. The reaction was cooled to 0°C and a further portion of (COCl)₂ (28 µL, 0.32 mmol) and a solution DMF (0.25 µL, 3.2 µmol) in DCM (0.1 mL) was added and the reaction allowed to warm to RT over 4h. The reaction was cooled to 0°C and
 10 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (UL1-012) (55 mg, 0.16 mmol) was added, followed by Et₃N (133 µL, 0.96 mmol). The reaction was allowed to warm to RT and stirred for 16h. The volatiles were concentrated *in vacuo*, the crude was suspended in EtOAc (5 mL) filtered, concentrated *in vacuo* and the crude product was purified by preparative HPLC (C-18 column, 19 mm i.d. x 50 mm, 5 micron particle size,
 15 gradient 60-90 % MeCN in water + 0.1 % aq. formic acid over 16 min) to afford 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoate) (56) (42 mg, 11 %) as a pale yellow gum: m/z: no ionisation observed. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.37-7.32 (m, 2H), 7.18-7.11 (m, 2H), 6.95-6.89 (m, 2H), 5.06-4.95 (m, 8H), 4.05-3.95 (m, 6H) 3.78 (s, 3H), 3.45-
 20 3.36 (m, 8H), 2.76 (s, 3H), 2.66 (s, 3H), 1.80-1.75 (m, 4H), 1.23 (s, 6H), 1.13 (s, 6H), 0.98 (t, J = 7.1 Hz, 3H).

Step (iv): 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(3-(phosphonoxy)propoxy)propanoate) (UL1-118)

25 A solution of 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(3-((bis(benzyloxy)phosphoryl)oxy)propoxy)-2,2-dimethylpropanoate) (56) (37 mg, 0.03 mmol) in MeOH (4 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 40°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to
 30 afford 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(3-(phosphonoxy)propoxy)propanoate) (UL1-118) (25 mg, 95 %) as a white gum: m/z 825 (M+H)⁺ (ES⁺); 823 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.24-7.16 (m, 2H), 6.98-6.91 (m, 2H), 4.01 (q, J = 7.1 Hz, 2H), 3.90-3.81 (m, 4H), 3.79 (s, 3H), 3.51-3.43 (m, 8H), 2.82 (s, 3H), 2.70 (s, 3H), 1.86-1.73 (m, 4H), 1.25 (s, 6H), 1.19 (s, 6H), 1.01 (t, J = 7.1 Hz,
 35 3H).

Example H1: 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate) (UL1-119)



Step (i): *tert*-Butyl 25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate (58)

Sodium hydride (60 % wt in oil) (400 mg, 10 mmol) was added to a stirred solution of *tert*-butyl 3-hydroxy-2,2-dimethylpropanoate (57) (1.74 g, 10 mmol) in DMF (20 mL) at 0°C, after 30 min a solution of 2,5,8,11,14,17,20-heptaoadocosan-22-yl methanesulfonate (2.79 g, 6.67 mmol) in DMF (10 mL) was added dropwise, and the reaction mixture was allowed to warm to RT and stirred for 16h. The reaction was quenched with water (100 mL) and the aqueous layer was extracted with DCM (2 x 100 mL), the combined organic layers were washed with brine (3 x 100 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was purified by silica gel chromatography (120 g, 0-10 % MeOH in EtOAc) to afford *tert*-butyl 25,25-dimethyl-2,5,8,11,14,17,20,23-octaohexacosan-26-oate (58) (1.59 g, 48 %) as a colourless oil: ¹H NMR (400 MHz, CDCl₃) δ: 3.65-3.51 (m, 32H), 3.40 (s, 2H), 3.36 (s, 3H), 1.41 (s, 9H), 1.11 (s, 6H).

Step (ii): 25,25-Dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oic acid (59)


TFA (1.5 mL, 19.3 mmol) was added dropwise to a stirred solution of *tert*-butyl 25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate (58) (0.48 g, 0.97 mmol) in DCM (5 mL), and the reaction was stirred at RT for 4h. The volatiles were removed *in vacuo* to afford 25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oic acid (59) (0.49 g, 95 %) as a colourless oil: ¹H NMR (400 MHz, CDCl₃) δ: 3.68-3.60 (m, 26H), 3.55-3.52 (m, 2H), 3.47 (s, 2H), 3.36 (s, 3H), 1.18 (s, 6H).

25 Step (iii): 2-(Dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl
bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate) (**UL1-119**)

Thionyl chloride (43 mg, 0.36 mmol) was added to a stirred solution of 25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oic acid (59) (140 mg, 0.32 mmol) in DCM (2 mL) and the reaction was stirred at RT for 2h. The volatiles were removed *in vacuo*, the residue dissolved in DCM (2 mL) and added to a stirred solution of ethyl 5-(dimethylcarbamoyl)-3,4-

dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**UL1-012**) (50 mg, 0.14 mmol) and DIPEA (46 mg, 0.36 mmol) in DCM (3 mL) at 0°C. The reaction mixture was allowed to warm to RT and stirred for 16h. The volatiles were concentrated *in vacuo* and the resulting residue was suspended in EtOAc (10 mL), filtered and the filtrate concentrated *in vacuo*. The crude residue
 5 was purified by silica gel chromatography (12 g, 0-3 % MeOH in DCM) to give a crude oil. The product was further purified by preparative HPLC (Waters, Acidic (0.1 % Formic acid), Waters X-Select Prep-C18, 5 µm, 19x50 mm column, 25-70 % MeCN in water) to afford 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate) (**UL1-119**) (52 mg, 30 %) as a
 10 colourless oil: *m/z* 1193 (*M*+*H*)⁺ (*ES*⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.21-7.16 (m, 2H), 6.96-6.92 (m, 2H), 4.02 (q, *J* = 7.1 Hz, 2H), 3.79 (s, 3H), 3.58-3.46 (m, 56H), 3.43-3.40 (m, 4H), 3.23 (s, 6H), 2.82 (s, 3H), 2.70 (s, 3H), 1.25 (s, 6H), 1.19 (s, 6H), 1.02 (t, *J* = 7.1 Hz, 3H).

Example I1: Ethyl 5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-3-
 15 ((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate (**UL1-115**)



Step (i): Ethyl 4-(benzyloxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**60**)

20

HBr (33 % in AcOH, 970 µL, 5.34 mmol) was added to a stirred solution of ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (**6**) (2.82 g, 5.34 mmol) in AcOH (40 mL) and the reaction was allowed to stir for 16h at RT. The reaction mixture was diluted with DCM (100 mL), washed with water (100 mL), brine (2 x 100 mL), the
 25 organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was

redissolved in AcOH (40 mL) and HBr (33 % in AcOH, 970 μ L, 5.34 mmol) was added dropwise and the reaction was allowed to stir at RT for 40h. The reaction mixture was diluted with DCM (100 mL), washed with water (100 mL) and brine (2 x 100 mL). The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product was purified by silica gel

5 chromatography (40 g, 0-30 % EtOAc in toluene) to afford ethyl 4-(benzyloxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (60) (1.48 g, 57 %) as a colourless oil: *m/z* 439 (M+H)⁺ (ES⁺); 437 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.75 (s, 1H), 7.42-7.28 (m, 5H), 7.12-7.05 (m, 2H), 6.91-6.84 (m, 2H), 5.01 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 2.68 (s, 3H), 2.66 (s, 3H), 1.0 (t, J = 7.1 Hz, 3H).

10


Step (ii): Ethyl 4-(benzyloxy)-3-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (61)

A solution of dibenzyl (chloromethyl) phosphate (227 mg, 0.70 mmol) in DMF (1 mL) was added
15 dropwise to a stirred suspension of ethyl 4-(benzyloxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (60) (203 mg, 0.46 mmol) and K₂CO₃ (128 mg, 0.93 mmol) in DMF (4 mL) at 0°C, the reaction was stirred for 1h, then allowed to warm to RT over 16h. The reaction mixture was poured into water (50 mL), extracted with Et₂O (2 x 50 mL). The combined organic layers were washed with brine (3 x 100 mL), dried (MgSO₄), filtered and
20 concentrated *in vacuo*. The crude product was purified by silica gel chromatography (40 g, 0-30 % EtOAc in toluene) to afford ethyl 4-(benzyloxy)-3-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (61) (178 mg, 51 %) as a clear colourless oil: *m/z* 729 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.38-7.27 (m, 15H), 7.10-7.03 (m, 2H), 6.92-6.86 (m, 2H), 5.49 (d, J = 11.1 Hz, 2H), 5.11 (s, 2H), 5.07-4.95 (m, 6H),
25 4.00 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.69 (s, 3H), 2.68 (s, 3H), 0.99 (t, J = 7.0 Hz, 3H).

Step (iii): Ethyl 5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-3-((phosphonooxy)methoxy)-1*H*-pyrrole-2-carboxylate (UL1-115)

30 A solution of ethyl 4-(benzyloxy)-3-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate (61) (102 mg, 0.14 mmol) in MeOH (5 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 45°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford ethyl 5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-3-((phosphonooxy)methoxy)-1*H*-pyrrole-2-
35 carboxylate (UL1-115) (61 mg, 93 %) as a white solid: *m/z* 459 (M+H)⁺ (ES⁺); 457 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.11-7.05 (m, 2H), 6.91-6.84 (m, 2H), 5.45 (d, J = 16 Hz, 2H), 3.98 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.98 (br s, 3H) 2.74 (br s, 3H), 1.01 (t, J = 7.0 Hz, 3H).

Example J1: 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-
40 dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate) (UL1-121)



Step (i): 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (62)

5

DIC (160 mg, 1.27 mmol) was added to a solution of 3,4-dihydroxy-1-(4-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide (UL1-005) (200 mg, 0.58 mmol), 3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoic acid (51) (591 mg, 1.27 mmol), and DMAP (28 mg, 0.23 mmol) in EtOAc (4 mL) and the reaction mixture was allowed to stir at RT for 96h. The mixture was diluted with EtOAc (150 mL) washed with 1M HCl (aq.) (50 mL), water (2 x 50 mL), and brine (50 mL), dried (MgSO₄), filtered and concentrated *in vacuo*.

10

The crude residue was purified by preparative HPLC (Waters, Acidic (0.1 % Formic acid), Waters X-Select Prep-C18, 5 μm, 19x50 mm column, 50-95 % MeCN in water) to afford 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-

15

((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (62) (228 mg, 32 %) as a yellow solid: *m/z* not observed. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.40-7.31 (m, 20H), 7.09-7.07 (m, 2H), 6.95-6.93 (m, 2H), 5.02 (d, *J* = 7.6 Hz, 8H), 4.08-4.04 (m, 4H), 3.77 (s, 3H), 3.58-3.56 (m, 4H), 3.56-3.47 (m, 8H), 3.44 (s, 4H), 2.72 (s, 6H), 1.13 (s, 12H).

20

Step (ii) 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate) (UL1-121)

A solution of 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-((bis(benzyloxy)phosphoryl)oxy)ethoxy)ethoxy)-2,2-dimethylpropanoate) (62) (278 mg, 0.22


25

mmol) in MeOH (112 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 45°C under H₂ (10 bar). The output was concentrated *in vacuo* to afford 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate) (UL1-121) (175 mg, 88 %) as a light yellow oil: *m/z* 884 (M+H)⁺ (ES⁺); 882 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.11-7.09 (m, 2H), 6.97-6.95 (m, 2H), 3.91-3.87 (m, 4H), 3.78 (s, 3H), 3.58-3.50 (m, 16H), 2.89 (s, 6H), 2.76 (s, 6H), 1.19 (s, 12H).

30

Example K1: 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(piperidine-4-carboxylate) (UL1-123)

35



Step (i): O^4, O^4 -(2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl) 1-di-*tert*-butyl bis(piperidine-1,4-dicarboxylate) (63)

5

DIC (633 μ L, 4.10 mmol) was added to a solution of 3,4-dihydroxy-1-(4-methoxyphenyl)- N^2, N^2, N^5, N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide (**UL1-005**) (284 mg, 0.82 mmol), 1-(*tert*-butoxycarbonyl)piperidine-4-carboxylic acid (525 mg, 2.29 mmol) and DMAP (40 mg, 0.33 mmol) in EtOAc (5 mL) the reaction mixture was allowed to stir at RT for 2h. The reaction mixture was washed with 1M HCl (aq.) (20 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (40 g, 0-3 % MeOH in DCM) to afford O^4, O^4 -(2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl) 1-di-*tert*-butyl bis(piperidine-1,4-dicarboxylate) (63) (565 mg, 76 %) as a colourless oil: 792 (M+Na)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 7.12-7.08 (m, 2H), 6.98-6.93 (m, 2H), 3.88-3.81 (br m, 4H), 3.77 (s, 3H), 2.96-2.73 (m, 18H), 1.89-1.81 (br m, 4 H), 1.50-1.37 (m, 22H).

15

Step (ii): 4,4'-(((2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl)bis(oxy))bis(carbonyl))bis(piperidin-1-ium) 2,2,2-trifluoroacetate (**UL1-123**)

TFA (1.12 mL, 14.7 mmol) was added dropwise to a solution of O^4, O^4 -(2,5-


20

bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl) 1-di-*tert*-butyl bis(piperidine-1,4-dicarboxylate) (565 mg, 0.73 mmol) in DCM (20 mL) and the mixture was allowed to stir at RT for 2h. The reaction was concentrated *in vacuo* to afford 4,4'-(((2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl)bis(oxy))bis(carbonyl))bis(piperidin-1-ium) 2,2,2-trifluoroacetate (**UL1-123**) (360 mg, 58 %) as a white solid: *m/z* 570 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.71-8.61 (br m, 2H), 8.49-8.36 (br m, 2H), 7.13-7.08 (m, 2H), 7.00-6.95 (m, 2H), 3.78 (s, 3H), 3.33-3.25 (br m, 4H), 3.05-2.92 (m, 6H), 2.79 (br s, 6H), 2.75 (br s, 6H), 2.08-2.00 (br m, 4H), 1.82-1.69 (m, 4H).

25

Example L1: 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)benzoate) (**UL1-124**)

30



Step (i): 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(4-(((di-tert-butoxyphosphoryl)oxy)methyl)benzoate) (**64**)

5

DIC (633 μ l, 4.10 mmol) was added to a solution of 3,4-dihydroxy-1-(4-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1H-pyrrole-2,5-dicarboxamide (**UL1-005**) (252 mg, 0.73 mmol), 4-(((di-tert-butoxyphosphoryl)oxy)methyl)benzoic acid (500 mg, 1.45 mmol) and DMAP (71.0 mg, 0.58 mmol) in EtOAc (8 mL) the reaction mixture was allowed to stir at RT for 16h. The mixture was quenched with water (20 mL) and extracted with EtOAc (3 x 20 mL), the combined organics were washed with brine (100 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (12 g, 0-5 % MeOH in EtOAc) to afford 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(4-(((di-tert-butoxyphosphoryl)oxy)methyl)benzoate) (**64**) (91 mg, 6 %) as a yellow solid: *m/z* 1001 (*M*+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.01-7.99 (m, 4H), 7.55-7.52 (m, 4H), 7.21-7.18 (m, 2H), 7.01-6.99 (m, 2H), 5.00 (s, 4H), 3.80 (s, 3H), 2.89 (s, 6H), 2.74 (s, 6H), 1.38 (s, 36H).

15

Step (ii) 2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)benzoate) (**UL1-124**)


20

TFA (16 mL, 208 mmol) was added dropwise to a solution of 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(4-(((di-tert-butoxyphosphoryl)oxy)methyl)benzoate) (**64**) (88 mg, 0.09 mmol) in DCM (64 mL) the mixture was left to stand for 72h, and then concentrated *in vacuo* to afford 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)benzoate) (**UL1-124**) as a yellow oil: *m/z* 776 (*M*+H)⁺ (ES⁺); 774 (*M*-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 8.00-7.98 (m, 4H), 7.54-7.52 (m, 4H), 7.20-7.18 (m, 2H), 7.00-6.98 (m, 2H), 4.98-4.96 (d, 4H), 3.79 (s, 3H), 2.89 (s, 6H), 2.74 (s, 6H).

25

Example M1: 5-(Dimethylphosphoryl)-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1H-pyrrole-2-carboxamide (**UL1-125**)

30



Step (i): 3,4-Bis(benzyloxy)-5-(dimethylphosphoryl)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (66)

5


Isopropylmagnesium chloride. lithium chloride complex (1.3 M in THF, 315 μ L, 0.410 mmol) was added dropwise to a stirred solution of 3,4-bis(benzyloxy)-5-iodo-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (65) [*prepared using the same procedure as Example S step (i) using (9) as starting material*] (211 mg, 0.36 mmol) in THF (1.2 mL) at 0°C, the reaction mixture was allowed to stir for 15 min and isopropylmagnesium chloride. lithium chloride complex (1.3 M in THF, 100 μ L, 0.13 mmol) was added, and the reaction mixture was allowed to stir for a further 15 min. A solution of dimethylphosphinic chloride (61 mg, 0.54 mmol) in THF (0.6 mL) was added and the reaction allowed to warm to RT and stirred for a further 16h. The reaction mixture was quenched with 5 % AcOH in MeOH (5 mL) and the volatiles removed *in vacuo*. The residue was purified by silica gel chromatography (12 g, 0-5 % MeOH in DCM) to afford a crude residue. The crude residue was further purified by preparative HPLC (Waters, Acidic (0.1 % Formic acid), Waters X-Select Prep-C18, 5 μ m, 19x50 mm column, 30-60 % MeCN in water) to afford 3,4-bis(benzyloxy)-5-(dimethylphosphoryl)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (66) (29 mg, 15 %) as a colourless gum: m/z 533 ($M+H$)⁺ (ES⁺). ¹H NMR (400 MHz, CDCl₃) δ : 7.44-7.28 (m, 12H), 6.92-6.87 (m, 2H), 5.22 (s, 2H), 5.05 (s, 2H), 3.82 (s, 3H), 2.76 (s, 3H), 2.63 (s, 3H), 1.41 (br d, J = 13 Hz, 6H).

Step (ii): 5-(Dimethylphosphoryl)-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (UL1-125)

25

A solution of 3,4-bis(benzyloxy)-5-(dimethylphosphoryl)-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (66) (29 mg, 0.054 mmol) in MeOH (5 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 25°C under H₂ (full H₂ mode). The output was concentrated *in vacuo* to afford 5-(dimethylphosphoryl)-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide (UL1-125) (13 mg, 67 %) as a pale yellow solid: m/z 353 ($M+H$)⁺ (ES⁺), 351 ($M-H$)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-*d*₆) δ : 9.35 (s, 1H), 8.55 (s, 1H), 7.23-7.14 (m, 2H), 6.96-6.88 (m, 2H), 3.77 (s, 3H), 2.86 (br s, 6H), 1.33 (s, 3H), 1.30 (s, 3H).

35 Example N1: (1*R*,1'*R*,4*R*,4'*R*)-2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)cyclohexanecarboxylate) (UL1-126)



Step (i): (1R,4R)-Methyl 4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylate (67)

- 5 5-methyl-1H-tetrazole (4.4 g, 52.3 mmol) was added to a stirred solution of (1R,4R)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate (4.5 g, 26.1 mmol) and dibenzyl diethylphosphoramidite (11.73 mL, 39.2 mmol) in THF (60 mL), after 2h the reaction mixture was cooled to 0°C and a solution of m-CPBA (10.5 g, 47 mmol) in THF (30 mL) was added dropwise. The reaction was allowed to warm to RT and stirred for 16h. The volatiles were removed *in vacuo* and the reaction was diluted with Et₂O (200 mL) and washed with sat. NaHCO₃ (aq.) (5 x 50 mL), brine (30 mL), dried (MgSO₄) filtered and the concentrated *in vacuo*. The crude residue was purified by silica gel chromatography (80 g, 0-50 % Et₂O in isohexane) to afford (1R,4R)-methyl 4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylate (67) (6.35 g, 53 %) as a colourless oil: m/z 433 (M+H)⁺ (ES⁺). ¹H NMR (400 MHz, DMSO-*d*₆) δ: 7.42-7.32 (m, 10H), 5.02 (dd, J = 1.0, 5.4 Hz, 4H), 3.74 (t, J = 6.5 Hz, 2H), 3.58 (s, 3H), 2.20 (tt, J = 12.2, 3.5 Hz, 1H), 1.90-1.83 (m, 2H), 1.70-1.62 (m, 2H), 1.26 (ddd, J = 3.4, 13.1, 16.6 Hz, 2H), 0.93 (ddd, J = 3.4, 13.1, 16.6 Hz, 2H).

Step (ii): (1R,4R)-4-(((Bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylic acid (68)

20

- NaOH (290 mg, 7.17 mmol) was added to a stirred solution of (1R,4R)-methyl 4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylate (67) (3.1 g, 7.17 mmol) in MeOH (50 mL) and water (50 mL) and the reaction was allowed to stir for 24h. The volatiles were removed *in vacuo* diluted with 1 M HCl (aq.) (20 mL) and extracted with DCM (2 x 100 mL), the combined organic layers were dried (MgSO₄), filtered and concentrated *in vacuo* to afford (1R,4R)-4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylic acid (68) (2.74 g, 88 %) as a white solid: m/z 419 (M+H)⁺ (ES⁺); 417 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO-

d_6) δ : 12.03 (s, 1H), 7.42-7.30 (m, 10H), 5.02 (dd, $J = 8.4, 1.0$ Hz, 4H), 3.74 (t, $J = 6.5$ Hz, 2H), 2.12-2.03 (tt, $J = 12.3, 3.5$ Hz, 1H), 1.91-1.81 (m, 2H), 1.71-1.61 (m, 2H), 1.54-1.41 (m, 1H), 1.24 (ddd, $J = 3.3, 13.1, 16.3$ Hz, 2H), 0.92 (ddd, $J = 3.3, 13.1, 16.3$ Hz, 2H).

- 5 Step (iii): (1R,1'R,4R,4'R)-2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylate) (69)

PS-DCC (2.3 mmol/g, 1.25 g, 17.6 mmol) was added to a solution of 3,4-dihydroxy-1-(4-methoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide (UL1-005) (200 mg, 10 0.58 mmol), DMAP (0.028 g, 0.230 mmol) and (1R,4R)-4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylic acid (68) (578 mg, 1.38 mmol) in THF (20 mL) and the reaction mixture was shaken at RT for 96h. The reaction mixture was diluted with EtOAc (50 mL) and washed with 1 M HCl (aq.) (50 mL), sat. NaHCO₃ (aq.) (50 mL), brine (50 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. 15 The product was purified by silica gel chromatography (12 g, 0-3 % MeOH in DCM) to afford (1R,1'R,4R,4'R)-2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylate) (69) (325 mg, 49 %) as a yellow oil: m/z not observed. ¹H NMR (400 MHz, DMSO- d_6) δ : 7.41-7.32 (m, 20H), 7.11-7.07 (m, 2H), 6.97-6.92 (m, 2H), 5.07-4.98 (m, 8H), 3.77 (s, 3H), 3.75 (d, $J = 6.2$ Hz, 4H), 2.83 (br s, 6H), 20 2.75 (br s, 6H), 2.44 (tt, $J = 3.5, 12.2$ Hz, 2H), 1.96-1.87 (m, 4H), 1.75-1.65 (m, 4H), 1.59-1.46 (m, 2H), 1.33 (ddd, $J = 3.4, 13.1, 16.2$ Hz, 4H), 1.01 (ddd, $J = 3.4, 13.1, 16.2$ Hz, 4H).





Step (iv): (1R,1'R,4R,4'R)-2,5-Bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)cyclohexanecarboxylate) (UL1-126)





25





A solution of (1R,1'R,4R,4'R)-2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-(((bis(benzyloxy)phosphoryl)oxy)methyl)cyclohexanecarboxylate) (69) (323 mg, 0.28 mmol) in MeOH (8 mL) was passed through a Thales 'H-cube' cartridge (10 % Pd/C) at a flow rate of 1 mL/min at 50°C under H₂ (full H₂ mode). The output was concentrated *in vacuo*, and a 30 solid was collected by filtration after trituration with EtOAc (5 mL) to afford (1R,1'R,4R,4'R)-2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)cyclohexanecarboxylate) (UL1-126) (121 mg, 43 %) as a pale yellow solid: m/z 788 (M+H)⁺ (ES⁺); 786 (M-H)⁻ (ES⁻). ¹H NMR (400 MHz, DMSO- d_6) δ : 10.90 (br s, 2H), 7.12-7.06 (m, 2H), 6.97-6.92 (m, 2H), 3.77 (s, 3H), 3.63 (t, $J = 6.4$ Hz, 4H), 2.83 (br s, 6H), 35 2.75 (br s, 6H), 2.50-2.45 (m, 2H), 2.00-1.93 (m, 4H), 1.84-1.76 (m, 4H), 1.63-1.51 (m, 2H), 1.38 (ddd, 3.1, 12.7, 16.0 Hz, 4H), 1.05 (ddd, 3.1, 12.7, 16.0 Hz, 4H).





The following Examples in Table 1 were prepared using the general methods outlined above:





Table 1





Entry	Structure	Compound name	ID	IC ₅₀	¹ H NMR Data (DMSO- <i>d</i> ₆)	Ionisation	Preparation
1		<i>N</i> ² , <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁵ -tetraethyl-1-(4-fluorophenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-001	+++	δ: 8.37 (s, 2H), 7.19-7.08 (m, 2H), 7.05-6.95 (m, 2H), 3.29 (q, <i>J</i> = 7.1 Hz, 8H), 0.98 (t, <i>J</i> = 7.1 Hz, 12H).	m/z 392 (M+H) ⁺ , 390 (ES ⁺), 390 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i)
2		1-(4-ethoxyphenyl)- <i>N</i> ² , <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁵ -tetraethyl-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-002	+++	δ: 8.23 (s, 2H), 6.94-6.88 (m, 2H), 6.85-6.79 (m, 2H), 3.98 (q, <i>J</i> = 7.0 Hz, 2H), 3.27 (q, <i>J</i> = 7.0 Hz, 8H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H), 0.95 (t, <i>J</i> = 7.0 Hz, 12H).	m/z 418 (M+H) ⁺ , 416 (ES ⁺), 416 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate was used in step (i)
3		<i>N</i> ² , <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁵ -tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-003	+++	δ: 8.26 (s, 2H), 6.96-6.88 (m, 2H), 6.87-6.81 (m, 2H), 3.72 (s, 3H), 3.27 (q, <i>J</i> = 7.1 Hz, 8H), 0.96 (t, <i>J</i> = 7.0 Hz, 12H).	m/z 404 (M+H) ⁺ , 402 (ES ⁺), 402 (M-H) ⁻ (ES ⁻)	Example A
4		(3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-diy)bis(morpholinomethanone)	UL1-004	+++	δ: 8.51 (s, 2H), 7.00-6.98 (m, 2H), 6.91-6.83 (m, 2H), 3.75 (s, 3H), 3.50-3.37 (m, 16H).	m/z 432 (M+H) ⁺ , 430 (ES ⁺), 430 (M-H) ⁻ (ES ⁻)	As example A except morpholine used in step (ii)





5		3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁶ , <i>N</i> ⁷ -tetramethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-005	+++	δ : 8.38 (s, 2H), 6.96-6.87 (m, 2H), 6.86-5.79 (m, 2H), 3.73 (s, 3H), 2.88 (br s, 12H).	m/z 348, (M+H) ⁺ (ES ⁺), 346 (M-H) ⁻ (ES ⁻)	As example A except dimethylamine hydrochloride used in step (ii)
6		(1-(4-fluorophenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-diy)bis(morpholinomethanone)	UL1-006	+++	δ : 8.60 (s, 2H), 7.20-7.12 (m, 2H), 7.10-7.03 (m, 2H), 3.52-3.39 (m, 16H).	m/z 420 (M+H) ⁺ (ES ⁺), 418 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and morpholine used in step (ii).
7		1-(4-fluorophenyl)-3,4-dihydroxy- <i>N</i> ² , <i>N</i> ⁵ -dimethyl- <i>N</i> ² , <i>N</i> ⁵ -diphenyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-007	+	δ : 8.34 (s, 2H), 7.24-7.06 (m, 8H), 6.79-6.70 (m, 4H), 6.86-6.60 (m, 2H), 3.12 (s, 6H).	m/z 460 (M+H) ⁺ (ES ⁺), 458 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and <i>N</i> -methylaniline used in step (ii).
8		1-(4-fluorophenyl)-3,4-dihydroxy- <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁶ , <i>N</i> ⁷ -tetramethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-008	+++	δ : 8.48 (s, 2H), 7.16-7.07 (m, 2H), 7.06-6.96 (m, 2H), 2.90 (s, 12H).	m/z 336 (M+H) ⁺ (ES ⁺), 334 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and dimethylamine hydrochloride used in step (ii).





9		di-tert-butyl 4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1H-pyrazole-2,5-dicarbonyl)bis(piperazine-1-carboxylate)	UL1-009	+++	δ : 8.62 (s, 2H), 7.17-7.10 (m, 2H), 7.08-7.02 (m, 2H), 3.47-3.36 (m, 8H), 3.29-3.22 (m, 8H), 1.40 (s, 18H).	m/z 618 (M+H) ⁺ , 616 (ES ⁺), 616 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1H-pyrrole-2,5-dicarboxylate used in step (i) and tert-butyl piperazine-1-carboxylate used in step (ii).
10		1,1'-(4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1H-pyrazole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone	UL1-010	+++	δ : 8.66 (s, 2H), 7.17-7.10 (m, 2H), 7.09-7.02 (m, 2H), 3.51-3.44 (m, 4H), 3.43-3.35 (m, 12H), 1.40 (s, 6H).	m/z 502 (M+H) ⁺ , 500 (ES ⁺), 500 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1H-pyrrole-2,5-dicarboxylate used in step (i) and 1-(piperazin-1-yl)ethanone used in step (ii).
11		(1-(4-fluorophenyl)-3,4-dihydroxy-1H-pyrazole-2,5-diyl)bis(piperidin-1-ylmethanone)	UL1-011	+++	δ : 8.42 (s, 2H), 7.22-7.10 (m, 2H), 7.05-6.96 (m, 2H), 3.45-3.33 (m, 8H), 1.60-1.47 (m, 4H), 1.44-1.29 (m, 8H).	m/z 416 (M+H) ⁺ , 414 (ES ⁺), 414 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1H-pyrrole-2,5-dicarboxylate used in step (i) and piperidine used in step (ii).
12		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrazole-2-carboxylate	UL1-012	+++	δ : 8.60 (s, 1H), 8.46 (s, 1H), 7.08-7.01 (m, 2H), 6.90-6.82 (m, 2H), 4.00 (q, J = 7.0 Hz, 2H), 3.76 (s, 3H), 2.83 (br s, 6H), 0.99 (t, J = 7.1 Hz, 6H).	m/z 349 (M+H) ⁺ , 347 (ES ⁺), 347 (M-H) ⁻ (ES ⁻)	Example B





13		1-(4-fluorophenyl)-3,4-dihydroxy- <i>N</i> ² , <i>N</i> ⁵ -diisopropyl- <i>N</i> ² , <i>N</i> ⁵ -dimethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-013	+++	δ: 8.40 (s, 2H), 7.19-7.10 (m, 2H), 7.02-6.94 (m, 2H), 4.28 (m, 2H), 2.71 (s, 6H), 0.99 (d, J = 6.7 Hz, 12H).	m/z 392 (M+H) ⁺ , 390 (ES ⁺), 390 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and <i>N</i> -methylpropan-2-amine used in step (ii).
14		<i>N</i> ² , <i>N</i> ⁵ -dibenzyl-1-(4-fluorophenyl)-3,4-dihydroxy- <i>N</i> ² , <i>N</i> ⁵ -dimethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-014	+++	δ: 8.17 (s, 2H), 7.30-7.19 (m, 6H), 7.11-7.04 (m, 8H), 4.50 (s, 4H), 2.85 (s, 6H).	m/z 488 (M+H) ⁺ , 486 (ES ⁺), 486 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and <i>N</i> -methyl-1-phenylmethanamine used in step (ii).
15		di-tert-butyl 4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate)	UL1-015	+++	δ: 8.49 (s, 2H), 6.99-6.91 (m, 2H), 6.89-6.81 (m, 2H), 3.73 (s, 3H), 3.47-3.35 (m, 8H), 3.30-3.14 (m, 8H), 1.40 (br s, 18H).	m/z 630 (M+H) ⁺ , 628 (ES ⁺), 628 (M-H) ⁻ (ES ⁻)	As example A except tert-butyl piperazine-1-carboxylate used in step (ii)
16		(3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-diy)bis(piperazin-1-ylmethanone)	UL1-016	+++	δ: 8.86-8.64 (m, 6H), 7.06-6.95 (m, 2H), 6.89-6.80 (m, 2H), 3.75 (s, 3H), 3.67-3.54 (m, 8H), 3.11-2.96 (m, 8H).	m/z 430 (M+H) ⁺ , 428 (ES ⁺), 428 (M-H) ⁻ (ES ⁻)	Obtained as the di-TFA salt from TFA mediated Boc-deprotection of UL1-015





17		1-(4-fluorophenyl)-3,4-dihydroxy- <i>N</i> ² , <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁵ -tetraisopropyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-017	+++	δ : 8.16 (s, 2H), 7.23-7.12 (m, 2H), 7.09-6.97 (m, 2H), 3.89-3.51 (m, 4H), 1.22-0.98 (m, 24H).	m/z 448 (M+H) ⁺ , 446 (ES ⁺), 446 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and diisopropylamine used in step (ii)
18		(3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-diy)bis(piperidin-1-ylmethanone)	UL1-018	+++	δ : 8.30 (s, 2H), 6.95-6.89 (m, 2H), 6.88-6.83 (m, 2H), 3.74 (s, 3H), 3.39-3.33 (m, 8H), 1.57-1.47 (m, 4H), 1.40-1.32 (m, 8H).	m/z 428 (M+H) ⁺ , 426 (ES ⁺), 426 (M-H) ⁻ (ES ⁻)	As example A except piperidine used in step (ii)
19		3,4-dihydroxy-1-(2-methoxyphenyl)- <i>N</i> ² , <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁵ -tetramethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-019	+++	δ : 8.29 (s, 2H), 7.19-7.10 (m, 1H), 6.99-6.92 (m, 1H), 6.91-6.79 (m, 2H), 3.63 (s, 3H), 2.90 (s, 12H).	m/z 348 (M+H) ⁺ , 346 (ES ⁺), 346 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(2-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and dimethylamine hydrochloride used in step (ii)
20		(3,4-dihydroxy-1-(2-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-diy)bis(morpholinomethanone)	UL1-020	+++	δ : 8.42 (s, 2H), 7.25-7.13 (m, 1H), 7.02-6.93 (m, 2H), 6.92-6.83 (m, 1H), 3.67 (s, 3H), 3.54-3.35 (m, 16H).	m/z 432 (M+H) ⁺ , 430 (ES ⁺), 430 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(2-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and morpholine used in step (ii)





21		1-(4-ethoxyphenyl)-3,4-dihydroxy- <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁶ -tetramethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-021	+++	δ : 8.35 (s, 2H), 6.94-6.86 (m, 2H), 6.84-6.77 (m, 2H), 3.99 (q, J = 7.0 Hz, 2H), 2.87 (br s, 12H), 1.32 (t, J = 7.0 Hz, 3H).	m/z 362 (M+H) ⁺ , 360 (ES ⁺), 360 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate was used in step (i) and dimethylamine hydrochloride used in step (ii)
22		(1-(4-ethoxyphenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-diyldis(morpholinomethanone))	UL1-022	+++	δ : 8.47 (s, 2H), 6.98-6.91 (m, 2H), 6.90-6.81 (m, 2H), 4.01 (q, J = 7.0 Hz, 2H), 3.51-3.35 (m, 16H), 1.32 (t, J = 7.0 Hz, 3H).	m/z 446 (M+H) ⁺ , 444 (ES ⁺), 444 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate was used in step (i) and dimethylamine hydrochloride used in step (ii)
23		(3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1 <i>H</i> -pyrrole-2,5-diyldis(morpholinomethanone))	UL1-023	+++	δ : 8.84 (s, 2H), 7.73-7.67 (m, 2H), 7.24-7.19 (m, 2H), 3.60-3.44 (m, 16H).	m/z 470 (M+H) ⁺ , 468 (ES ⁺), 468 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-(trifluoromethyl)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate was used in step (i) and morpholine used in step (ii)
24		<i>N</i> ² -ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N</i> ⁵ , <i>N</i> ⁶ -dimethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-024	+++	δ : 9.44 (s, 1H), 8.42 (s, 1H), 7.10-7.03 (m, 1H), 7.02-6.97 (m, 2H), 6.86-6.77 (m, 2H), 3.75 (s, 3H), 3.14-3.06 (m, 2H), 2.81 (br s, 6H), 0.97 (t, J = 7.2 Hz, 3H).	m/z 348 (M+H) ⁺ , 346 (ES ⁺), 346 (M-H) ⁻ (ES ⁻)	Example C





25		3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N,N</i> -dimethyl-5-(piperidine-1-carbonyl)-1 <i>H</i> -pyrrole-2-carboxamide	UL1-025	+++	δ : 8.40 (s, 1H), 8.32 (s, 1H), 6.94-6.88 (m, 2H), 6.87-6.80 (m, 2H), 3.73 (s, 3H), 3.39-3.35 (m, 4H), 2.88 (br s, 6H), 1.59-1.47 (m, 2H), 1.45-1.25 (m, 4H).	m/z 388 (M+H) ⁺ (ES ⁺), 386 (M-H) ⁻ (ES ⁻)	As example C except piperidine used in step (i)
26		3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N,N</i> -dimethyl-5-(morpholine-4-carbonyl)-1 <i>H</i> -pyrrole-2-carboxamide	UL1-026	+++	δ : 8.48 (s, 1H), 8.42 (s, 1H), 6.97-6.91 (m, 2H), 6.89-6.83 (m, 2H), 3.75 (s, 3H), 3.51-3.38 (m, 8H), 2.88 (br s, 6H).	m/z 390 (M+H) ⁺ (ES ⁺), 388 (M-H) ⁻ (ES ⁻)	As example C except morpholine used in step (i)
27		3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N,N</i> -dimethyl-5-(4-methylpiperazine-1-carbonyl)-1 <i>H</i> -pyrrole-2-carboxamide	UL1-027	+++	δ : 8.46 (br s, 2H), 6.98-6.90 (m, 2H), 6.89-6.80 (m, 2H), 3.75 (s, 3H), 3.48-3.37 (m, 4H), 2.88 (br s, 6H), 2.26-2.18 (m, 4H), 1.91 (s, 3H).	m/z 403 (M+H) ⁺ (ES ⁺), 401 (M-H) ⁻ (ES ⁻)	As example C except 1-methylpiperazine used in step (i)
28		3,4-dihydroxy- <i>N</i> ² , <i>N</i> ² , <i>N</i> ⁶ , <i>N</i> ⁶ -tetramethyl-1-(4-(trifluoromethyl)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-028	+++	δ : 8.68 (s, 2H), 7.69-7.60 (m, 2H), 7.18-7.11 (m, 2H), 2.96 (m, 12H).	m/z 386 (M+H) ⁺ (ES ⁺), 384 (M-H) ⁻ (ES ⁻)	As example A except diethyl 3,4-bis(benzyloxy)-1-(4-(trifluoromethyl)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate was used in step (i) and dimethylamine hydrochloride used in step (ii)





29		1-(4-(dimethylcarbamoyl)phenyl)-3,4-dihydroxy-N ² ,N ⁵ ,N ⁶ -tetramethyl-1H-pyrrole-2,5-dicarboxamide	UL1-029	+++	δ : 8.57 (s, 2H), 7.36-7.29 (m, 2H), 7.03-6.96 (m, 2H), 3.01-2.85 (m, 12H).	m/z 389 (M+H) ⁺ , 387 (ES ⁺), 387 (M-H) ⁻ (ES ⁻)	As example A except 1-(4-carboxyphenyl)-3,4-dihydroxy-1H-pyrrole-2,5-dicarboxylic acid and dimethylamine hydrochloride used in step (ii)
30		tert-butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)sulfonylcarbamate)-1H-pyrrol-2-yl)sulfonylcarbamate	UL1-030	+	δ : 11.04 (s, 1H), 8.75 (s, 1H), 8.35 (s, 1H), 7.07-7.00 (m, 2H), 6.92-6.86 (m, 2H), 3.77 (s, 3H), 2.80 (br s, 6H), 1.35 (s, 9H).	m/z 456 (M+H) ⁺ , 454 (ES ⁺), 454 (M-H) ⁻ (ES ⁻)	Example E
31		5-cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide	UL1-031	+++	δ : 9.80 (s, 1H), 8.80 (s, 1H), 7.21-7.11 (m, 2H), 7.03-6.93 (m, 2H), 3.79 (s, 3H), 2.88 (br s, 6H).	m/z 302 (M+H) ⁺ , 300 (ES ⁺), 300 (M-H) ⁻ (ES ⁻)	Example F
32		ethyl 5-(dimethylcarbamoyl)-1-(4-fluorophenyl)-3,4-dihydroxy-1H-pyrrole-2-carboxylate	UL1-032	+++	δ : 8.70 (s, 1H), 8.55 (s, 1H), 7.32-7.10 (m, 4H), 4.00 (q, J = 7.1 Hz, 4H), 2.85 (br s, 6H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 337 (M+H) ⁺ , 335 (ES ⁺), 335 (M-H) ⁻ (ES ⁻)	As example B except 4-fluoroaniline used in step (i)





37		ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(4-methylpiperazine-1-carbonyl)-1H-pyrrole-2-carboxylate	UL1-037	+++	δ : 8.60 (s, 1H), 8.46 (s, 1H), 7.08-7.01 (m, 2H), 6.90-6.82 (m, 2H), 4.00 (q, J = 7.0 Hz, 2H), 3.76 (s, 3H), 3.45-3.29 (m, 4H), 2.34-1.97 (m, 7H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 404 (M+H) ⁺ (ES ⁺), 402 (M-H) ⁻ (ES ⁻)	As example B except 1-methylpiperazine used in step (v)
38		ethyl 5-(dibutylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-038	+++	δ : 8.18-7.96 (m, 2H), 7.11-7.02 (m, 2H), 6.90-6.82 (m, 2H), 4.01 (q, J = 7.0 Hz, 2H), 3.78 (s, 3H), 3.16 (t, J = 7.4 Hz, 4H), 1.29 (quin., J = 7.6 Hz, 4H), 1.12 (sext., J = 7.4 Hz, 4H), 1.29 (t, J = 7.1 Hz, 3H), 0.81 (t, J = 7.3 Hz, 6H).	m/z 433 (M+H) ⁺ (ES ⁺), 431 (M-H) ⁻ (ES ⁻)	As example B except dibutylamine used in step (v)
39		ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1H-pyrrole-2-carboxylate	UL1-039	+	δ : 10.14 (s, 1H), 8.99 (s, 1H), 7.44-7.36 (m, 2H), 7.35-7.26 (m, 2H), 4.05 (q, J = 7.1 Hz, 2H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 291 (M+H) ⁺ (ES ⁺), 289 (M-H) ⁻ (ES ⁻)	Example H
40		ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(morpholine-4-carbonyl)-1H-pyrrole-2-carboxylate	UL1-040	+++	δ : 8.65 (s, 1H), 8.47 (s, 1H), 7.11-7.01 (m, 2H), 6.91-6.83 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 3.50-3.32 (m, 8H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 391 (M+H) ⁺ (ES ⁺), 389 (M-H) ⁻ (ES ⁻)	As example B except morpholine used in step (v)





41		ethyl 5-(diethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-041	+++	δ : 8.08 (br s, 2H), 7.10-7.01 (m, 2H), 6.92-6.79 (m, 2H), 4.03 (q, J = 7.0 Hz, 2H), 3.22 (q, J = 7.0 Hz, 4H), 3.77 (s, 3H), 1.01 (t, J = 7.0 Hz, 3H), 0.92 (t, J = 7.1 Hz, 6H).	m/z 377 (M+H) ⁺ (ES ⁺), 375 (M-H) ⁻ (ES ⁻)	As example B except diethylamine used in step (v)
42		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-iodophenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-042	+++	δ : 8.75 (s, 1H), 8.59 (s, 1H), 7.69-7.63 (m, 2H), 6.95-6.89 (m, 2H), 4.01 (q, J = 7.1 Hz, 2H), 2.85 (br s, 6H), 1.00 (t, J = 7.1 Hz, 3H).	m/z 445 (M+H) ⁺ (ES ⁺), 443 (M-H) ⁻ (ES ⁻)	As example B except 4-iodoaniline used in step (i)
43		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-043	+++	δ : 8.70 (s, 1H), 8.53 (s, 1H), 7.52 (d, J = 2.5 Hz, 1H), 7.11 (dd, J = 8.7, 2.5 Hz, 1H), 6.92 (d, J = 8.7 Hz, 1H), 4.00 (q, J = 7.1 Hz, 2H), 3.83 (s, 3H), 2.85 (br s, 6H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 475 (M+H) ⁺ (ES ⁺), 472 (M-H) ⁻ (ES ⁻)	As example B except 3-iodo-4-methoxyaniline used in step (i)
44		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl diacetate	UL1-044*	+++	δ 7.27-7.11 (2H, m), 7.00-6.88 (2H, m), 4.00 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 2.79 (s, 3H), 2.71 (s, 3H), 2.26 (s, 6H) 1.05 (t, J = 7.1 Hz, 3H).	m/z 433 (M+H) ⁺ (ES ⁺)	Example J





45		3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-N ² ,N ² ,N ⁵ ,N ⁵ -tetraethyl-1H-pyrrole-2,5-dicarboxamide	UL1-045	+++	δ : 7.43-7.26 (m, 10 H), 7.05-6.99 (m, 2H), 6.93-6.84 (m, 2H), 4.97 (s, 4H), 4.00 (t, J = 6.9 Hz, 2H), 3.29-3.19 (m, 4H), 3.18-3.07 (m, 4H), 1.31 (t, J = 6.9 Hz, 3H), 0.95-0.79 (m, 12H).	m/z 598 (M+H) ⁺ (ES ⁺)	UL1-002
46		3,4-bis(benzyloxy)-N ² ,N ² ,N ⁵ ,N ⁵ -tetraethyl-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxamide	UL1-046	+++	δ : 7.40-7.28 (m, 10 H), 7.07-7.00 (m, 2H), 6.95-6.87 (m, 2H), 4.97 (s, 4H), 3.74 (s, 3H), 3.29-3.20 (m, 4H), 3.19-3.11 (m, 4H), 0.95-0.79 (m, 12H).	m/z 584 (M+H) ⁺ (ES ⁺)	Example A
47		3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-N ² ,N ² ,N ⁵ ,N ⁵ -tetramethyl-1H-pyrrole-2,5-dicarboxamide	UL1-047	++	(CDCl ₃) δ : 7.40-7.27 (m, 10 H), 7.17-7.04 (m, 2H), 6.88-6.75 (m, 2H), 5.08 (s, 4H), 3.78 (s, 3H), 2.81 (s, 6H), 2.65 (s, 6H).	m/z 529 (M+H) ⁺ (ES ⁺)	UL1-005
48		di-tert-butyl 4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate)	UL1-048	+++	δ : 7.47-7.26 (m, 10 H), 7.10-7.00 (m, 2H), 6.97-6.87 (m, 2H), 5.01 (s, 4H), 3.75 (s, 3H), 5.09-4.95 (m, 16H), 1.39 (s, 18H).	m/z 810 (M+H) ⁺ (ES ⁺)	UL1-015

49		(3,4-bis(benzoyloxy)-1-(4-methoxyphenyl)-1H-pyrazole-2,5-diyl)bis(piperidin-1-ylmethanone)	UL1-049	+++	δ : 7.42-7.27 (m, 10 H), 7.03-6.98 (m, 2H), 6.97-6.90 (m, 2H), 4.98 (s, 4H), 3.75 (s, 3H), 3.42-3.28 (m, 4H), 3.20-3.07 (m, 4H), 1.48-1.39 (m, 4H), 1.38-1.06 (m, 8H).	m/z 608 (M+H) ⁺ (ES ⁺)	UL1-018
50		3,4-bis(benzoyloxy)-1-(2-methoxyphenyl)-N ² ,N ² ,N ⁵ ,N ⁵ -tetramethyl-1H-pyrazole-2,5-dicarboxamide	UL1-050	++	δ : 7.43-7.28 (m, 10 H), 7.28-7.20 (m, 1H), 7.06-6.94 (m, 2H), 6.93-6.86 (m, 1H), 5.08-4.88 (m, 4H), 3.66 (s, 3H), 2.87 (s, 6H), 2.75 (s, 6H).	m/z 528 (M+H) ⁺ (ES ⁺)	UL1-019
51		(3,4-bis(benzoyloxy)-1-(4-methoxyphenyl)-1H-pyrazole-2,5-diyl)bis(morpholinomethanone)	UL1-051	+	δ : 7.42-7.24 (m, 11 H), 7.08-7.00 (m, 2H), 6.98-6.91 (m, 1H), 5.07-4.95 (m, 4H), 3.69 (s, 3H), 3.47-3.05 (m, 16H).	m/z 612 (M+H) ⁺ (ES ⁺)	UL1-020
52		3,4-bis(benzoyloxy)-1-(4-ethoxyphenyl)-N ² ,N ² ,N ⁵ ,N ⁵ -tetramethyl-1H-pyrazole-2,5-dicarboxamide	UL1-052	+++	δ : 7.42-7.27 (m, 10 H), 7.01-6.94 (m, 2H), 6.91-6.84 (m, 2H), 5.00 (s, 4H), 4.00 (q, J = 6.9 Hz, 2H), 2.76-2.67 (m, 12H), 1.32 (t, J = 6.9 Hz, 3H).	m/z 542 (M+H) ⁺ (ES ⁺)	UL1-021





53		(3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-diyl)bis(morpholinomethanone)	UL1-053	++	δ : 7.42-7.29 (m, 10 H), 7.05-6.99 (m, 2H), 6.97-6.90 (m, 2H), 5.01 (s, 4H), 4.01 (q, J = 7.0 Hz, 2H), 3.42-3.33 (m, 8H), 3.25-3.10 (m, 8H), 1.32 (t, J = 7.0 Hz, 3H).	m/z 626 (M+H) ⁺ (ES ⁺)	UL1-022
54		3,4-bis(benzyloxy)- <i>N</i> ² , <i>N</i> ² , <i>N</i> ⁵ , <i>N</i> ⁵ -tetramethyl-1-(4-(trifluoromethyl)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-054	++	δ : 7.78-7.69 (m, 2H), 7.42-7.30 (m, 10 H), 7.29-7.23 (m, 2H), 5.03 (s, 4H), 2.89 (s, 6H), 2.79 (s, 6H).	m/z 566 (M+H) ⁺ (ES ⁺)	UL1-028
55		3,4-bis(benzyloxy)- <i>N</i> ² -ethyl-1-(4-methoxyphenyl)- <i>N</i> ⁵ , <i>N</i> ⁵ -dimethyl-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-055	++	(CDCl ₃) δ : 7.42-7.30 (m, 10 H), 7.20-7.09 (m, 2H), 7.06-6.96 (m, 1H), 6.89-6.80 (m, 2H), 5.20 (s, 2H), 5.07 (s, 2H), 3.79 (s, 3H), 3.25-3.13 (m, 2H), 2.79 (s, 3H), 2.72 (s, 3H), 0.97 (t, J = 7.3 Hz, 3H).	m/z 528 (M+H) ⁺ (ES ⁺)	Example C
56		3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- <i>N</i> , <i>N</i> -dimethyl-5-(4-methylpiperazine-1-carbonyl)-1 <i>H</i> -pyrrole-2-carboxamide	UL1-056	++	(CDCl ₃) δ : 7.42-7.26 (m, 10 H), 7.15-7.06 (m, 2H), 6.88-6.79 (m, 2H), 5.07 (s, 4H), 3.78 (s, 3H), 3.53 (br s, 2H), 3.30-3.18 (m, 2H), 2.83 (s, 3H), 2.70 (s, 3H), 2.21 (br s, 2H), 2.17 (s, 3H), 2.02 (br s, 2H).	m/z 583 (M+H) ⁺ (ES ⁺)	UL1-027





57		3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-N,N-dimethyl-5-(piperidine-1-carbonyl)-1H-pyrrole-2-carboxamide	UL1-057	+++	(CDCl ₃) δ: 7.45-7.26 (m, 10 H), 7.19-7.06 (m, 2H), 6.90-6.77 (m, 2H), 5.07 (s, 4H), 3.78 (s, 3H), 3.46 (br s, 2H), 3.21-3.05 (m, 2H), 2.82 (s, 3H), 2.68 (s, 3H), 1.56-1.31 (m, 4H), 1.21 (br s, 2H).	m/z 568 (M+H) ⁺ (ES ⁺)	UL1-025
58		3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-N,N-dimethyl-5-(morpholine-4-carbonyl)-1H-pyrrole-2-carboxamide	UL1-058	+	(CDCl ₃) δ: 7.42-7.27 (m, 10 H), 7.15-7.06 (m, 2H), 6.89-6.80 (m, 2H), 5.13-5.03 (m, 4H), 3.79 (s, 3H), 3.56-3.37 (m, 4H), 3.32-3.09 (m, 4H), 2.82 (s, 3H), 2.69 (s, 3H).	m/z 570 (M+H) ⁺ (ES ⁺)	UL1-026
59		1,1'-(4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone	UL1-059	+	δ: 7.42-7.27 (m, 10 H), 7.11-7.02 (m, 2H), 6.97-6.88 (m, 2H), 5.02 (s, 4H), 3.77 (s, 3H), 3.41-3.17 (m, 16H), 1.96 (s, 6H).	m/z 694 (M+H) ⁺ (ES ⁺)	UL1-033
60		ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1H-pyrrole-2-carboxylate	UL1-060	+	δ: 7.51-7.32 (m, 14H), 5.27 (s, 2H), 5.11 (s, 2H), 4.05 (q, J = 7.1 Hz, 2H), 1.00 (t, J = 7.1 Hz, 3H).	m/z 471 (M+H) ⁺ (ES ⁺)	Example H





61		3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-N,N-dimethyl-1H-pyrrole-2-carboxamide	UL1-061	+++	δ : 7.49-7.30 (m, 14 H), 5.30 (s, 2H), 5.00 (s, 2H), 2.79-2.74 (m, 6H).	m/z 470 (M+H) ⁺ (ES ⁺)	As example F except triethylammonium 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-fluorophenyl)-1H-pyrrole-2-carboxylate used in step (i)
62		ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-iodophenyl)-1H-pyrrole-2-carboxylate	UL1-062	+++	δ : 7.76-7.68 (m, 2H), 7.47-7.42 (m, 2H), 7.41-7.29 (m, 8H), 7.03-6.96 (m, 2H), 5.13 (s, 2H), 4.97 (s, 2H), 4.01 (q, J = 7.1 Hz, 2H), 2.77 (s, 3H), 2.73 (s, 3H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 625 (M+H) ⁺ (ES ⁺)	UL1-042
63		ethyl 5-(dimethylcarbamoyl)-3,4-bis((dimethylcarbamoyl)oxy)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-063*	-	δ : 7.21-7.11 (m, 2H), 6.98-6.88 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.01 (s, 3H), 2.96 (s, 3H), 2.90 (s, 3H), 2.88 (s, 3H), 2.80 (s, 3H), 2.70 (s, 3H) 1.05 (t, J = 7.1 Hz, 3H).	m/z 491 (M+H) ⁺ (ES ⁺)	Example O
64		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(4-methylpiperazine-1-carboxylate)	UL1-064*	-	δ : 7.20-7.14 (m, 2H), 6.96-6.91 (m, 2H), 4.01 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.60-3.36 (br m, 8H), 2.82 (s, 3H), 2.72 (s, 3H), 2.40-2.29 (br m, 8H), 2.23 (s, 3H), 2.22 (s, 3H) 1.07 (t, J = 7.1 Hz, 3H).	m/z 301 (M+H) ⁺ (ES ⁺)	As example O except 4-methylpiperazine-1-carbonyl chloride used





65		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis([1,4'-bipiperidine]-1'-carboxylate)	UL1-065*	-	δ : 7.18-7.14 (m, 2H), 6.95-6.91 (m, 2H), 4.14-3.94 (m, 6H), 3.79 (s, 3H), 3.01-2.80 (m, 7H), 2.71 (s, 3H) 2.45-2.44 (br m, 10H) 1.78-1.75 (m, 4H) 1.48-1.26 (m, 16H) 1.05 (t, J = 7.1 Hz, 3H).	m/z 369 (M+H) ⁺ (ES ⁺)	As example O except [1,4'-bipiperidine]-1'-carbonyl chloride used
66		ethyl 5-(dimethylcarbamoyl)-4-((dimethylcarbamoyl)oxy)-3-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-066*	+++	δ : 8.85 (s, 1H), 7.16-7.06 (m, 2H), 6.95-6.86 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.98 (s, 3H), 2.88 (s, 3H), 2.78 (s, 3H), 2.69 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H).	m/z 420 (M+H) ⁺ (ES ⁺)	Example P
67		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(2-methylpropanoate)	UL1-067*	+	δ : 7.23-7.16 (m, 2H), 6.95-6.86 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 2.83-2.74 (s, 5H), 2.71 (s, 3H), 1.20 (d, J = 7.0 Hz, 6H), 1.20 (d, J = 7.0 Hz, 6H), 1.03 (t, J = 7.1 Hz, 3H).	m/z 489 (M+H) ⁺ (ES ⁺)	As example J except isobutyl chloride used
68		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(2,2-dimethylpropanoate)	UL1-068*	-	δ : 7.23-7.17 (m, 2H), 6.97-6.91 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 2.82 (s, 3H), 2.71 (s, 3H), 1.27 (s, 9H), 1.21 (s, 9H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 517 (M+H) ⁺ (ES ⁺)	As example J except pivaloyl chloride used





69		ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(sulfamoyloxy)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-069*	+++	δ : 8.87 (s, 1H), 7.92 (s, 2H), 7.16-7.08 (m, 2H), 6.96-6.88 (m, 2H), 4.03 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 2.75 (s, 3H), 2.67 (s, 3H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 428 (M+H) ⁺ (ES ⁺), 426 (M-H) ⁻ (ES ⁻)	As example Q
70		ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonoxy)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-070*	+	δ : 7.11-7.03 (m, 2H), 6.93-6.85 (m, 2H), 3.99 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.82 (s, 3H), 2.71 (s, 3H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 429 (M+H) ⁺ (ES ⁺), 427 (M-H) ⁻ (ES ⁻)	Example R
71		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-4-hydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrol-3-yl [1,4'-bipiperidine]-1'-carboxylate	UL1-071*	+	δ : 8.86 (s, 1H) 7.17-7.05 (m, 2H), 6.95-6.85 (m, 2H), 4.15-3.91 (m, 4H), 3.77 (s, 3H), 3.04-2.89 (m, 1H), 2.89-2.75 (m, 4H), 2.69 (s, 3H), 2.44 (br s, 5H), 1.75-1.73 (br m, 2H), 1.54-1.43 (br m, 4H), 1.43-1.29 (br m, 2H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 543 (M+H) ⁺ (ES ⁺), 541 (M-H) ⁻ (ES ⁻)	As example P except [1,4'-bipiperidine]-1'-carbonyl chloride used
72		3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-072	+	δ : 7.49-7.33 (m, 10H), 7.28 (s, 2H), 7.13 (s, 2H), 7.09-7.03 (m, 2H), 6.88-6.81 (m, 2H), 5.13 (s, 4H), 3.77 (s, 3H).	m/z 472 (M+H) ⁺ (ES ⁺)	As Example A except ammonium chloride used in step (ii)





73		3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-073	+++	δ : 9.72 (s, 2H), 7.16-7.10 (m, 2H), 6.93-6.68 (m, 2H), 3.79 (s, 3H).	m/z 292 (M+H) ⁺ (ES ⁺), 290 (M-H) ⁻ (ES ⁻)	As Example A except ammonium chloride used in step (ii)
74		3,4-bis(benzyloxy)-N2,N5-diethyl-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-074	+	δ : 7.67 (t, J = 5.7 Hz, 2H), 7.48-7.32 (m, 10H), 7.08-6.99 (m, 2H), 6.88-6.80 (m, 2H), 5.11 (s, 4H), 3.76 (s, 3H), 3.08-2.96 (m, 4H), 0.87 (t, J = 7.2 Hz, 6H).	m/z 528 (M+H) ⁺ (ES ⁺)	As Example A except ethylamine used in step (ii)
75		3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-075	+	δ : 7.48-7.34 (m, 10H), 7.32 (br s, 2H), 7.20-7.09 (m, 6H), 5.15 (s, 4H).	m/z 460 (M+H) ⁺ (ES ⁺)	As Example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and ammonium chloride used in step (ii)
76		1-(4-fluorophenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-076	++	δ : 9.54 (s, 2H), 7.20-7.09 (m, 4H), 6.87 (br s, 4H).	m/z 280 (M+H) ⁺ (ES ⁺), 278 (M-H) ⁻ (ES ⁻)	As Example A except diethyl 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and ammonium chloride used in step (ii)




77		1-(4-ethoxyphenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-077	+	δ : 9.72 (s, 2H), 7.15-7.09 (m, 2H), 6.92-6.86 (m, 2H), 4.05 (q, J = 7.0 Hz, 2H), 1.35 (t, J = 7.0 Hz, 3H).	m/z 306 (M+H) ⁺ (ES ⁺), 304 (M-H) ⁻ (ES ⁻)	As Example A except diethyl 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and ammonium chloride used in step (ii)
78		1-(4-ethoxyphenyl)- <i>N</i> 2, <i>N</i> 5-diethyl-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxamide	UL1-078	+++	δ : 9.46 (s, 2H), 7.01-6.93 (m, 2H), 6.87-6.80 (m, 2H), 4.04 (q, J = 7.0 Hz, 2H), 3.12-2.99 (m, 4H), 1.34 (t, J = 7.0 Hz, 3H), 0.92 (t, J = 7.2 Hz, 6H).	m/z 362 (M+H) ⁺ (ES ⁺), 360 (M-H) ⁻ (ES ⁻)	As Example A except diethyl 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate used in step (i) and ethylamine used in step (ii)
79		ethyl 3,4-bis(benzyloxy)-5-carbamoyl-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-079	+++	δ : 7.52-7.24 (m, 12 H), 7.16-7.03 (m, 2H), 6.95-6.82 (m, 2H), 5.12 (s, 2H), 5.10 (s, 2H), 3.97 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 0.97 (t, J = 7.1 Hz, 3H).	m/z 501 (M+H) ⁺ (ES ⁺)	As Example B except ammonium chloride used in step (v)
80		ethyl 5-carbamoyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-080	+++	δ : 9.67 (s, 1H), 8.54 (s, 1H), 7.07-7.03 (m, 2H), 6.87-6.84 (m, 2H), 3.96 (t, J = 7.1 Hz, 2H), 3.77 (s, 3H), 0.95 (t, J = 7.1 Hz, 3H).	m/z 321 (M+H) ⁺ (ES ⁺), 319 (M-H) ⁻ (ES ⁻)	As Example B except ammonium chloride used in step (v)





81		ethyl 3,4-bis(benzyloxy)-5-(2-methoxyphenyl)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-081	+	δ : 7.52-7.46 (m, 2H), 7.43-7.31 (m, 3H), 7.31-7.22 (m, 4H), 7.16-7.11 (m, 2H), 7.10-7.05 (m, 1H), 7.02-6.92 (m, 2H), 6.91-6.82 (m, 2H), 6.77-6.69 (m, 2H), 5.19-5.09 (m, 2H), 4.88-4.74 (m, 2H), 3.99 (q, J = 7.1 Hz, 2H), 3.68 (s, 3H), 3.56 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H).	m/z 564 (M+H) ⁺ (ES ⁺)	As example S except (2-methoxyphenyl)boronic acid and PdCl ₂ (dppf) used in step (ii)
82		ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate	UL1-082	++	δ : 8.47-8.40 (m, 1H), 7.71-7.63 (m, 1H), 7.54-7.47 (m, 2H), 7.45-7.16 (m, 10H), 7.12-7.03 (m, 2H), 6.83-6.76 (m, 2H), 5.18 (s, 2H), 4.96 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.72 (s, 3H), 1.03 (t, J = 7.1 Hz, 3H).	m/z 535 (M+H) ⁺ (ES ⁺)	Example S
83		ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1H-pyrrole-2-carboxylate	UL1-083	+++	δ : 10.84 (s, 1H), 8.62 (s, 1H), 8.56-8.47 (m, 1H), 7.67-7.55 (m, 1H), 7.26-7.12 (m, 3H), 7.01-6.89 (m, 2H), 6.62-6.49 (m, 1H), 4.01 (q, J = 7.1 Hz, 2H), 3.80 (s, 3H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 355 (M+H) ⁺ (ES ⁺), 353 (M-H) ⁻ (ES ⁻)	Example S
84		ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-4-yl)-1H-pyrrole-2-carboxylate	UL1-084	+++	δ : 8.39-8.33 (m, 1H), 8.28-8.24 (m, 1H), 7.54-7.48 (m, 2H), 7.45-7.33 (m, 4H), 7.30-7.21 (m, 4H), 7.19-7.14 (m, 2H), 7.14-7.07 (m, 2H), 6.87-6.80 (m, 2H), 5.20 (s, 2H), 4.91 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.73 (s, 3H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 535 (M+H) ⁺ (ES ⁺)	As example S except pyridin-4-ylboronic acid and PdCl ₂ (dppf) used in step (ii)




85		ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-3-yl)-1H-pyrrole-2-carboxylate	UL1-085	+++	δ : 8.42-8.37 (m, 2H), 7.54-7.47 (m, 2H), 7.46-7.33 (m, 3H), 7.32-7.26 (m, 3H), 7.25-7.18 (m, 2H), 7.16-7.09 (m, 2H), 7.05-7.00 (m, 2H), 6.92-6.83 (m, 2H), 5.19 (s, 2H), 4.74 (s, 2H), 4.03 (q, J = 7.1 Hz, 2H), 3.75 (s, 3H), 1.03 (t, J = 7.1 Hz, 3H).	m/z 535 (M+H) ⁺ (ES ⁺)	As example S except pyridin-3-ylboronic acid and PdCl ₂ (dppf) used in step (ii)
86		ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-086	+++	δ : 9.82 (s, 1H), 8.68 (s, 1H), 7.28-7.19 (m, 2H), 7.06-7.03 (m, 1H), 7.03-6.97 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.82 (s, 3H), 2.67 (q, J = 7.5 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 389 (M+H) ⁺ (ES ⁺)	Example T
87		ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrrole-2-carboxylate	UL1-087	+++	δ : 7.51-7.46 (m, 2H), 7.43-7.31 (m, 8H), 7.18-7.12 (m, 2H), 6.93-6.87 (m, 2H), 5.17 (s, 2H), 5.07 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.35 (s, 3H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 540 (M+H) ⁺ (ES ⁺)	Example U
88		ethyl 3,4-bis(benzyloxy)-5-(5-ethyl-1,3,4-oxadiazol-2-yl)-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-088	++	δ : 7.51-7.45 (m, 2H), 7.44-7.31 (m, 8H), 7.19-7.13 (m, 2H), 6.95-6.88 (m, 2H), 5.17 (s, 2H), 5.09 (s, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.69 (q, J = 7.6 Hz, 2H), 1.04 (t, J = 7.6 Hz, 3H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 554 (M+H) ⁺ (ES ⁺)	As example U except propionohydrazide used in step (i)




89		ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2 <i>H</i> -tetrazol-5-yl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-089	+++	δ : 9.30 (br s, 1H), 8.67 (s, 1H), 7.10-7.05 (m, 2H), 6.87-6.81 (m, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 346 (M+H) ⁺ (ES ⁺), 344 (M-H) ⁻ (ES ⁻)	Example V
90		ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2 <i>H</i> -tetrazol-5-yl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-090	+++	δ : 7.51-7.45 (m, 2H), 7.42-7.25 (m, 8H), 7.10-7.03 (m, 2H), 6.83-6.76 (m, 2H), 5.15 (s, 2H), 4.95 (s, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.74 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H).	m/z 526 (M+H) ⁺ (ES ⁺), 524 (M-H) ⁻ (ES ⁻)	Example V
91		5-acetyl-3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N,N</i> -dimethyl-1 <i>H</i> -pyrrole-2-carboxamide	UL1-091	+++	δ : 9.77 (s, 1H), 8.57 (s, 1H), 7.09-7.07 (m, 2H), 6.88-6.86 (m, 2H), 3.77 (s, 3H), 2.81 (br s, 6H), 2.05 (s, 3H).	m/z 319 (M+H) ⁺ (ES ⁺), 317 (M-H) ⁻ (ES ⁻)	Example W
92		ethyl 3,4-bis((diethoxyphosphoryloxy)-5-bis((dimethylcarbamoyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-092*	-	δ : 7.18-7.15 (m, 2H), 6.97-6.94 (m, 2H), 4.22-4.02 (m, 10H), 3.79 (s, 3H), 2.75 (s, 3H), 2.71 (s, 3H), 1.31-1.24 (m, 12H), 1.07 (t, J = 7.2 Hz, 3H).	m/z 621 (M+H) ⁺ (ES ⁺)	Example X




93		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(2-methoxyethoxy)phenyl)-1H-pyrrole-2-carboxylate	UL1-093	+++	δ : 8.58 (s, 1H), 8.44 (s, 1H), 7.07-6.98 (m, 2H), 6.89-6.81 (m, 2H), 4.12-4.05 (m, 2H), 3.29 (q, J = 7.1 Hz, 2H), 3.69-3.63 (m, 2H), 3.31 (s, 3H), 2.82 (br s, 6H), 0.98 (t, J = 7.1 Hz, 3H).	m/z 393 (M+H) ⁺ (ES ⁺); 391 (M-H) ⁻ (ES ⁻)	As example B except 4-(2-methoxyethoxy)aniline used in step (i)
94		ethyl 3-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-094*	+	δ : 8.95 (s, 1H), 7.08-7.10 (m, 2H), 6.89-6.91 (m, 2H), 4.15-4.25 (m, 4H), 4.00 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.84 (br s, 6H), 1.28 (dt, J = 7.1, 1.1 Hz, 6H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 485 (M+H) ⁺ (ES ⁺); 482 (M-H) ⁻ (ES ⁻)	As example R, step (i) except using diethyl phosphite
95		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(2-(2-methoxyethoxy)ethoxy)ph enyl)-1H-pyrrole-2-carboxylate	UL1-095	+++	δ : 8.60 (s, 1H), 8.47 (s, 1H), 7.06-6.99 (m, 2H), 6.89-6.82 (m, 2H), 4.10-4.05 (m, 2H), 3.99 (q, J = 7.0 Hz, 2H), 3.78-3.70 (m, 2H), 3.62-3.57 (m, 2H), 3.55-3.49 (m, 4H), 3.45-3.40 (m, 2H), 3.23 (s, 3H), 2.81 (br s, 6H), 0.98 (t, J = 7.0 Hz, 3H).	m/z 481 (M+H) ⁺ (ES ⁺); 479 (M-H) ⁻ (ES ⁻)	As example B except 4-(2-(2-methoxyethoxy)ethoxy)ethoxy)aniline used in step (i)
96		ethyl 1-(4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)-5-(dimethylcarbamoyl)-3,4-dihydroxy-1H-pyrrole-2-carboxylate	UL1-096	+++	δ : 8.60 (s, 1H), 8.46 (s, 1H), 7.05-7.00 (m, 2H), 6.89-6.83 (m, 2H), 4.11-4.05 (m, 2H), 3.99 (q, J = 7.0 Hz, 2H), 3.76-3.72 (m, 2H), 3.61-3.56 (m, 2H), 3.55-3.48 (m, 8H), 3.44-3.39 (m, 2H), 3.23 (s, 3H), 2.81 (br s, 6H), 0.98 (t, J = 7.1 Hz, 3H).	m/z 525 (M+H) ⁺ (ES ⁺); 523 (M-H) ⁻ (ES ⁻)	As example B except 4-(2,5,8,11-tetraoxatridecan-13-yloxy)aniline used in step (i)




97		ethyl 4- ((diethoxyphosphoryl)oxy)-5- (dimethylcarbamoyl)-3-hydroxy-1- (4-methoxyphenyl)-1 <i>H</i> -pyrrole-2- carboxylate	UL1- 097*	-	δ : 8.87 (s, 1H), 7.16-7.09 (m, 2H), 6.93-6.87 (m, 2H), 4.22-4.07 (m, 2H), 4.05-3.98 (m, 2H), 3.77 (s, 3H), 2.78 (s, 3H), 2.70 (s, 3H), 1.29-1.20 (m, 6H), 1.05-0.97 (m, 3H).	m/z 485 (M+H) ⁺ (ES ⁺); 483 (M-H) ⁻ (ES ⁻)	As example R, step (i) except using diethyl phosphite
98		2-(dimethylcarbamoyl)-5- (ethoxycarbonyl)-1-(4-(2-(2- methoxyethoxy)ethoxy)ethoxy)ph enyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(2- methylpropanoate)	UL1- 098*	-	δ : 7.22 (m, 2H), 6.98-6.92 (m, 2H), 4.15-4.09 (m, 2H), 4.01 (q, J = 7.2 Hz, 2H), 3.75-3.77 (m, 2H), 3.59-3.61 (m, 2H), 3.52-3.55 (m, 4H), 3.42-3.45 (m, 2H), 3.24 (s, 3H), 2.75-2.82 (m, 5H), 2.71 (s, 3H), 1.21 (d, J = 6.8 Hz, 6H), 1.16 (d, J = 6.8 Hz, 6H), 1.03 (t, J = 7.2 Hz, 3H).	m/z 621 (M+H) ⁺ (ES ⁺)	As Example J, except isobutyril chloride and UL1-095 used in step (i).
99		ethyl 3,4-dihydroxy-1-(4- methoxyphenyl)-5- (methylcarbamoyl)-1 <i>H</i> -pyrrole-2- carboxylate	UL1- 099	+++	δ : 9.56 (s, 1H), 8.51 (s, 1H), 7.51-7.48 (m, 1H), 7.04-7.00 (m, 2H), 6.86-6.82 (m, 2H), 3.96 (q, J = 7.2 Hz, 2H), 3.77 (s, 3H), 2.61 (d, J = 4.7 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H).	m/z 335 (M+H) ⁺ (ES ⁺); 333 (M-H) ⁻ (ES ⁻)	As example B except methylamine used in step (v)



100		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-hydroxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-100	+++	δ : 9.50 (s, 1H), 8.54 (s, 1H), 8.42 (s, 1H), 6.94-6.86 (m, 2H), 6.69-6.62 (m, 2H), 3.99 (q, J = 7.0 Hz, 2H), 2.81 (br s, 6H), 0.98 (t J = 7.0 Hz, 3H).	m/z 335 (M+H) ⁺ (ES ⁺); 333 (M-H) ⁻ (ES ⁻)	Example Y
101		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(phosphonoxy)phenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-101	+++	δ : 8.66 (br s, 2H), 8.50 (br s, 1H), 7.09 (s, 4H), 4.00 (q, J = 7.1 Hz, 2H), 2.85 (br s, 6H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 415 (M+H) ⁺ (ES ⁺); 413 (M-H) ⁻ (ES ⁻)	As example R except 36 used in step (i)
102		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-102	+++	δ : 8.58 (s, 1H), 8.44 (s, 1H), 7.05-6.99 (m, 2H), 6.86-6.82 (m, 2H), 4.03-3.95 (m, 4H), 3.61-3.53 (m, 4H), 2.82 (br s, 6H), 2.45-2.34 (m, 6H), 1.93-1.81 (m, 2H), 0.98 (t, J = 7.0 Hz, 3H).	m/z 462 (M+H) ⁺ (ES ⁺); 460 (M-H) ⁻ (ES ⁻)	Example Z
103		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-103	+++	δ : 8.59 (s, 1H), 8.45 (s, 1H), 7.06-6.99 (m, 2H), 6.86-6.81 (m, 2H), 4.02-3.94 (m, 4H), 2.82 (br s, 6H), 2.46-2.33 (m, 10H), 2.17 (s, 3H), 1.92-1.79 (m, 2H), 0.98 (t, J = 7.1 Hz, 3H).	m/z 475 (M+H) ⁺ (ES ⁺); 473 (M-H) ⁻ (ES ⁻)	As example Z except 1-(3-chloropropyl)-4-methylpiperazine dihydrochloride used in step (i)



104		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(3-methoxypropanoate)	UL1-104*	+++	δ : 7.24-7.15 (m, 2H), 6.98-6.89 (m, 2H), 4.00 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.65-3.59 (m, 4H), 3.27 (s, 3H), 3.25 (s, 3H), 2.82 (s, 3H), 2.78 (t, J = 6.0 Hz, 4H), 2.71 (s, 3H), 1.05 (t, J = 7.1 Hz, 3H).	m/z 521 (M+H) ⁺ (ES ⁺)	Example A1
105		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)propanoate)	UL1-105*	+++	δ : 7.23-7.17 (m, 2H), 6.98-6.92 (m, 2H), 4.01 (q, J = 7.0 Hz, 2H), 3.79 (s, 3H), 3.73-3.68 (m, 4H), 3.45-3.42 (m, 4H), 3.45-3.42 (m, 4H), 3.24 (s, 6H), 3.82 (s, 3H), 2.80 (t, J = 6.2 Hz, 4H), 2.71 (s, 3H), 1.05 (t, J = 7.0 Hz, 3H).	m/z 609 (M+H) ⁺ (ES ⁺)	As Example A1 except 3-(2-methoxyethoxy)propanoic acidused.
106		ethyl 1-(4-(3-(diethoxyphosphoryl)propoxy)phenyl)-5-(dimethylcarbamoyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2-carboxylate	UL1-106	+++	δ : 8.58 (s, 1H), 8.44 (s, 1H), 7.05-7.00 (m, 2H), 6.87-6.81 (m, 2H), 4.06-3.91 (m, 8H), 2.82 (br s, 6H), 1.97-1.80 (m, 4H), 1.23 (t, J = 7.0 Hz, 6H), 0.98 (t, J = 7.0 Hz, 3H).	m/z 513 (M+H) ⁺ (ES ⁺); 511 (M-H) ⁻ (ES ⁻)	As Example Z except diethyl (3-bromopropyl)phosphonate used in step (i)



107		(3-(4-(2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-3,4-dihydroxy-1H-pyrrol-1-yl)phenoxy)propyl)phosphonic acid	UL1-107	+++	δ : 8.70-8.23 (m, 1H), 7.06-6.99 (m, 2H), 6.86-6.81 (m, 2H), 4.05-3.95 (m, 5H), 2.82 (br s, 6H), 1.95-1.84 (m, 2H), 1.72-1.60 (m, 2H), 0.99 (t, J = 7.0 Hz, 3H).	m/z 456 (M+H) ⁺ (ES ⁺); 455 (M-H) ⁻ (ES ⁻)	Synthesised by standard TMSBr/DCM mediated hydrolysis of UL1-106
108		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)-2,2-dimethylpropanoate)	UL1-108*	++	δ : 7.23-7.15 (m, 2H), 6.98-6.89 (m, 2H), 4.02 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 3.58-3.39 (m, 12H), 3.24 (s, 3H), 3.23 (s, 3H), 2.81 (s, 3H), 2.70 (s, 3H), 1.25 (s, 6H), 1.19 (s, 6H), 1.05 (t, J = 7.2 Hz, 3H).	m/z 665 (M+H) ⁺ (ES ⁺)	Example B1
109		ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-((phosphonoxy)methoxy)-1H-pyrrole-2-carboxylate	UL1-109*	-	δ : 7.14-7.05 (m, 2H), 6.93-6.85 (m, 2H), 5.35-5.23 (br m, 2H), 3.99 (q, J = 7.2 Hz, 2H), 3.77 (s, 3H), 2.73 (s, 3H), 2.70 (s, 3H), 1.02 (t, J = 7.2 Hz, 3H).	m/z 459 (M+H) ⁺ (ES ⁺)	Example C1




110		ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1H-pyrrole-2-carboxylate	UL1-110	+++	δ : 8.58 (s, 1H), 8.45 (s, 1H), 7.07-7.02 (m, 2H), 6.89-6.84 (m, 2H), 4.08 (t, J = 7.2 Hz, 2H), 3.99 (q, J = 7.1 Hz, 2H), 3.29-3.25 (m, 2H), 3.02 (s, 3H), 2.92-2.71 (br s, 6H), 2.21-2.07 (m, 2H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 455 (M+H) ⁺ (ES ⁺); 453 (M-H) ⁻ (ES ⁻)	Example D1
111		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(3-(2-(2-methoxyethoxy)ethoxy)-2,2-dimethylpropanoate)	UL1-111*	+++	δ : 7.21-7.18 (m, 2H), 6.96-6.94 (m, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.56-3.48 (m, 16H), 3.43-3.41 (m, 4H), 3.24 (s, 3H), 3.23 (s, 3H), 2.82 (s, 3H), 3.27 (s, 3H), 1.26 (s, 6H), 1.19 (s, 6H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 753 (M+H) ⁺ (ES ⁺)	As example B1 except 1-bromo-2-(2-methoxyethoxy)ethane used in step (i)
112		neopentyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-112	+++	δ : 8.63 (s, 1H), 8.62 (s, 1H), 7.11-7.08 (m, 2H), 6.89-6.86 (m, 2H), 3.74 (s, 3H), 3.67 (s, 2H), 3.00-2.55 (br s, 6H), 0.64 (s, 9H).	m/z 391 (M+H) ⁺ (ES ⁺)	As Example D, except 1-iodo-2,2-dimethylpropane used in step (i)





113		2,6-dimethylcyclohexyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2-carboxylate	UL1-113	+++	δ : 8.67-8.40 (m, 2H), 7.15-7.05 (m, 2H), 6.91-6.85 (m, 2H), 5.05 (br s, 1H), 3.76-3.75 (m, 3H), 2.82 (br s, 6H), 1.64-0.94 (m, 6H), 0.74-0.57 (m, 6H), 0.57-0.40 (m, 2H).	m/z 431 (M+H) ⁺ (ES ⁺); 429 (M-H) ⁻ (ES ⁻)	Example E1
114		2,5-bis((dimethylcarbamoyl)-1-(4-methoxyphenyl)-1H-pyrrole-3,4-diyl bis(2-methylpropanoate))	UL1-114*	++	δ : 7.12-7.08 (m, 2H), 6.97-6.93 (m, 2H), 3.77 (s, 3H), 2.85 (br s, 6H), 2.79-2.72 (m, 8H), 1.15 (d, J = 7.0 Hz, 12 H).	m/z 488 (M+H) ⁺ (ES ⁺)	As Example J, except UL1-005 used in step (i).
115		ethyl 5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-3-((phosphonoxy)methoxy)-1H-pyrrole-2-carboxylate	UL1-115*	+	δ : 7.11-7.05 (m, 2H), 6.91-6.84 (m, 2H), 5.45 (d, J = 16 Hz, 2H), 3.98 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 2.98 (br s, 3H), 2.74 (br s, 3H), 1.01 (t, J = 7.0 Hz, 3H).	m/z 459 (M+H) ⁺ (ES ⁺); 457 (M-H) ⁻ (ES ⁻)	Example H1





116		cyclopentyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2-carboxylate	UL1-116	+++	δ : 8.65 (s, 1H), 8.51 (s, 1H), 7.09-7.03 (m, 2H), 6.89-6.84 (m, 2H), 5.07-5.01 (m, 1H), 3.75 (s, 3H), 2.82 (br s, 6H), 1.66-1.52 (m, 2H), 1.40-1.17 (m, 6H).	m/z 389 (M+H) ⁺ (ES ⁺); 387 (M-H) ⁻ (ES ⁻)	As Example D, except bromocyclopentane used in step (i)	
117		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonoxy)ethoxy)ethoxy)propanoate)	UL1-117*	++	(CDCl ₃) δ 7.25-7.15 (m, 2H, m), 6.91-6.86 (m, 2H), 4.20-4.02 (m, 6H), 3.82 (s, 3H), 3.75-3.50 (m, 16H), 2.83 (s, 3H), 2.77 (s, 3H), 2.69 (br s, 4H), 1.35 (s, 6H), 1.28 (s, 6H), 1.08 (t, J = 7.2 Hz, 3H).	m/z 885 (M+H) ⁺ (ES ⁺); 883 (M-H) ⁻ (ES ⁻)	Example F1	





118		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(2,2-dimethyl-3-(3-(phosphonoxy)propoxy)propanoate)	UL1-118*	+++	δ : 7.24-7.16 (m, 2H), 6.98-6.91 (m, 2H), 4.01 (q, J = 7.1 Hz, 2H), 3.90-3.81 (m, 4H), 3.79 (s, 3H), 3.51-3.43 (m, 8H), 2.82 (s, 3H), 2.70 (s, 3H), 1.86-1.73 (m, 4H), 1.25 (s, 6H), 1.19 (s, 6H), 1.01 (t, J = 7.1 Hz, 3H).	m/z 825 (M+H) ⁺ (ES ⁺); 823 (M-H) ⁻ (ES ⁻)	Example G1
119		2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate)	UL1-119*	+++	δ : 7.21-7.16 (m, 2H), 6.96-6.92 (m, 2H), 4.02 (q, J = 7.1 Hz, 2H), 3.79 (s, 3H), 3.58-3.46 (m, 56H), 3.43-3.40 (m, 4H), 3.23 (s, 6H), 2.82 (s, 3H), 2.70 (s, 3H), 1.25 (s, 6H), 1.19 (s, 6H), 1.02 (t, J = 7.1 Hz, 3H).	m/z 1193 (M+H) ⁺ (ES ⁺)	Example I1





120		2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaohexacosan-26-oate)	UL1-120*	++	δ : 7.12-7.07 (m, 2H), 6.97-6.93 (m, 2H), 3.77 (s, 3H), 3.52-3.47 (m, 56H), 3.44-3.40 (m, 4H), 3.23 (s, 6H), 2.87 (s, 6H), 2.75 (s, 6H), 1.18 (s, 12H).	m/z 1193 (M+H) ⁺ (ES ⁺)	As example H1 except UL1-005 used in step (iii)
121		2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonoethoxy)ethoxy)ethoxy)propanoate)	UL1-121*	++	δ : 7.11-7.09 (m, 2H), 6.97-6.95 (m, 2H), 3.91-3.87 (m, 4H), 3.78 (s, 3H), 3.58-3.50 (m, 16H), 2.89 (s, 6H), 2.76 (s, 6H), 1.19 (s, 12H).	m/z 884 (M+H) ⁺ (ES ⁺); 882 (M-H) ⁻ (ES ⁻)	Example J1





122		2-(dimethylcarbamoyl)-5-(isopropoxycarbonyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonoxy)ethoxy)ethoxy)propanoate)	UL1-122*	+++	δ: 7.21-7.18 (m, 2H), 6.97-6.92 (m, 2H), 4.83 (sept, J = 6.3 Hz, 1H), 3.92-3.85 (m, 4H), 3.79 (s, 3H), 3.59-3.48 (m, 16H), 2.82 (s, 3H), 2.70 (s, 3H), 1.26 (s, 6H), 1.19 (s, 6H), 0.98 (d, J = 6.3 Hz, 6H).	m/z 889 (M+H) ⁺ (ES ⁺); 897 (M-H) ⁻ (ES ⁻)	As Example J1 but UL1-035 used in step (i)
123		2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(piperidine-4-carboxylate)	UL1-123*	+++	δ: 8.71-8.61 (br m, 2H), 8.49-8.36 (br m, 2H), 7.13-7.08 (m, 2H), 7.00-6.95 (m, 2H), 3.78 (s, 3H), 3.33-3.25 (br m, 4H), 3.05-2.92 (m, 6H), 2.79 (br s, 6H), 2.75 (br s, 6H), 2.08-2.00 (br m, 4H), 1.82-1.69 (m, 4H).	m/z 570 (M+H) ⁺ (ES ⁺)	Example K1 isolated as the di-TFA salt
124		2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(4-((phosphonoxy)methyl)benzoate)	UL1-124*	+++	δ: 8.00-7.98 (m, 4H), 7.54-7.52 (m, 4H), 7.20-7.18 (m, 2H), 7.00-6.98 (m, 2H), 4.98-4.96 (d, 4H), 3.79 (s, 3H), 2.89 (s, 6H), 2.74 (s, 6H).	m/z 776 (M+H) ⁺ (ES ⁺); 774 (M-H) ⁻ (ES ⁻)	Example L1





125		5-(dimethylphosphoryl)-3,4-dihydroxy-1-(4-methoxyphenyl)- <i>N,N</i> -dimethyl-1 <i>H</i> -pyrrole-2-carboxamide	UL1-125	+++	δ : 9.35 (s, 1H), 8.55 (s, 1H), 7.23-7.14 (m, 2H), 6.96-6.88 (m, 2H), 3.77 (s, 3H), 2.86 (br s, 6H), 1.33 (s, 3H), 1.30 (s, 3H).	m/z 353 (M+H) ⁺ (ES ⁺), 351 (M-H) ⁻ (ES ⁻)	Example M1
126		(1 <i>R</i> ,1' <i>R</i> ,4 <i>R</i> ,4' <i>R</i>)-2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-3,4-diyl bis(4-(phosphonoxy)methyl)cyclohexanecarboxylate	UL1-126*	+++	δ : 10.90 (br s, 2H), 7.12-7.06 (m, 2H), 6.97-6.92 (m, 2H), 3.77 (s, 3H), 3.63 (t, <i>J</i> = 6.4 Hz, 4H), 2.83 (br s, 6H), 2.75 (br s, 6H), 2.50-2.45 (m, 2H), 2.00-1.93 (m, 4H), 1.84-1.76 (m, 4H), 1.63-1.51 (m, 2H), 1.38 (ddd, 3.1, 12.7, 16.0 Hz, 4H), 1.05 (ddd, 3.1, 12.7, 16.0 Hz, 4H).	m/z 788 (M+H) ⁺ (ES ⁺), 786 (M-H) ⁻ (ES ⁻)	Example N1
127		diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-001	+++	δ : 8.64 (s, 2H), 7.13-7.01 (m, 2H), 6.92-6.81 (m, 2H), 3.99 (q, <i>J</i> = 7.1 Hz, 4H), 3.78 (s, 3H), 0.99 (t, <i>J</i> = 7.1 Hz, 6H).	m/z 350 (M+H) ⁺ (ES ⁺), 348 (M-H) ⁻ (ES ⁻)	UL1-012
128		diethyl 3,4-dihydroxy-1-phenyl-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-002	+++	δ : 8.72 (s, 2H), 7.39-7.27 (m, 3H), 7.20-7.09 (m, 2H), 3.95 (q, <i>J</i> = 7.1 Hz, 4H), 0.92 (t, <i>J</i> = 7.1 Hz, 6H).	m/z 320 (M+H) ⁺ (ES ⁺), 318 (M-H) ⁻ (ES ⁻)	As UL1-012 except aniline used in step (i)




129		diethyl 1-(4-fluorophenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-003	++	δ : 7.88 (s, 2H), 7.20-7.14 (m, 2H), 7.09-7.01 (m, 2H), 4.09 (q, J = 7.1 Hz, 4H), 0.99 (t, J = 7.1 Hz, 6H).	m/z 338 (M+H) ⁺ (ES ⁺), 336 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-fluoroaniline used in step (i)
130		diethyl 3,4-dihydroxy-1-(3-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-004	++	δ : 8.75 (br s, 2H), 7.22 (t, J = 8.0 Hz, 1H), 6.95-6.88 (m, 1H), 6.76-6.73 (m, 1H), 6.72-6.69 (m, 1H), 3.73 (s, 3H), 3.98 (q, J = 7.1 Hz, 4H), 0.95 (t, J = 7.1 Hz, 6H).	m/z 350 (M+H) ⁺ (ES ⁺), 348 (M-H) ⁻ (ES ⁻)	As UL1-012 except 3-methoxyaniline used in step (i)
131		diethyl 3,4-dihydroxy-1-(4-(trifluoromethoxy)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-005	+++	δ : 8.82 (br s, 2H), 7.38-7.24 (m, 4H), 3.97 (q, J = 7.1 Hz, 4H), 0.93 (t, J = 7.1 Hz, 6H).	m/z 404 (M+H) ⁺ (ES ⁺), 402 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-(trifluoromethoxy)aniline used in step (i)
132		diethyl 3,4-dihydroxy-1-(4-isopropylphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-006	+++	δ : 8.68 (br s, 2H), 7.22-7.15 (m, 2H), 7.08-7.01 (m, 2H), 3.95 (q, J = 7.1 Hz, 4H), 2.93 (sept., J = 6.9 Hz, 1H), 1.22 (d, J = 6.9 Hz, 6H), 0.89 (t, J = 7.1 Hz, 6H).	m/z 362 (M+H) ⁺ (ES ⁺), 360 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-isopropylaniline used in step (i)




133		diethyl 3,4-dihydroxy-1-(4-phenoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-007	+++	δ : 8.73 (s, 2H), 7.46-7.39 (m, 2H), 7.20-7.13 (m, 3H), 7.06-7.00 (m, 2H), 6.97-6.91 (m, 2H), 4.01 (q, J = 7.1 Hz, 4H), 1.00 (t, J = 7.1 Hz, 6H).	m/z 412 (M+H) ⁺ (ES ⁺)	As UL1-012 except 4-phenoxyaniline used in step (i)
134		diethyl 1-(4-ethoxyphenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-008	+++	δ : 8.65 (s, 2H), 7.07-6.99 (m, 2H), 6.88-6.80 (m, 2H), 4.03 (q, J = 7.0 Hz, 2H), 3.97 (q, J = 7.1 Hz, 4H), 1.34 (t, J = 7.0 Hz, 3H), 0.97 (t, J = 7.1 Hz, 6H).	m/z 364 (M+H) ⁺ (ES ⁺), 362 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-ethoxyaniline used in step (i)
135		diethyl 1-(4-ethylphenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-009	+++	δ : 8.67 (s, 2H), 7.19-7.11 (m, 2H), 7.08-6.99 (m, 2H), 3.95 (q, J = 7.1 Hz, 4H), 2.63 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H), 0.92 (t, J = 7.1 Hz, 6H).	m/z 348 (M+H) ⁺ (ES ⁺), 346 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-ethylaniline used in step (i)
136		diethyl 3,4-dihydroxy-1-(p-tolyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-010	+++	δ : 8.67 (s, 2H), 7.15-7.09 (m, 2H), 7.04-6.98 (m, 2H), 3.97 (q, J = 7.1 Hz, 4H), 2.33 (s, 3H), 0.96 (t, J = 7.1 Hz, 6H).	m/z 334 (M+H) ⁺ (ES ⁺), 332 (M-H) ⁻ (ES ⁻)	As UL1-012 except p-toluidine used in step (i)




137		diethyl 1-(3,4-dimethoxyphenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-011	+++	δ : 8.65 (s, 2H), 6.89-6.83 (m, 1H), 6.81-6.77 (m, 1H), 6.68-6.61 (m, 1H), 3.99 (q, J = 7.1 Hz, 4H), 3.77 (s, 3H), 3.69 (s, 3H), 0.97 (t, J = 7.1 Hz, 6H).	m/z 380 (M+H) ⁺ (ES ⁺)	As UL1-012 except 3,4-dimethoxyaniline used in step (i)
138		diethyl 1-(4-chlorophenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-012	+++	(CDCl ₃) δ : 7.85 (s, 2H), 7.36-7.31 (m, 2H), 7.15-7.10 (m, 2H), 4.10 (q, J = 7.1 Hz, 4H), 1.00 (t, J = 7.1 Hz, 6H).	m/z 354 (M+H) ⁺ (ES ⁺), 352 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-chloroaniline used in step (i)
139		diethyl 3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-013	+++	(CDCl ₃) δ : 7.88 (s, 2H), 7.67-7.61 (m, 2H), 7.36-7.31 (m, 2H), 4.08 (q, J = 7.1 Hz, 4H), 0.93 (t, J = 7.1 Hz, 6H).	m/z 388 (M+H) ⁺ (ES ⁺), 386 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-(trifluoromethyl)aniline used in step (i)
140		diethyl 3,4-dihydroxy-1-(3,4,5-trimethoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-014	+++	(CDCl ₃) δ : 7.94 (s, 2H), 6.44 (s, 2H), 4.11 (q, J = 7.1 Hz, 4H), 3.88 (s, 3H), 3.82 (s, 6H), 1.01 (t, J = 7.1 Hz, 6H).	m/z 410 (M+H) ⁺ (ES ⁺), 408 (M-H) ⁻ (ES ⁻)	As UL1-012 except 3,4,5-trimethoxyaniline used in step (i)





141		diethyl 1-(2,4-dimethoxyphenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-015	+++	(CDCl ₃) δ: 7.79 (s, 2H), 7.04-6.98 (m, 1H), 6.51-6.40 (m, 2H), 4.19-4.01 (m, 4H), 3.84 (s, 3H), 3.70 (s, 3H), 1.01 (t, J = 7.1 Hz, 6H).	m/z 380 (M+H) ⁺ (ES ⁺), 378 (M-H) ⁻ (ES ⁻)	As UL1-012 except 2,4-dimethoxyaniline used in step (i)
142		diethyl 1-(4-dihydroxy-1-(4-propoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-016	+++	(CDCl ₃) δ: 7.85 (s, 2H), 7.10-7.03 (m, 2H), 6.88-6.81 (m, 2H), 4.09 (q, J = 7.1 Hz, 4H), 3.95 (t, J = 6.6 Hz, 2H), 1.82 (sext., J = 7.4 Hz, 2H), 1.05 (t, J = 7.4 Hz, 3H), 1.00 (t, J = 7.1 Hz, 6H).	m/z 378 (M+H) ⁺ (ES ⁺), 376 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-propoxyaniline used in step (i)
143		diethyl 1-(4-ethoxy-3,5-difluorophenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-017	+++	(CDCl ₃) δ: 7.91 (s, 2H), 6.85-6.76 (m, 2H), 4.25 (q, J = 7.1 Hz, 2H), 4.14 (q, J = 7.1 Hz, 4H), 1.43 (t, J = 7.1 Hz, 2H), 1.07 (t, J = 7.1 Hz, 6H).	m/z 400 (M+H) ⁺ (ES ⁺), 398 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-ethoxy-3,5-difluoroaniline used in step (i)
144		diethyl 1-(3-dihydroxy-1-(3-phenoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-018	+++	(CDCl ₃) δ: 7.88 (s, 2H), 7.38-7.27 (m, 3H), 7.15-7.09 (m, 1H), 7.08-7.04 (m, 1H), 7.03-6.97 (m, 2H), 6.95-6.91 (m, 1H), 6.89-6.85 (m, 1H), 4.12 (q, J = 7.1 Hz, 4H), 1.04 (t, J = 7.1 Hz, 6H).	m/z 412 (M+H) ⁺ (ES ⁺), 410 (M-H) ⁻ (ES ⁻)	As UL1-012 except 3-phenoxyaniline used in step (i)




145		diethyl 1-(benzo[d][1,3]dioxol-5-yl)-3,4-dihydroxy-1H-pyrrole-2,5-dicarboxylate	UL2-019	+	(CDCl ₃) δ: 7.82 (s, 2H), 6.79-6.74 (m, 1H), 6.71-6.62 (m, 2H), 6.02 (s, 2H), 4.13 (q, J = 7.1 Hz, 4H), 1.06 (t, J = 7.1 Hz, 6H).	m/z 364 (M+H) ⁺ (ES ⁺), 362 (M-H) ⁻ (ES ⁻)	As UL1-012 except benzo[d][1,3]dioxol-5-amine used in step (i)
146		diisopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-020	+++	δ: 8.62 (s, 2H), 7.12-7.01 (m, 2H), 6.93-6.84 (m, 2H), 4.80 (sept., J = 6.3 Hz, 2H), 3.78 (s, 3H), 0.95 (d, J = 6.2 Hz, 12H).	m/z 378 (M+H) ⁺ (ES ⁺)	Example L
147		2-ethyl 5-isopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-021	+++	δ: 8.66 (s, 1H), 8.62 (s, 1H), 7.09-7.03 (m, 2H), 6.90-6.85 (m, 2H), 4.80 (sept., J = 6.2 Hz, 1H), 3.98 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 1.00 (t, J = 7.1 Hz, 3H), 0.93 (d, J = 6.2 Hz, 6H).	m/z 364 (M+H) ⁺ (ES ⁺)	Example L
148		di-tert-butyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-022	+++	(CDCl ₃) δ: 8.12 (s, 2H), 7.10-7.02 (m, 2H), 6.89-6.82 (m, 2H), 3.83 (s, 3H), 1.22 (s, 18H).	m/z 404 (M-H) ⁻ (ES ⁻)	As example B except <i>tert</i> -butyl 2-bromoacetate used in step (i) and di- <i>tert</i> -butyl oxalate and KO ^t Bu/ ^t BuOH used in step (iii)

149		diethyl 3,4-dihydroxy-1-(2-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-023	+	(CDCl ₃) δ: 7.83 (s, 2H), 7.38-7.30 (m, 1H), 7.14-7.08 (m, 1H), 6.96-6.87 (m, 2H), 4.16-3.97 (m, 4H), 3.73 (s, 3H), 0.94 (t, J = 7.1 Hz, 6H).	m/z 350 (M+H) ⁺ (ES ⁺)	As UL1-012 except 2-methoxyaniline used in step (i)
150		diethyl 1-(4-cyanophenyl)-3,4-dihydroxy-1H-pyrrole-2,5-dicarboxylate	UL2-024	++	δ: 8.91 (s, 2H), 7.86-7.80 (m, 2H), 7.44-7.37 (m, 2H), 4.00 (t, J = 7.1 Hz, 4H), 0.98 (t, J = 7.1 Hz, 6H).	m/z 345 (M+H) ⁺ (ES ⁺), 343 (M-H) ⁻ (ES ⁻)	As UL1-012 except 4-aminobenzonitrile used in step (i)
151		diethyl 1-(4-fluorophenyl)-3-hydroxy-4-(2-hydroxyethoxy)-1H-pyrrole-2,5-dicarboxylate	UL2-025	+	δ: 8.94 (br s, 1H), 7.29-7.22 (m, 2H), 7.21-7.14 (m, 2H), 5.01 (br s, 1H), 4.08-3.97 (m, 6H), 3.73-3.65 (m, 2H), 1.02 (t, J = 7.1 Hz, 3H), 0.99 (t, J = 7.1 Hz, 3H).	m/z 382 (M+H) ⁺ (ES ⁺), 380 (M-H) ⁻ (ES ⁻)	Example M

152		diethyl 3-(2-hydroxy-4-(2-(hydroxyethoxy)-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate)-1-(4-hydroxyethoxy)-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-026	+	(CDCl ₃) δ: 8.11 (br s, 1H), 7.13-7.02 (m, 2H), 6.92-6.79 (m, 2H), 4.33-4.28 (m, 2H), 4.10-4.01 (m, 4H), 3.85-3.80 (m, 5H), 3.26 (br s, 2H), 1.03 (t, J = 7.1 Hz, 3H), 0.98 (t, J = 7.1 Hz, 3H).	m/z 394 (M+H) ⁺ (ES ⁺), 392 (M-H) ⁻ (ES ⁻)	As example M except UL2-001 used in step (i)
153		diethyl 3-(2-(tert-butoxy)-4-(2-(hydroxyethoxy)-1-(4-fluorophenyl)-1H-pyrrole-2,5-dicarboxylate)-1-(4-hydroxyethoxy)-1-(4-fluorophenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-027	++	δ: 8.92 (s, 1H), 7.28-7.14 (m, 4H), 4.60 (s, 2H), 4.03-3.94 (m, 4H), 1.45 (s, 9H), 1.03-0.94 (m, 6H).	m/z 396 (M+H - CH ₂ C(CH ₃) ₂) ⁺ (ES ⁺)	As example N except UL2-003 used in step (i)
154		diethyl 3-(benzyloxy)-4-(2-(tert-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-028	+	δ: 7.49-7.44 (m, 2H), 7.43-7.31 (m, 3H), 7.15-7.08 (m, 2H), 6.94-6.88 (m, 2H), 5.12 (s, 2H), 4.59 (s, 2H), 4.02-3.94 (m, 4H), 3.79 (s, 3H), 1.40 (s, 9H), 1.03-0.93 (m, 6H).	m/z 554 (M+H) ⁺ (ES ⁺)	Example N

155		diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-fluorophenyl)-4-hydroxy-1H-pyrrole-2,5-dicarboxylate	UL2-029	+	δ : 9.72 (s, 1H), 7.80-7.67 (m, 2H), 7.31-7.23 (m, 2H), 7.22-7.14 (m, 2H), 4.50 (s, 2H), 4.04-3.94 (m, 4H), 1.04-0.97 (m, 6H).	m/z 395 (M+H) ⁺ (ES ⁺), 393 (M-H) ⁻ (ES ⁻)	As example N except UL2-003 used in step (i)
156		diethyl 3-(2-(tert-butoxy)-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-4-hydroxy-1H-pyrrole-2,5-dicarboxylate	UL2-030	++	δ : 8.85 (s, 1H), 7.14-7.06 (m, 2H), 6.93-6.86 (m, 2H), 4.59 (s, 2H), 4.02-3.93 (m, 4H), 3.78 (s, 3H), 1.44 (s, 9H), 1.03-0.92 (m, 6H).	m/z 408 (M+H) ⁻ CH ₂ C(CH ₃) ₂ ⁺ (ES ⁺)	Prepared from standard Pd/C hydrogenation of UL2-028
157		diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-4-hydroxy-1H-pyrrole-2,5-dicarboxylate	UL2-031	+	δ : 9.61 (s, 1H), 7.82-7.63 (m, 2H), 7.10-7.06 (m, 2H), 6.93-6.84 (m, 2H), 4.49 (s, 2H), 4.03-3.93 (m, 4H), 3.79 (s, 3H), 1.05-0.94 (m, 6H).	m/z 407 (M+H) ⁺ (ES ⁺), 405 (M-H) ⁻ (ES ⁻)	Example N

158		diethyl 1-(4-(tert-butyl)phenyl)-3,4-dihydroxy-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-032	+++	δ : 8.68 (s, 2H), 7.36-7.31 (m, 2H), 7.08-7.03 (m, 2H), 3.94 (q, <i>J</i> = 7.1 Hz, 4H), 1.30 (s, 9H), 0.88 (t, <i>J</i> = 7.1 Hz, 6H).	m/z 376 (M+H) ⁺ (ES ⁺)	As UL1-012 except 4-(<i>tert</i> -butyl)aniline used in step (i)
159		diethyl 3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-033	+++	δ : 8.75 (s, 2H), 7.59-7.53 (m, 1H), 7.15-7.08 (m, 1H), 6.96-6.88 (m, 1H), 4.00 (t, <i>J</i> = 7.1 Hz, 4H), 3.84 (s, 3H), 0.99 (t, <i>J</i> = 7.1 Hz, 6H).	m/z 476 (M+H) ⁺ (ES ⁺), 473 (M-H) ⁻ (ES ⁻)	As UL1-012 except 3-iodo-4-methoxyaniline used in step (i)
160		diethyl 3,4-dihydroxy-1-(4-(2-methoxyethoxy)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-034	+++	δ : 8.63 (s, 2H), 7.07-7.00 (m, 2H), 6.90-6.83 (m, 2H), 4.13-4.06 (m, 2H), 3.97 (q, <i>J</i> = 7.1 Hz, 4H), 3.71-3.63 (m, 2H), 3.32 (s, 3H), 0.97 (t, <i>J</i> = 7.1 Hz, 6H).	m/z 394 (M+H) ⁺ (ES ⁺); 392 (M-H) ⁻ (ES ⁻)	As example B except 4-(2-methoxyethoxy)aniline used in step (i)
161		diethyl 3,4-dihydroxy-1-(4-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-1 <i>H</i> -pyrrole-2,5-dicarboxylate	UL2-035	+++	δ : 8.64 (m, 2H), 7.04-7.07 (m, 2H), 6.86-6.90 (m, 2H), 4.10-4.12 (m, 2H), 3.99 (q, <i>J</i> = 7.0 Hz, 4H), 3.75-3.77 (m, 2H), 3.59-3.62 (m, 2H), 3.52-3.56 (m, 4H), 3.43-3.45 (m, 2H), 3.25 (s, 3H), 0.98 (t, <i>J</i> = 7.0 Hz, 6H).	m/z 482 (M+H) ⁺ (ES ⁺); 480 (M-H) ⁻ (ES ⁻)	As example B except 4-(2-(2-methoxyethoxy)ethoxy)aniline used in step (i)

162		diethyl 1-(4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)-3,4-dihydroxy-1H-pyrrole-2,5-dicarboxylate	UL2-036	+++	δ : 8.63 (s, 2H), 7.03-7.07 (m, 2H), 6.86-6.90 (m, 2H), 4.10-4.12 (m, 2H), 3.98 (q, J = 7.1 Hz, 4H), 3.75-3.77 (m, 2H), 3.59-3.62 (m, 2H), 3.51-3.57 (m, 8H), 3.42-3.44 (m, 2H), 3.24 (s, 3H), 0.98 (t, J = 7.0 Hz, 6H).	m/z 526 (M+H) ⁺ (ES ⁺); 524 (M-H) ⁻ (ES ⁻)	As example B except 4-(2,5,8,11-tetraoxatridecan-13-yloxy)aniline used in step (i)
163		diethyl 1-(4-(3-morpholinopropoxy)phenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-037	+++	δ : 8.67 (s, 2H), 7.07-7.01 (m, 2H), 6.88-6.82 (m, 2H), 4.05-3.93 (m, 6H), 3.59 (br s, 4H), 2.48-2.34 (6H, br m), 1.96-1.84 (m, 2H), 0.97 (t, J = 7.1 Hz, 6H).	m/z 463 (M+H) ⁺ (ES ⁺); 461 (M-H) ⁻ (ES ⁻)	As example B except 4-(3-morpholinopropoxy)aniline used in step (i)
164		diethyl 1-(4-((4-methoxybenzyl)oxy)phenyl)-1H-pyrrole-2,5-dicarboxylate	UL2-038	+++	δ : 8.66 (br s, 2H), 7.41-7.36 (m, 2H), 7.06-7.01 (m, 2H), 6.97-6.89 (m, 4H), 5.04 (s, 2H), 3.97 (q, J = 7.2 Hz, 4H), 3.75 (s, 3H), 0.94 (t, J = 7.2 Hz, 6H).	m/z 456 (M+H) ⁺ (ES ⁺)	As example B except 4-((4-methoxybenzyl)oxy)aniline used in step (i)

* compounds are prodrug derivatives of UL1-012

Biological Testing

There is provided below a summary of the primary *in vitro* assay performed with all the
 5 compounds of the invention, and further assays performed with the compounds UL1-012 and
 UL2-001 as representatives for the biological activity of the compounds of the invention.

A. PRIMARY *IN VITRO* ASSAY: INHIBITION OF THE HAEMOLYTIC ACTIVITY OF PNEUMOLYSIN

10

Rationale

The basis of this assay is that when pneumolysin is added to red blood cells, it induces their
 lysis and leads to the release of haemoglobin. In the presence of an inhibitory compound,
 pneumolysin-induced lysis is abolished, the red blood cells pellet at the bottom of the microtitre
 15 plate well and the supernatant is clear. However, if the compound is not inhibitory, the red blood
 cells are lysed and haemoglobin is released into the supernatant.

Experimental procedure

Test compound solutions (typically at 5 mM in DMSO) were diluted 1:1 in 100% DMSO. The
 20 compounds were then two-fold serially diluted in 100% DMSO across 11 wells of 96-well round-
 bottomed microtitre plate. PBS was then added to all the wells to achieve a 1:10 (v/v) dilution of
 the compound in PBS. Pneumolysin was then added at a concentration equal to its LD100.
 Plates were then incubated at 37°C for 30-40 min. After the incubation period, an equal volume
 of 4% (v/v) sheep erythrocyte suspension was added to each well and the plates incubated
 25 again at 37°C, for at least 30 min. Controls with only erythrocytes in PBS (control for no lysis)
 or erythrocytes plus pneumolysin (control for lysis) were prepared following the same
 procedure. Following the incubation with the erythrocytes, the Absorbance at 595 nm of each
 well was measured and the data used to determine the IC₅₀ for each test compound. The IC₅₀
 values were determined using non-linear regression curve fitting. For that, the Log of the
 30 concentrations of the test compound was plotted against the percentage inhibition, estimated
 from the A₅₉₅ values, followed by fitting a Hill Slope to the data.

Results

IC₅₀ values for compounds of the invention generated in this assay are shown in Table 1 as
 35 follows: +++ = IC₅₀ < 10 µM; ++ = IC₅₀ 10 to <20 µM; + = IC₅₀ 20 to <60 µM.

Specific IC₅₀ values for representative compounds of the invention are:

UL1-004: IC₅₀ 0.17 µM; UL1-012: IC₅₀ 0.15 µM; UL1-024: IC₅₀ 0.182 µM; UL1-028: IC₅₀ 0.068
 40 µM; UL1-049: IC₅₀ 0.479 µM; UL2-001: IC₅₀ 0.3 µM; UL1-005: IC₅₀ 0.15 µM; UL1-035: IC₅₀ 0.15
 µM; UL1-089: IC₅₀ 0.4 µM; UL1-106: IC₅₀ 0.17 µM; UL1-116: IC₅₀ 0.18 µM.

B. PRIMARY *IN VITRO* ASSAY: INHIBITION OF THE HAEMOLYTIC ACTIVITY OF OTHER CHOLESTEROL DEPENDENT CYTOLYSINS

45

Compounds UL1-012 and UL2-001 were tested for their ability to inhibit the haemolytic activity
 of Streptolysin O (SLO), Perfringolysin O (PFO), Listeriolysin O (LLO), Anthrolysin O (ALO) and

Suilysin (SLY) using the assay protocol outlined in the above Section A. Inhibition of haemolysis of these toxins was obtained with IC₅₀ as indicated in the table below (Table 2).

Table 2

5

Toxin	IC ₅₀ for UL1-012	IC ₅₀ for UL2-001
SLO	+++	+
PFO	+++	+++
LLO	+++	+++
ALO	+++	+++
SLY	+++	+++

+++ = IC₅₀ < 10 µM; ++ = IC₅₀ 10 to < 20 µM; + = IC₅₀ 20 to < 60 µM

C. SECONDARY *IN VITRO* ASSAY: INHIBITION OF PNEUMOLYSIN-INDUCED LACTATE DEHYDROGENASE RELEASE

10

Rationale

Pneumolysin induces the release of lactate dehydrogenase (LDH) from human monocytes and lung epithelial cells: a phenomenon that is indicative of plasma membrane damage or rupture [Infect. Immun. (2002) **70** 1017-1022]. The LDH assay was applied to demonstrate the ability of the disclosed compounds to inhibit the cytotoxic effect of pneumolysin on human lung epithelial cells in culture. The use of this assay can provide two main pieces of information on (1) *Activity*, to demonstrate the inhibition of LDH release from cells exposed to pneumolysin in the presence of inhibitory compounds versus the LDH release from cells exposed to pneumolysin alone, (2) *Compound toxicity*, the assay format was designed so it allows, in the control wells, the testing of the LDH release from cells exposed to the compound only.

20

Experimental procedure

Human lung epithelial cells (A549) were seeded in flat-bottomed 96-well tissue culture plates and grown in RPMI 1640 medium supplemented with Glutamine, at 37°C, 5% CO₂, for 24h. Before use, the cells were washed with PBS. Test compound dilutions were incubated with pneumolysin as described in Section A, then transferred to wells containing the human lung epithelial cells and the plates were incubated at 37°C, 5% CO₂, for 30 min. The following controls were included on the plate (1) Negative controls, called low control (PBS only) to measure the natural release of LDH from the cells in culture, (2) positive controls (1% (v/v) Triton-X in PBS) to measure the maximum release of LDH from the cells (3) Pneumolysin solution only to measure pneumolysin-induced LDH release, (4) Test compound solution to assess the toxicity of the compound alone. After incubation, the supernatant was transferred to the wells of round-bottomed 96-well microtitre plates containing a double volume of lactate dehydrogenase assay mixture (TOX7, Sigma) prepared according to manufacturer's instructions. Incubation in a light-proof chamber at RT for 5-10 min was followed by the addition of 1N HCl to all wells. Absorbance at 490 nm and 655 nm was then measured. The percentage of LDH release induced by pneumolysin in the presence and absence of test compounds was plotted against the Log of the concentration of the compound and the IC₅₀ was determined, as described above in the inhibition of haemolysis assay, Section A.

35

Results

UL1-012 was tested in the LDH assay in triplicate over a range of concentration from 62.5 μ M to 0.49 μ M. The results obtained are shown in Figure 1.

5

In Figure 1: (1) The horizontal dotted line at 100%, PLY control (○), indicates the maximum release of LDH from the cells under the effect of pneumolysin, as opposed to the horizontal solid line at 0% (low control), which corresponds to the supernatant of cells exposed to the assay buffer alone that shows the natural LDH release under the assay conditions. (2) The grey solid line (⊖) shows that the LDH release from cells exposed to pneumolysin was significantly reduced in the presence of UL1-012, in a dose response manner, when compared to the PLY control. This demonstrates that UL1-012 prevents pneumolysin from damaging the human lung epithelial cells in culture, with an $IC_{50} < 0.4 \mu$ M. (3) The dotted black line (×) shows that UL1-012 does not exhibit cytotoxicity at the concentrations tested, up to approximately 150 times the therapeutic IC_{50} value.

Conclusion

UL1-012 inhibits the damaging activity of pneumolysin on human lung epithelial cells in culture. UL1-012 did not exhibit cytotoxic effects on the human lung epithelial cells at 150 times the therapeutic IC_{50} value.

D. EX VIVO ASSAY: INHIBITION OF THE EFFECT OF PNEUMOLYSIN ON THE CILIARY FUNCTION OF CULTURED EPENDYMAL CELLS

25 Rationale

The ependymal ciliated cells line the cerebral ventricles of the brain and the central canal of the spinal cord and are covered with cilia responsible for the circulation of the cerebrospinal fluid (CSF) around the central nervous system. This layer acts as a selective brain barrier to and from the cerebrospinal fluid and plays a role in controlling the CSF volume. Long standing research in this field in the laboratory of the inventors resulted in the development of a rat *ex vivo* model of meningitis that was proven to predict the *in vivo* situation during meningitis. This model is based on culturing and differentiating ciliated ependymal cells from neonate rat brains, which recreate the *in vivo* situation, where cells lining the brain ventricles, are exposed to *S. pneumoniae* and its toxic products.

35

The use of the *ex vivo* model of meningitis constitutes a powerful means to predict the ability of a compound to prevent pneumolysin from causing damage *in vivo*.

Experimental procedure

Ependymal cell cultures were prepared by the method previously described [Microb. Pathog. (1999) 27 303-309]. Tissue culture trays were coated with bovine fibronectin and incubated at 37°C in 5% (v/v) CO₂ for 2h before use. The growth medium was minimum essential medium (MEM) with added penicillin (100 IU/ml), streptomycin (100 μ g/ml), fungizone (2.5 μ g/ml), BSA (5 μ g/ml), insulin (5 μ g/ml), transferrin (10 μ g/ml) and selenium (5 μ g/ml). Neo-natal (0-1 day old) rats were killed by cervical dislocation, and their brains were removed. The cerebellum was removed along with edge regions of the left and right cortical hemispheres and the frontal

cortex. The remaining brain areas were mechanically dissociated in 4 ml of growth medium. The dissociated tissue from one or two brains was added to the wells of the tissue culture trays (500 µl/well), each containing 2.5 ml of growth medium. The cells then were incubated at 37°C in 5% (v/v) CO₂. The medium was replaced after three days and thereafter the ependymal cells were
 5 fed every two days with 2 ml of fresh growth medium supplemented with thrombin.

After approximately two weeks, the cells were fully ciliated and ready for experiments. For experiments, the growth medium replaced with 1 ml of medium MEM containing 25 mM HEPES, pH 7.4. The tissue culture trays were placed inside a thermostatically controlled incubation
 10 chamber surrounding the stage of an inverted light microscope. The cell cultures were allowed to equilibrate until the temperature of the assay medium was 37°C. At this point, either recombinant purified pneumolysin or *S.pneumoniae* cell lysate containing native pneumolysin - obtained following the lytic effect of the antibiotic Penicillin - with and without test compound, pre-incubated in 1 ml of medium MEM at 37°C for 40 min, were added to the wells containing
 15 the ciliated cells. To the control cells, 1 ml of MEM medium was added. Beating cilia were recorded before and after exposure over 30 min, with a digital high-speed video camera at a rate of 500 frames/s. The recorded video sequences were played back at reduced frame rates and the ciliary beat frequency (CBF) was determined by the following equation:

$$20 \quad \text{CBF (Hz)} = \frac{500 \text{ frames/s}}{(\text{frames elapsed for 5 ciliary beat cycles})} \times 5 (\text{conversion per beat cycle}).$$

Results

The parameter measured was the ciliary beating frequency (CBF). Pneumolysin or bacterial
 25 lysate, added to ciliated cells in culture induces a severe or total loss of ciliary beating. UL1-012 and UL2-001 inhibited this damaging effect induced by pneumolysin on the ciliary function of ependymal cells in culture (Figure 2.A and Figure 3, respectively). Furthermore, UL1-012 was also shown to inhibit the detrimental effect caused by a bacterial lysate, using the same *ex vivo* model (Figure 2.B).

30 In Figure 2.A: Each time point represents the normalised mean $\pm$ SD of ciliary beating frequency (CBF) measurements of four individual cilia from each well, in three independent experiments. (1) Control 1, assay medium only: the symbol (-|-) represents measurements of the CBF in the assay medium which was used as a reference for the normal cilia beating. No damaging effect
 35 on the CBF was seen throughout the recording. (2) Control 2, pneumolysin only: The symbol (●) represents measurements of the CBF in the wells where pneumolysin was added. A progressive drop in the CBF to 27% of the original frequency was observed. (3) Treatment with UL1-012: Symbols (⊗; ⊞; ■; *) represent the measurements of the CBF in the presence of pneumolysin and UL1-012 (1.56 µM - 25 µM). No significant loss of the CBF was seen, showing
 40 that UL1-012 inhibits pneumolysin-induced damage on the ciliary beating frequency of the brain ependymal cells. There was no statistical difference between the CBF of Control 1 (medium only) and the CBF in the presence of the treatment (⊗; ⊞; ■; *), indicating that the inhibition of the damaging effect of pneumolysin by UL1-012 was achieved to an extent comparable to the control medium alone.

45

In Figure 2.B: Each time point represents the normalised mean $\pm$ SD of ciliary beating frequency (CBF) measurements of four individual cilia from each well, in three independent experiments.

(1) Control 1, assay medium only: the symbol (-|-) represents measurements of the CBF in the assay medium which was used as a reference for the normal cilia beating. No damaging effect

5 on the CBF was seen throughout the recording. (2) Control 2, bacterial lysate: the symbol (●) represents measurements of the CBF in the wells where the bacterial lysate obtained from penicillin-lysed *S. pneumoniae* induced a significant reduction in the CBF within the first five minutes of the recording, to 16% of the original frequency. (3) Treatment with UL1-012: the symbol (⌘) represents the measurements of the CBF in the presence of treatment UL1-012 and
10 bacterial lysate obtained from penicillin-lysed *S. pneumoniae*. UL1-012 significantly prevented the drop of the CBF, indicating that UL1-012 inhibits pneumolysin released from penicillin-lysed bacteria, to a similar extent of the control 1 (-|-); healthy cilia in the presence of the assay medium.

15 In Figure 3: Each time point represents the normalised mean $\pm$ SD of ciliary beating frequency (CBF) measurements of four individual cilia from each well, in three independent experiments. (1) Control 1, assay medium only: the symbol (-|-) represents measurements of the CBF in the assay medium which was used as a reference for the normal cilia beating. No damaging effect on the CBF was seen throughout the recording (2) Control 2, pneumolysin only: The symbol (●)
20 represents measurements of the CBF in the wells where pneumolysin was added. A rapid drop in the CBF, with complete inhibition by 1 minute after the addition of pneumolysin was observed (3) Treatment with UL2-001: Symbol (■) represent the measurements of the CBF in the presence of pneumolysin and UL2-001 (2.00 μ M). No significant loss of the CBF was seen, showing that UL2-001 inhibits pneumolysin-induced damage on the ciliary beating frequency of
25 the brain ependymal cells. There was no statistical difference between the CBF of Control 1 (medium only) and the CBF in the presence of the treatment, indicating that the inhibition of the damaging effect of pneumolysin by UL2-001 was achieved to an extent comparable to the control medium alone.

30 Conclusion

UL1-012 and UL2-001 inhibit the damaging effect that pneumolysin induces on the brain ependymal ciliated cells in culture which predicts its ability to prevent pneumolysin from causing damage *in vivo*. In addition, UL1-012 demonstrated the ability to also inhibit the native pneumolysin, released by pneumococcus following antibiotic-mediated lysis. It is remarkable that the
35 inhibition of pneumolysin only, amongst all other bacterial products present in *S.pneumoniae* bacterial lysate, was sufficient to abolish the damaging effect of the whole bacterial lysate, which highlights again the substantial involvement of pneumolysin in the damaging effect of antibiotic lysed bacteria.

40 These findings support the use of this novel-approach as an adjunctive therapy in patients.

E. *IN VIVO* EFFICACY ASSAY USING A MOUSE PNEUMONIA MODEL

Rationale

45 This model has been long developed and well established in the laboratory of the inventors and has become adapted by other research groups working in this field. Using this model,

pneumolysin was shown to be essential for the pathogenesis of *S. pneumoniae* and for its survival *in vivo*. With this disease model, mice infected with a strain of *S. pneumoniae* mutant deficient in pneumolysin (PLN-A), exhibited (1) a significant increase in the survival, (2) significant delay and attenuation of the signs of the disease and (3) substantial decrease in the pulmonary inflammation and less bacteraemia (infiltration of the bacteria from the lungs to the circulation). Therefore, this *in vivo* disease model constitutes a powerful tool to study the disease progression of mice infected with wild-type *S. pneumoniae* and treated with pneumolysin inhibitors. To assess the severity of the disease, the parameters that are followed are the survival and the disease score.

Experimental Procedures: Infection, Treatment and Disease Signs Scoring

Outbred MF1 female mice, 8 weeks old or more and weighing 25-30 g were used. The animals were maintained under controlled conditions of temperature, humidity and day length. They had free access to tap water and pelleted food. The *in vivo* experiments were performed using two control groups: Control 1 (infected and not treated), Control 2 (not infected and treated) and one Treatment group (infected and treated). Mice in control group 1 and in the treatment group were infected intranasally with *Streptococcus pneumoniae* strain D39 (procedure described below). After completing the infections, the viable count of the given dose was determined (as described below). Subsequently, every six hours, animals in the Treatment group and in Control group 2, received the test compound intravenously or intranasally as appropriate while excipient alone was administered to Control group 1. The progress of the signs of disease (Table 3) was assessed every 6h based on the scheme of Morton and Griffiths [Veterinary Record. (1985) 111, 431-436].

Animals were killed if they became 2+ lethargic and the time was recorded. After approximately 72h the experiment was ended. The survival rates of control and test groups were compared with a log-rank test, while the signs of disease were compared with the Mann-Whitney test.

Table 3 Scoring scheme of the disease signs

	Sign	Description	Score
5	Normal	Healthy appearance.	0
		Highly active.	
10	1+/2+ Hunched	Slight (1+) or pronounced (2+) convex curvature of the upper spine.	1; 2
	1+/2+ Starey coat (Piloerection)	Slight (1+) or pronounced (2+) piloerection of the coat.	3; 4
15	1+/2+ Lethargic	Pronounced hunching and piloerection accompanied by a	5; 6
20		considerable (1+) or severe (2+) reduction of activity.	
	Moribund	Complete inertia.	N/A
25		Drastic reduction of breathing rate.	
		Drop of the body temperature.	
30	N/A – Not applicable		

The administration of *S. pneumoniae*/Treatment and the determination of the bacterial viable counts mentioned in the above procedure are detailed as follows:

35 - *Intranasal administration*

Mice were lightly anaesthetised with 2.5% (v/v) isoflurane over 1.6-1.8 L O₂/min. The confirmation of effective anaesthesia was made by observation of no pedal reflex. A mouse was held by the scruff of the neck in a vertical position with its nose upward. The dose was then administered in sterile PBS, given drop by drop into the nostrils, allowing the animal to inhale it in between drops. Once the dose was given, the mouse was returned to its cage, placed on its back to recover from the effects of anaesthetic.

- *Intravenous administration*

Mice were placed in a cage inside an incubator at 37°C, for 20 min, to dilate their veins. After incubation, the cage was brought outside and the mice were kept warm under an infra-red (IR) lamp. A mouse was then placed inside a restrainer, leaving the tail of the animal exposed. The tail was disinfected with 10% (v/v) Microsol in water. The dose was then gently administered intravenously using a 0.5 mL insulin syringe inserted carefully into one of the tail lateral veins.

50 - *Determination of viable counts*

Viable counting was performed by the method of Miles and Misra [J. Hyg. (1938) 38 732-749]. 20 µl of the sample were serially diluted in 180 µl PBS in round-bottomed 96-wells microtitre plates, up to a dilution of 10⁶. Blood agar plates were divided into six sectors and 60 µl of each dilution plated onto an individual sector. The plates were incubated in CO₂ gas jars overnight at

37°C. The following day, colonies were counted in the sector where 30-300 colonies were visible. The concentration of colony forming units (CFU) per millilitre was determined by using the following equation:

$$5 \quad \text{CFU per ml} = \frac{\text{Number of colonies in sector}}{60 \mu\text{l}} \times \text{Dilution} \times 1000 \text{ (conversion factor)}$$

Results of the *in vivo* efficacy assay obtained with Example UL1-012

10 - *Experimental design*

The experimental design is shown in Figure 4. The treatment with UL1-012 was administered intravenously every 6h. Based on the IC₁₀₀ concentration seen in the primary assay, the amount of compound required to neutralise pneumolysin released *in vivo* during the most severe phase of infection, was calculated. A dose of 4 mg/kg prepared in 2% (v/v) DMSO in PBS was given.

15 This proved effective. In subsequent PD experiments, 16 mg/kg prepared in 4% (v/v) DMSO in PBS was also used. The doses were prepared freshly and administered intravenously to the animals.

- *Survival Results*

20 **4 mg/kg** of body weight of UL1-012 was administered intravenously every 6h to mice infected with *S. pneumoniae* and the outcome compared against a control group of infected mice, which had not received the compound (only the excipient). The p-value was calculated by means of the log-rank (Mantel-Cox) test (n = 10/group). The survival curves of the control (solid line) and treatment (dotted line) groups obtained with this experiment are presented in Figure 5. Up to
25 approximately 40h after infection, there was a significant improvement in the survival of the treatment group over the control group (p<0.05). 4 mg/kg of UL1-012 produced a good outcome with a significant increase of the survival at critical time points where we usually see a rapid disease progression of untreated animals (p<0.05).

16 mg/kg of body weight of UL1-012 was used. Six hours post infection with wild-type *S. pneumoniae*, animals received intravenously UL1-012 (16 mg/kg) and every 6h thereafter. The
30 p-value was calculated by means of the log-rank (Mantel-Cox) test (n = 10/group). This was performed to test if protection could be enhanced but also to test if a higher dose is as tolerated. As shown in Figure 6, a significant increase in the survival was seen with 50% of mice surviving at the endpoint of the experiment at 72h post infection (p<0.05).

35

- *Disease score results*

During the course of the experiment, the signs of the disease were assessed at least every 6h and disease scores were noted for each mouse. At various time points of the experiment, infected/non-treated mice exhibited pronounced signs of the disease, reflected by their hunched
40 spine, piloerect coat and reduction in their activity. On the other hand, a significantly higher number of infected mice that received the treatment with UL1-012 had a healthy appearance (spine not hunched, coat not standing) and were highly active, exploring the cage surroundings.

Disease scoring with 16 mg/kg of UL1-012 recorded at multiple time points during the course of
45 the experiment is shown in Figure 7. Each symbol (■;●) represents an individual mouse in the control and treatment group, respectively; horizontal lines represent medians; p-values were calculated by using a Mann-Whitney test. A delay in the onset of the signs of the disease for the

group that was treated with UL1-012 was obtained. The difference in the disease scoring between the two groups was statistically significant ($p < 0.05$) at 30 h, 36 h, 60 h and 66 h post-infection. The results indicate a delay in the onset of the disease and a significant attenuation of the signs of the disease.

5

- *Conclusion*

(1) *In vivo* protection was obtained with UL1-012 at both dosing regimen tested. (2) Higher dose of UL1-012 provided an enhanced protection showing that there is a dose dependent response. (3) Protection is seen even in the absence of an antibiotic, which is a remarkable outcome, suggesting that the neutralisation of pneumolysin alone, without the killing of the bacterium, is providing protection to the animals. This is consistent with the disease profile obtained with *S. pneumoniae* deficient in pneumolysin (PLN-A). (4) Even at the highest concentration of UL1-012, no visible adverse effects were seen in the control group of mice receiving the compound alone.

10
15

Results of the *in vivo* efficacy assay obtained with Example UL2-001

- *Experimental set up*

The *in vivo* efficacy of Example UL2-001 was tested using a pneumonia model. The experimental design is shown in Figure 8. The treatment with UL2-001 was administered intranasally every 6h. Based on the IC_{100} concentration seen in the primary assay, the amount of compound required to neutralise pneumolysin released *in vivo* during the most severe phase of infection, was calculated. A dose of 0.8 mg/kg prepared in 2% (v/v) DMSO in PBS was given. This proved effective. The doses were prepared freshly and administered intranasally to the animals.

20
25

- *Survival Results*

0.8 mg/kg of body weight of UL2-001 was administered intranasally every 6h to mice infected intranasally with *S. pneumoniae* and the outcome compared against a control group of infected mice, which had not received the compound (only the excipient). The p-value was calculated by means of the log-rank (Mantel-Cox) test ($n = 5/\text{group}$). The survival curves of the control (solid line) and treatment (dotted line) groups obtained with this experiment are presented in Figure 9. 36 hours post-infection infection, all mice in the control group had died. At this time-point, the percentage of survival of the treatment group had dropped to 60%, and then remained constant until the endpoint of the experiment at 60 hours post-infection. This experimental outcome has shown a significant improvement in the survival of the treatment group over the control group ($p < 0.05$).

30
35

- *Conclusion*

(1) *In vivo* protection was obtained with UL2-001 following intranasal administration. (2) Protection is seen even in the absence of an antibiotic, suggesting that the neutralisation of pneumolysin alone, without the killing of the bacterium, is providing protection to the animals. This is consistent with the disease profile obtained with *S. pneumoniae* deficient in pneumolysin (PLN-A).

40
45

F. CONVERSION OF PRODRUG DERIVATIVES TO ACTIVE INHIBITORS IN MOUSE AND HUMAN PLASMA

Rationale

- 5 To demonstrate that the prodrug derivatives are converted to the active ingredient in the presence of plasma enzymes, a prodrug derivative was incubated with mouse and human plasma at 37°C at 5 time points over a 2h period. The samples were then analysed by LC-MS/MS to obtain the amount of active compound appearing and prodrug derivative remaining over time. The mouse plasma assay system is considered to be a good model for human
10 behaviour. Nevertheless data obtained in a human plasma assay system was obtained in some cases.

Experimental procedure

- Prodrug derivatives were assessed in the mouse and human plasma stability assay at a
15 concentration of 10 µM. Test compounds were diluted in DMSO to a final stock concentration of 10 mM. For the purpose of the assay, the stocks prepared were further diluted in DMSO to a concentration of 400 µM and 5 were added to 195 µl of mouse or human plasma (pH 7.4) and then incubated at 37°C. The final concentration of DMSO in the plate was 2.5% (v/v). Reactions were terminated at 0, 15, 30, 60 and 120 min after incubation by adding 400 µl of acetonitrile
20 containing 0.55 µM metoprolol and 1% (v/v) formic acid. The plate was then centrifuged at 3000 rpm, for 45 min, at 4°C. 80 µl of supernatant were transferred into a conical bottom 96 well glass coated plate. 40 µl of water were added prior to analysis for prodrug derivative and active species by LC-MS/MS. This assay was performed by a contract research organisation, Cyprotex Discovery Limited, UK, at the request of the inventors at Leicester.
25

Results

The quantification of the parent compound (prodrug derivative) remaining and the active ingredient appearing was performed as follows:

- (1) The active compound was quantified using a 6 point calibration curve prepared in
30 deactivated mouse and human plasma. (2) The percentage of parent compound remaining at each time point relative to 0 min sample was calculated from LC-MS/MS peak area ratios (compound peak area/internal standard peak area). This percentage was then used to determine the concentration of the parent compound at each time point in reference to the starting concentration (10 µM) at time 0 min.
35 A summary of the conversion of the prodrug derivatives to active inhibitors is shown Table 4.

Conclusion

- The results presented in Table 4 clearly indicate the therapeutic benefits of the prodrugs of the invention, which is demonstrated by their conversion in plasma into the pharmacologically active
40 ingredient. The rate of conversion of the prodrug derivatives to the active ingredients is variable amongst the prodrug derivatives. This offers a range of different therapeutic strategies ranging from immediate to slow release, in order to achieve the desired therapeutic benefits.

Table 4

Prodrug ID	Prodrug/ Active*	[] (μM) t ₀ min.	[] (μM) t ₁₅ min.	[] (μM) t ₃₀ min.	[] (μM) t ₆₀ min.	[] (μM) t ₁₂₀ min.
UL1-044	Prodrug (UL1-044)	10	0	0	0	0
	Active (UL1-012)	0	9	11	11	13
UL1-063	Prodrug (UL1-063)	10	10	9.20	9.40	8.50
	Active (UL1-012)	0	0	0.02	0.03	0.05
UL1-064	Prodrug (UL1-064)	10	3.10	7.00	5.00	2.20
	Active (UL1-012)	0	0.02	0.11	0.24	0.37
UL1-065	Prodrug (UL1-065)	10	4.21	3.72	2.57	1.14
	Active (UL1-012)	0	0.05	0.07	0.12	0.19
UL1-066	Prodrug (UL1-066)	10	9.90	10.00	9.78	9.50
	Active (UL1-012)	0	0.23	0.23	0.21	0.20
UL1-067	Prodrug (UL1-067)	10	0	0	0	0
	Active (UL1-012)	0	10.40	10.60	10.10	10.80
UL1-068	Prodrug (UL1-068)	10	3.02	1.00	0.136	0
	Active (UL1-012)	0	6.12	8.98	9.00	9.00
UL1-069	Prodrug (UL1-069)	10	9.90	9.70	9.60	9.90
	Active (UL1-012)	0	0.44	0.42	0.40	0.40
UL1-070	Prodrug (Mouse plasma) (UL1-070)	10	6.40	4.73	2.43	0.93
	Active (Mouse plasma) (UL1-012)	0	3.22	5.85	7.72	8.71
	Prodrug (Human) (UL1-070)	10	8.02	8.28	7.70	7.48
	Active (Human) (UL1-012)	0	0.25	0.45	0.78	1.29
UL1-071	Prodrug (UL1-071)	10	9.50	9.00	8.72	7.39
	Active (UL1-012)	0	0.47	0.87	1.65	2.56
UL1-092	Prodrug (UL1-092)	10	5.12	4.67	4.59	3.70

WO 2013/083975

PCT/GB2012/053022


	Active (UL1-012)	0	0.01	0.01	0.01	0.012
UL1-094	Prodrug (UL1-094)	10	9.99	9.22	8.78	8.49
	Active (UL1-012)	0.059	0.01	0.01	0.03	0.05
UL1-098	Prodrug (Mouse) (UL1-098)	10	0	0	0	0
	Active (Mouse) (UL1-095)	0	10.40	11.00	11.40	11.40
	Prodrug (Human) (UL1-098)	10	5.42	3.45	1.76	0.65
	Active (Human) (UL1-095)	0	4.45	6.84	8.93	10
UL1-105	Prodrug (UL1-105)	10	0	0	0	0
	Active (UL1-012)	0.22	14.50	12.83	13.60	13.83
UL1-109	Prodrug (Mouse) (UL1-109)	10	6.87	4.84	2.45	0.73
	Active (Mouse) (UL1-012)	0.06	3.47	6.01	8.40	9.92
	Prodrug (Human) (UL1-109)	10	6.22	5.37	3.39	1.72
	Active (Human) (UL1-012)	0	1.96	3.31	5.81	8.71
UL1-111	Prodrug (Mouse) (UL1-111)	10	4.74	2.47	1.16	0.47
	Active (Mouse) (UL1-012)	0.22	6.31	8.55	10.45	13.8
	Prodrug (Human) (UL1-111)	10	2.84	0.80	0.09	0.00
	Active (Human) (UL1-012)	<LOQ	6.98	9.01	9.23	9.23
UL1-114	Prodrug (Mouse) (UL1-114)	10	0	0	0	0
	Active (Mouse) (UL1-005)	0	14.14	14.16	13.14	10.85
	Prodrug (Human) (UL1-114)	10	9.53	9.48	8.22	7.22
	Active (Human) (UL1-005)	0	1.72	3.11	4.96	7.62

UL1-115	Prodrug (Mouse) (UL1-115)	10	7.56	4.04	1.54	0.38
	Active (Mouse) (UL1-012)	0	4.16	6.22	8.41	9.65
	Prodrug (Human) (UL1-115)	10	10.8	9.41	6.69	2.98
	Active (Human) (UL1-012)	0	2.36	4.41	6.55	8.84
UL1-117	Prodrug (Mouse) (UL1-117)	10	5.92	4.26	1.41	0.21
	Active (Mouse) (UL1-012)	0	0.76	1.26	3.17	5.95
	Prodrug (Human) (UL1-117)	10	14.9	10.1	4.28	1.12
	Active (Human) (UL1-012)	0.17	1.94	3.60	5.86	8.88
UL1-118	Prodrug (Mouse) (UL1-118)	10	6.04	4.00	1.68	0.23
	Active (Mouse) (UL1-012)	0	1.04	1.63	3.44	6.32

*If the species is not specified in the table it is referring to mouse.

A set of clauses defining certain aspects of the invention is as follows:

5 1. A compound of formula (I):



(I)

10

wherein:

R¹ and R² are independently selected from -C(O)NR⁵R⁶, -C(O)OR⁷, CN, -C(O)R⁷, -C(O)NHC(O)R⁷, -NO₂, -SO₃R⁷, -SO₂R⁷, -SO₂NR⁵R⁶, -SOR⁷, -SO₂NH-C(O)OR⁸ and optionally substituted phenyl or heteroaryl;

15 R³ is optionally substituted phenyl;

R^{4a} and R^{4b} are independently selected from hydrogen, C₁-C₆ alkyl which alkyl group may optionally be substituted by hydroxyl, COOR¹² or CONR¹³R¹⁴, aryl and -C₁-C₃ alkylaryl in which said aryl groups may be optionally substituted;

R⁵ and R⁶ are independently selected from:

- (a) hydrogen,
- (b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl, heterocyclyl, -C₁-C₃ alkyl-C₃-C₁₀ cycloalkyl, -C₁-C₃ alkyl-C₅-C₁₀ cycloalkenyl or -C₁-C₃ alkylheterocyclyl, or R⁵ and R⁶ together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and NR⁹, in which any of the aforementioned R⁵ and R⁶ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R⁵ and R⁶ groups may be optionally substituted by one or more halogen atoms, and
- (c) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;

R⁷ is selected from:

- (a) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl, heterocyclyl, -C₁-C₃ alkyl-C₃-C₁₀ cycloalkyl, -C₁-C₃ alkyl-C₅-C₁₀ cycloalkenyl or -C₁-C₃ alkylheterocyclyl, in which any of the aforementioned R⁷ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R⁷ groups may be optionally substituted by one or more halogen atoms, and
- (b) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;

R⁸ is C₁-C₆ alkyl;

R⁹ is hydrogen, C₁-C₆ alkyl; -C(O)R¹⁰ or -C(O)OR¹¹;

R¹⁰ is C₁-C₆ alkyl;

R¹¹ is C₁-C₆ alkyl;

R¹² is C₁-C₆ alkyl;

R¹³ is hydrogen or C₁-C₆ alkyl; and

R¹⁴ is hydrogen or C₁-C₆ alkyl;

or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt or solvate thereof;

provided that the compound is not:

- a) diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- b) diethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate;
- c) dimethyl 3,4-dihydroxy-1-(4-bromophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- d) dimethyl 3,4-dihydroxy-1-(4-chlorophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- e) di-*tert*-butyl 3,4-dihydroxy-1-(4-nitrophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- f) dimethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
- g) dimethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate;
- h) diethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate; or
- i) dimethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate.

2. A compound according to clause 1 wherein R^1 and R^2 are independently selected from -C(O)NR⁵R⁶, -C(O)OR⁷ and CN.
- 5 3. A compound according to clause 1 wherein (i) R^1 is -C(O)NR⁵R⁶ and R^2 is -C(O)NR⁵R⁶ or (ii) R^1 is -C(O)NR⁵R⁶ and R^2 is -C(O)OR⁷.
4. A compound according to clause 1 wherein R^1 is -C(O)OR⁷ and R^2 is -C(O)OR⁷.
- 10 5. A compound according to any one of the preceding clauses wherein R^3 is substituted phenyl.
6. A compound according to clause 5 wherein R^3 is phenyl substituted by 1, 2 or 3 substituents selected from halo, cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl.
- 15 7. A compound according to clause 5 or 6 wherein R^3 is phenyl having a substituent in the meta or para positions relative to the pyrrole ring.
- 20 8. A compound according to any one of the preceding clauses wherein R^{4a} and R^{4b} are hydrogen or -C₁-C₃ alkylaryl.
9. A compound according to clause 8 wherein R^{4a} and R^{4b} are hydrogen.
- 25 10. A compound according to any one of the preceding clauses wherein R^5 and R^6 are independently selected from hydrogen, C₁-C₆ alkyl, aryl or C₁-C₃ alkylaryl in which said aryl may be optionally substituted, or R^5 and R^6 together with the N to which they are attached form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and NR⁹.
- 30 11. A compound according to clause 10 wherein R^5 and R^6 are not both hydrogen.
12. A compound according to any one of the preceding clauses wherein R^7 is C₁-C₆ alkyl.
- 35 13. A compound according to clause 1 which is selected from:
 N^2, N^2, N^5, N^5 -tetraethyl-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-ethoxyphenyl)- N^2, N^2, N^5, N^5 -tetraethyl-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 N^2, N^2, N^5, N^5 -tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
40 (3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
3,4-dihydroxy-1-(4-methoxyphenyl)- N^2, N^2, N^5, N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
1-(4-fluorophenyl)-3,4-dihydroxy- N^2, N^5 -dimethyl- N^2, N^5 -diphenyl-1*H*-pyrrole-2,5-dicarboxamide;
1-(4-fluorophenyl)-3,4-dihydroxy- N^2, N^2, N^5, N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
45 di-*tert*-butyl 4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate);

- 1,1'-(4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
 (1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 5 1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-diisopropyl-*N*²,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
*N*²,*N*⁵-dibenzyl-1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
 di-*tert*-butyl 4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate);
 10 (3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperazin-1-ylmethanone);
 1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetraisopropyl-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
 3,4-dihydroxy-1-(2-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-dihydroxy-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 15 1-(4-ethoxyphenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 (3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
*N*²-ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(piperidine-1-carbonyl)-1*H*-pyrrole-2-
 20 carboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxamide;
 25 3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-(dimethylcarbamoyl)phenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
tert-butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-2-
 30 yl)sulfonylcarbamate;
 5-cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide;
 ethyl 5-(dimethylcarbamoyl)-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;
 1,1'-(4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
 35 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile;
 isopropyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
tert-butyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxylate;
 40 ethyl 5-(dibutylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(diethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-iodophenyl)-1*H*-pyrrole-2-carboxylate;
 45 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;

- 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)- N^2,N^2,N^5,N^5 -tetraethyl-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)- N^2,N^2,N^5,N^5 -tetraethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 di-*tert*-butyl 4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 5 dicarbonyl)bis(piperazine-1-carboxylate);
 (3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
 3,4-bis(benzyloxy)-1-(2-methoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-bis(benzyloxy)-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 10 (3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 3,4-bis(benzyloxy)- N^2,N^2,N^5,N^5 -tetramethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-
 dicarboxamide;
 3,4-bis(benzyloxy)- N^2 -ethyl-1-(4-methoxyphenyl)- N^5,N^5 -dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N,N -dimethyl-5-(4-methylpiperazine-1-carbonyl)-1*H*-
 15 pyrrole-2-carboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N,N -dimethyl-5-(piperidine-1-carbonyl)-1*H*-pyrrole-2-
 carboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N,N -dimethyl-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-
 carboxamide;
 20 1,1'-(4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-
 diyl))diethanone;
 ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate;
 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)- N,N -dimethyl-1*H*-pyrrole-2-carboxamide;
 ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-iodophenyl)-1*H*-pyrrole-2-carboxylate;
 25 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)- N^2,N^5 -diethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 30 1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-ethoxyphenyl)- N^2,N^5 -diethyl-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 ethyl 3,4-bis(benzyloxy)-5-carbamoyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-carbamoyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-bis(benzyloxy)-5-(2-methoxyphenyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 35 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-4-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-3-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 40 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 3,4-bis(benzyloxy)-5-(5-ethyl-1,3,4-oxadiazol-2-yl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2*H*-tetrazol-5-yl)-1*H*-pyrrole-2-carboxylate;
 45 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2*H*-tetrazol-5-yl)-1*H*-pyrrole-2-carboxylate;
 diethyl 1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;

- diethyl 3,4-dihydroxy-1-(3-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-(trifluoromethoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-isopropylphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-phenoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 5 diethyl 1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-ethylphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(*p*-tolyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(3,4-dimethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-chlorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 10 diethyl 3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(3,4,5-trimethoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(2,4-dimethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-propoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-ethoxy-3,5-difluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 15 diethyl 3,4-dihydroxy-1-(3-phenoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(benzo[d][1,3]dioxol-5-yl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diisopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 2-ethyl 5-isopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 di-*tert*-butyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 20 diethyl 3,4-dihydroxy-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-cyanophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-fluorophenyl)-3-hydroxy-4-(2-hydroxyethoxy)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-hydroxy-4-(2-hydroxyethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-
 25 dicarboxylate;
 diethyl 3-(benzyloxy)-4-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 dicarboxylate;
 diethyl 3-(2-amino-2-oxoethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-(2-(*tert*-butoxy)-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 30 dicarboxylate;
 diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-(*tert*-butyl)phenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate; and
 diethyl 3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate; or a
 pharmaceutically acceptable prodrug derivative of any one thereof, or a pharmaceutically
 35 acceptable salt or solvate of any one thereof.

14. A compound according to any one of clauses 1 to 13 in the form of a prodrug derivative.

15. A compound according to clause 14 wherein the prodrug derivative is selected from
 40 carboxylate ester, sulfamate ester, phosphate ester and carbamate ester derivatives.

16. A compound according to clause 14 wherein one or both of R^{4a} and R^{4b} are
 independently selected from -C(O)R¹⁶, -SO₂NH₂, -PO(OR¹⁹)(OR²⁰) and -C(O)NR¹⁷R¹⁸, wherein
 R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰ are independently selected from

45 (a) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,
 heterocyclyl, -C₁-C₃ alkyl-C₃-C₁₀ cycloalkyl, -C₁-C₃ alkyl-C₅-C₁₀ cycloalkenyl or -C₁-C₃

alkylheterocyclyl, in which any of the aforementioned R¹⁶, R¹⁷ or R¹⁸ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R¹⁶, R¹⁷ or R¹⁸

5 groups groups may be optionally substituted by one or more halogen atoms, and
 (b) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;
 or R¹⁸, R¹⁹ and R²⁰ may independently represent hydrogen.

- 10 17. A compound according to clause 14 selected from:
 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl diacetate;
 ethyl 5-(dimethylcarbamoyl)-3,4-bis((dimethylcarbamoyl)oxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-
 2-carboxylate;
 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-
 15 methylpiperazine-1-carboxylate);
 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis([1,4'-
 biperidine]-1'-carboxylate);
 ethyl 5-(dimethylcarbamoyl)-4-((dimethylcarbamoyl)oxy)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-
 pyrrole-2-carboxylate;
 20 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2-
 methylpropanoate);
 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-
 dimethylpropanoate);
 ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(sulfamoyloxy)-1*H*-pyrrole-2-
 25 carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonooxy)-1*H*-pyrrole-2-
 carboxylate; and
 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl [1,4'-
 biperidine]-1'-carboxylate;
 30 or a pharmaceutically acceptable salt or solvate of any one thereof.

18. A compound according to clause 1 which is ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-
 1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate, or a pharmaceutically acceptable prodrug
 derivative, or a pharmaceutically acceptable salt or solvate thereof.

19. A pharmaceutical composition comprising a compound according to any one of clauses
 1 to 18, without provisos a) to i), optionally in combination with one or more pharmaceutically
 acceptable diluents or carriers.

20. A pharmaceutical composition according to clause 19 comprising one or more other
 therapeutically active ingredients.

21. A compound according to any one of clauses 1 to 18 without proviso a) to i) for use as a
 medicament.

22. A compound according to clause 21 for use as a medicament which is diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

5 23. A compound according to any one of clauses 1 to 18, 21 and 22 without provisos a) to i) for use in the treatment of bacterial infections caused by bacteria producing pore-forming toxins, such as cholesterol dependent cytolysins.

24. A compound for use according to clause 23 wherein the bacterial infection is caused by
10 *Streptococcus* spp. (e.g. *Streptococcus pneumoniae*, Group A Streptococci or *Streptococcus suis*), *Clostridium* spp. (e.g. *Clostridium perfringens*), *Listeria* spp. (e.g. *Listeria monocytogenes*) or *Bacillus* spp. (e.g. *Bacillus anthracis*).

25. A compound for use according to clause 24 for the treatment of bacterial infection which
15 is caused by *Streptococcus pneumoniae*.


26. A compound for use according to clause 25 for the treatment of pneumococcal pneumonia, pneumococcal meningitis, pneumococcal septicaemia/bacteraemia, pneumococcal keratitis or pneumococcal otitis media.

20 27. A compound for use according to clause 24 for the treatment of conditions selected from gas gangrene, gastrointestinal anthrax, inhalational anthrax, porcine meningitis, encephalitis, septicaemia/bacteraemia and pneumonia which are caused by bacteria other than pneumococcus.

25 28. A compound for use according to any one of clauses 21 to 27 wherein the compound is administered in combination with one or more other therapeutically active ingredients (e.g. one or more antibiotic agents).

30 29. A method of treatment of bacterial infections caused by bacteria producing pore-forming toxins, such as cholesterol dependent cytolysins which comprises administering to a subject in need thereof an effective amount of a compound according to any one of clauses 1 to 18, 21 and 22 without provisos a) to i).

35 30. A compound of formula (II):



(II)

40 wherein R¹, R² and R³ are as defined in clause 1 for the compounds of formula (I), or a salt or protected derivative thereof;
provided that when R⁵ or R⁶ is optionally substituted aryl it is optionally substituted by 1, 2 or 3 groups selected from hydroxyl, halo, cyano, C₁-C₆ alkoxy or C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl or C₁-C₆ fluoroalkyl, and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen

and C₁-C₆ alkyl; or when two adjacent hydroxyl substituents are present they may optionally be connected by a methylene group to form an acetal;

and provided that the compound is not:

- a) methyl 2-((2-oxo-2-(phenylamino)ethyl)(phenyl)amino)acetate;
- 5 b) methyl 2-((4-methoxyphenyl)(2-oxo-2-(phenylamino)ethyl)amino)acetate;
- c) ethyl 2-(phenyl(tosylmethyl)amino)acetate;
- d) ethyl 2-((cyanomethyl)(3,4-dichlorophenyl)amino)acetate;
- e) methyl 2-((cyanomethyl)(p-tolyl)amino)acetate; or
- f) ethyl 2-(mesityl(2-oxopropyl)amino)acetate.

10

31. A compound of formula (II) according to clause 30 wherein R¹ is -C(O)NR⁵R⁶ and R² is -C(O)NR⁵R⁶ or wherein R¹ is -C(O)NR⁵R⁶ and R² is -C(O)OR⁷.

32. A process for preparing compounds of formula (I) as defined in any one of clauses 1 to 15 18 in which R^{4a} and R^{4b} represent H which comprises reacting a compound of formula (II) as defined in clause 30 with a compound of formula R^xOCOCOR^x in which R^x represents C₁-C₆ alkyl.

Throughout the specification and the claims which follow, unless the context requires otherwise, 20 the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.


All patents and patent applications referred to herein are incorporated by reference in their 25 entirety.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the 30 form of product, composition, process, or use claims and may include, by way of example and without limitation, the claims.

Claims

1. A compound of formula (I):

5



(I)

wherein:

- 10 R¹ and R² are independently selected from -C(O)NR⁵R⁶, -C(O)OR⁷, CN, -C(O)R⁷, -C(O)NHC(O)R⁷, -NO₂, -SO₃R⁷, -SO₂R⁷, -SOR⁷, -SO₂NR⁵R⁶, -SO₂NH-C(O)OR⁸, -POR²¹R²² and optionally substituted phenyl or heteroaryl;
- R³ is optionally substituted phenyl;
- R^{4a} and R^{4b} are independently selected from hydrogen; C₁-C₆ alkyl which alkyl group may
- 15 optionally be substituted by hydroxyl, COOR¹² or CONR¹³R¹⁴; aryl and -C₁-C₃ alkylaryl in which said aryl groups may be optionally substituted;
- R⁵ and R⁶ are independently selected from:
- (a) hydrogen,
- (b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl,
- 20 heterocyclyl, -C₁-C₃ alkyl-C₃-C₁₀ cycloalkyl, -C₁-C₃ alkyl-C₅-C₁₀ cycloalkenyl or -C₁-C₃ alkylheterocyclyl, or R⁵ and R⁶ together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and NR⁹, in which any of the aforementioned R⁵ and R⁶ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy,
- 25 C₁-C₆ alkyl, C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R⁵ and R⁶ groups may be optionally substituted by one or more halogen atoms, and
- (c) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;
- 30 R⁷ is selected from:
- (a) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₁₀ cycloalkyl, C₅-C₁₀ cycloalkenyl, heterocyclyl, -C₁-C₃ alkyl-C₃-C₁₀ cycloalkyl, -C₁-C₃ alkyl-C₅-C₁₀ cycloalkenyl or -C₁-C₃ alkylheterocyclyl, in which any of the aforementioned R⁷ groups may be optionally substituted by a group selected from cyano, C₁-C₆ alkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl,
- 35 C₁-C₆ fluoroalkyl and -C(O)NR^aR^b, where R^a and R^b are independently selected from hydrogen and C₁-C₆ alkyl, and any of the aforementioned R⁷ groups may be optionally substituted by one or more halogen atoms, and
- (b) aryl, heteroaryl, C₁-C₃ alkylaryl and -C₁-C₃ alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;
- 40 R⁸ is C₁-C₆ alkyl;
- R⁹ is hydrogen, C₁-C₆ alkyl; -C(O)R¹⁰ or -C(O)OR¹¹;
- R¹⁰ is C₁-C₆ alkyl;

R¹¹ is C₁-C₆ alkyl;

R¹² is C₁-C₆ alkyl;

R¹³ is hydrogen or C₁-C₆ alkyl;

R¹⁴ is hydrogen or C₁-C₆ alkyl; and

- 5 R²¹ and R²² are independently selected from C₁-C₆ alkyl and C₁-C₆ hydroxyalkyl; or a pharmaceutically acceptable prodrug derivative thereof, or a pharmaceutically acceptable salt or solvate thereof;

provided that the compound is not:

- 10 a) diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 b) diethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate;
 c) dimethyl 3,4-dihydroxy-1-(4-bromophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 d) dimethyl 3,4-dihydroxy-1-(4-chlorophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 e) di-*tert*-butyl 3,4-dihydroxy-1-(4-nitrophenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 f) dimethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 15 g) dimethyl 3,4-dihydroxy-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate;
 h) diethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate; or
 i) dimethyl 3,4-bis(acetyloxy)-1-phenyl-1*H*-pyrrole-2,5-dicarboxylate.

2. A compound according to claim 1 wherein R¹ and R² are independently selected from -
 20 C(O)NR⁵R⁶, -C(O)OR⁷, CN, -C(O)R⁷, -C(O)NHC(O)R⁷, -NO₂, -SO₃R⁷, -SO₂R⁷, -SOR⁷, -
 SO₂NR⁵R⁶, -SO₂NH-C(O)OR⁸ and optionally substituted phenyl or heteroaryl.

3. A compound according to claim 2 wherein R¹ and R² are independently selected from -
 C(O)NR⁵R⁶, -C(O)OR⁷ and CN.
 25

4. A compound according to claim 3 wherein R¹ and R² are independently selected from -
 C(O)NR⁵R⁶ and -C(O)OR⁷.

5. A compound according to claim 4 wherein (i) R¹ is -C(O)NR⁵R⁶ and R² is -C(O)NR⁵R⁶ or
 30 (ii) R¹ is -C(O)NR⁵R⁶ and R² is -C(O)OR⁷.

6. A compound according to claim 4 wherein R¹ is -C(O)OR⁷ and R² is -C(O)OR⁷.

7. A compound according to any one of the preceding claims wherein R³ is substituted
 35 phenyl.

8. A compound according to claim 7 wherein R³ is phenyl substituted by one or more
 substituents independently selected from halo, cyano, hydroxyl, C₁-C₆ alkoxy, C₁-C₆
 hydroxyalkoxy, C₁-C₆ fluoroalkoxy, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, -C(O)NR^aR^b, where R^a and R^b
 40 are independently selected from hydrogen and C₁-C₆ alkyl; -O-R¹⁵ wherein R¹⁵ is -(CH₂)_x-
 P(O)(OR²³)₂, where x is 0, 1, 2, 3 or 4 and R²³ is independently selected from hydrogen and C₁-
 C₃ alkyl, -(CH₂)_y-S(O)₂Me where y is 1, 2, 3 or 4, -C₁-C₆ alkylheterocyclyl which heterocyclyl
 group may be optionally substituted by C₁-C₃ alkyl, -C₁-C₆ alkylphenyl which phenyl group may
 be optionally substituted by C₁-C₃ alkoxy, or phenyl or 5- or 6-membered heteroaryl which
 45 phenyl or heteroaryl group may optionally be substituted by a group selected from C₁-C₄ alkyl
 and halo; or -(O(CH₂)_z)_pOR²⁴, where each z, which may be the same or different, represents 2

or 3, p represents 1, 2, 3, 4 or 5 and R^{24} is hydrogen or C_1 - C_3 alkyl; or two adjacent carbon atoms within R^3 may be linked by $-O-CH_2-O-$.

9. A compound according to claim 8 wherein R^3 is phenyl substituted by 1, 2 or 3
 5 substituents independently selected from C_1 - C_6 alkoxy; $-O-R^{15}$ wherein R^{15} is $-(CH_2)_x-$
 $P(O)(OR^{23})_2$, where x is 0, 1, 2, 3 or 4 and R^{23} is independently selected from hydrogen and C_1 -
 C_3 alkyl or R^{15} is $-(CH_2)_y-S(O)_2Me$ where y is 1, 2, 3 or 4; and $-(O(CH_2)_z)_pOR^{24}$, where each z,
 which may be the same or different, represents 2 or 3, p represents 1, 2, 3, 4 or 5 and R^{24} is
 hydrogen or C_1 - C_3 alkyl.
10. A compound according to claim 8 wherein R^3 is phenyl substituted by 1, 2 or 3
 substituents selected from halo, cyano, C_1 - C_6 alkoxy, C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl, C_1 - C_6
 fluoroalkyl and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and
 C_1 - C_6 alkyl.
11. A compound according to any one of claims 7 to 10 wherein R^3 is phenyl having a
 substituent in the meta or para positions relative to the pyrrole ring, for example, R^3 is 4-
 methoxyphenyl.
12. A compound according to any one of the preceding claims wherein R^{4a} and R^{4b} are
 hydrogen or $-C_1$ - C_3 alkylaryl.
13. A compound according to claim 12 wherein R^{4a} and R^{4b} are hydrogen.
14. A compound according to any one of the preceding claims wherein R^5 and R^6 are
 independently selected from hydrogen, C_1 - C_6 alkyl, aryl or C_1 - C_3 alkylaryl in which said aryl may
 be optionally substituted, or R^5 and R^6 together with the N to which they are attached form a 5-
 or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S
 and NR^9 .
15. A compound according to claim 14 wherein R^5 and R^6 are not both hydrogen.
16. A compound according to any one of the preceding claims wherein R^7 is C_1 - C_6 alkyl.
17. A compound according to claim 1 which is selected from:
 N^2, N^2, N^5, N^5 -tetraethyl-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-ethoxyphenyl)- N^2, N^2, N^5, N^5 -tetraethyl-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 N^2, N^2, N^5, N^5 -tetraethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 3,4-dihydroxy-1-(4-methoxyphenyl)- N^2, N^2, N^5, N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 1-(4-fluorophenyl)-3,4-dihydroxy- N^2, N^5 -dimethyl- N^2, N^5 -diphenyl-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-fluorophenyl)-3,4-dihydroxy- N^2, N^2, N^5, N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 di-tert-butyl 4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-
 45 carboxylate);

- 1,1'-(4,4'-(1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
 (1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 5 1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-diisopropyl-*N*²,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
*N*²,*N*⁵-dibenzyl-1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
 di-*tert*-butyl 4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-1-carboxylate);
 10 (3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperazin-1-ylmethanone);
 1-(4-fluorophenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetraisopropyl-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
 3,4-dihydroxy-1-(2-methoxyphenyl)-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-dihydroxy-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 15 1-(4-ethoxyphenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 (3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
*N*²-ethyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(piperidine-1-carbonyl)-1*H*-pyrrole-2-
 20 carboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxamide;
 25 3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-(dimethylcarbamoyl)phenyl)-3,4-dihydroxy-*N*²,*N*²,*N*⁵,*N*⁵-tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
tert-butyl (5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-2-
 30 yl)sulfonylcarbamate;
 5-cyano-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide;
 ethyl 5-(dimethylcarbamoyl)-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;
 1,1'-(4,4'-(3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-diyl))diethanone;
 35 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonitrile;
 isopropyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
tert-butyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(4-methylpiperazine-1-carbonyl)-1*H*-pyrrole-2-carboxylate;
 40 ethyl 5-(dibutylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-cyano-1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(diethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-iodophenyl)-1*H*-pyrrole-2-carboxylate;
 45 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;

- 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)- N^2,N^2,N^5,N^5 -tetraethyl-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)- N^2,N^2,N^5,N^5 -tetraethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 di-*tert*-butyl 4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 5 dicarbonyl)bis(piperazine-1-carboxylate);
 (3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(piperidin-1-ylmethanone);
 3,4-bis(benzyloxy)-1-(2-methoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 (3,4-bis(benzyloxy)-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)- N^2,N^2,N^5,N^5 -tetramethyl-1*H*-pyrrole-2,5-dicarboxamide;
 10 (3,4-bis(benzyloxy)-1-(4-ethoxyphenyl)-1*H*-pyrrole-2,5-diyl)bis(morpholinomethanone);
 3,4-bis(benzyloxy)- N^2,N^2,N^5,N^5 -tetramethyl-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-
 dicarboxamide;
 3,4-bis(benzyloxy)- N^2 -ethyl-1-(4-methoxyphenyl)- N^5,N^5 -dimethyl-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N,N -dimethyl-5-(4-methylpiperazine-1-carbonyl)-1*H*-
 15 pyrrole-2-carboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N,N -dimethyl-5-(piperidine-1-carbonyl)-1*H*-pyrrole-2-
 carboxamide;
 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)- N,N -dimethyl-5-(morpholine-4-carbonyl)-1*H*-pyrrole-2-
 carboxamide;
 20 1,1'-(4,4'-(3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarbonyl)bis(piperazine-4,1-
 diyl))diethanone;
 ethyl 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)-1*H*-pyrrole-2-carboxylate;
 3,4-bis(benzyloxy)-5-cyano-1-(4-fluorophenyl)- N,N -dimethyl-1*H*-pyrrole-2-carboxamide;
 ethyl 3,4-bis(benzyloxy)-5-(dimethylcarbamoyl)-1-(4-iodophenyl)-1*H*-pyrrole-2-carboxylate;
 25 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)- N^2,N^5 -diethyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 3,4-bis(benzyloxy)-1-(4-fluorophenyl)-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 30 1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 1-(4-ethoxyphenyl)- N^2,N^5 -diethyl-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxamide;
 ethyl 3,4-bis(benzyloxy)-5-carbamoyl-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-carbamoyl-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-bis(benzyloxy)-5-(2-methoxyphenyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 35 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(pyridin-2-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-4-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(pyridin-3-yl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(4-ethylthiazol-2-yl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
 40 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 3,4-bis(benzyloxy)-5-(5-ethyl-1,3,4-oxadiazol-2-yl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(2*H*-tetrazol-5-yl)-1*H*-pyrrole-2-carboxylate;
 45 ethyl 3,4-bis(benzyloxy)-1-(4-methoxyphenyl)-5-(2*H*-tetrazol-5-yl)-1*H*-pyrrole-2-carboxylate;
 diethyl 1-(4-fluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;

- diethyl 3,4-dihydroxy-1-(3-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-(trifluoromethoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-isopropylphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-phenoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 5 diethyl 1-(4-ethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-ethylphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(*p*-tolyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(3,4-dimethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-chlorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 10 diethyl 3,4-dihydroxy-1-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(3,4,5-trimethoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(2,4-dimethoxyphenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(4-propoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-ethoxy-3,5-difluorophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 15 diethyl 3,4-dihydroxy-1-(3-phenoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(benzo[d][1,3]dioxol-5-yl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diisopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 2-ethyl 5-isopropyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 di-*tert*-butyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 20 diethyl 3,4-dihydroxy-1-(2-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-cyanophenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-fluorophenyl)-3-hydroxy-4-(2-hydroxyethoxy)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-hydroxy-4-(2-hydroxyethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-
 25 dicarboxylate;
 diethyl 3-(benzyloxy)-4-(2-(*tert*-butoxy)-2-oxoethoxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 dicarboxylate;
 diethyl 3-(2-amino-2-oxoethoxy)-1-(4-fluorophenyl)-4-hydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3-(2-(*tert*-butoxy)-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-
 30 dicarboxylate;
 diethyl 3-(2-amino-2-oxoethoxy)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 1-(4-(*tert*-butyl)phenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-dicarboxylate;
 diethyl 3,4-dihydroxy-1-(3-iodo-4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate;
 5-acetyl-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-carboxamide;
 35 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(2-methoxyethoxy)phenyl)-1*H*-pyrrole-2-
 carboxylate;
 ethyl 3-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-
 pyrrole-2-carboxylate;
 ethyl 1-(4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)-5-(dimethylcarbamoyl)-3,4-dihydroxy-1*H*-
 40 pyrrole-2-carboxylate;
 ethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-5-(methylcarbamoyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-hydroxyphenyl)-1*H*-pyrrole-2-carboxylate;
 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(phosphonooxy)phenyl)-1*H*-pyrrole-2-
 carboxylate;
 45 ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1*H*-pyrrole-2-
 carboxylate;

ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)-1*H*-pyrrole-2-carboxylate;

ethyl 1-(4-(3-(diethoxyphosphoryl)propoxy)phenyl)-5-(dimethylcarbamoyl)-3,4-dihydroxy-1*H*-pyrrole-2-carboxylate;

5 (3-(4-(2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-3,4-dihydroxy-1*H*-pyrrol-1-yl)phenoxy)propyl)phosphonic acid;

ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-(3-(methylsulfonyl)propoxy)phenyl)-1*H*-pyrrole-2-carboxylate;

neopentyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;

10 2,6-dimethylcyclohexyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;

cyclopentyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;

5-(dimethylphosphoryl)-3,4-dihydroxy-1-(4-methoxyphenyl)-*N,N*-dimethyl-1*H*-pyrrole-2-

15 carboxamide;

diethyl 3,4-dihydroxy-1-(4-(2-methoxyethoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;

diethyl 3,4-dihydroxy-1-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;

diethyl 1-(4-(2,5,8,11-tetraoxatridecan-13-yloxy)phenyl)-3,4-dihydroxy-1*H*-pyrrole-2,5-

20 dicarboxylate;

diethyl 3,4-dihydroxy-1-(4-(3-morpholinopropoxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate; and

diethyl 3,4-dihydroxy-1-(4-((4-methoxybenzyl)oxy)phenyl)-1*H*-pyrrole-2,5-dicarboxylate;

or a pharmaceutically acceptable prodrug derivative of any one thereof, or a pharmaceutically acceptable salt or solvate of any one thereof.

25

18. A compound according to any one of claims 1 to 17 in the form of a prodrug derivative.

19. A compound according to claim 18 wherein the prodrug derivative is selected from carboxylate ester, sulfamate ester, phosphate ester and carbamate ester derivatives.

30

20. A compound according to claim 19 wherein the prodrug derivative is a carboxylate ester derivative.

21. A compound according to claim 19 or 20 wherein one or both of R^{4a} and R^{4b} are independently selected from $-C(O)R^{16}$, $-SO_2NH_2$, $-PO(OR^{19})(OR^{20})$, $-CHR^{26}-OPO(OR^{19})(OR^{20})$ where R^{26} is hydrogen or C_1 - C_6 alkyl, and $-C(O)NR^{17}R^{18}$, wherein R^{16} , R^{17} , R^{18} , R^{19} and R^{20} are independently selected from:

35

- (a) C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_{10} cycloalkyl, C_5 - C_{10} cycloalkenyl, heterocyclyl, $-C_1$ - C_3 alkyl- C_3 - C_{10} cycloalkyl, $-C_1$ - C_3 alkyl- C_5 - C_{10} cycloalkenyl or $-C_1$ - C_3 alkylheterocyclyl, or R^{17} and R^{18} together with the N to which they are attached may form a 5- or 6-membered heterocyclic ring optionally containing a further heteroatom selected from O, S and $NR^{25a}R^{25b}$ where R^{25a} is hydrogen, C_1 - C_6 alkyl, $-CH_2-OPO(OR^{19})(OR^{20})$ or a 5- or 6-membered heterocyclic ring, and R^{25b} is absent or C_1 - C_6 alkyl; and in which any of the aforementioned R^{16} , R^{17} or R^{18} groups may be optionally substituted by one or more groups selected from cyano, $-OPO(OR^{19})(OR^{20})$, $-(O(CH_2)_z)_rOR^{24}$, wherein each z, which may be the same or different, represents 2 or 3, r represents an integer selected

40

45

from 1 to 20, and R^{24} is hydrogen, C_1 - C_3 alkyl or $-PO(OR^{19})(OR^{20})$, C_1 - C_6 alkoxy, C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl, and any of the aforementioned R^{16} , R^{17} or R^{18} groups may be optionally substituted by one or more halogen atoms; and

- 5 (b) aryl, heteroaryl, C_1 - C_3 alkylaryl and $-C_1$ - C_3 alkylheteroaryl, said aryl and heteroaryl groups being optionally substituted;
or R^{18} , R^{19} and R^{20} may independently represent hydrogen.

22. A compound according to claim 19 or 20 wherein one or both of R^{4a} and R^{4b} are
10 independently selected from $-C(O)R^{16}$, $-SO_2NH_2$, $-PO(OR^{19})(OR^{20})$ and $-C(O)NR^{17}R^{18}$, wherein R^{16} , R^{17} , R^{18} , R^{19} and R^{20} are independently selected from

- (a) C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_{10} cycloalkyl, C_5 - C_{10} cycloalkenyl, heterocyclyl, $-C_1$ - C_3 alkyl- C_3 - C_{10} cycloalkyl, $-C_1$ - C_3 alkyl- C_5 - C_{10} cycloalkenyl or $-C_1$ - C_3 alkylheterocyclyl, in which any of the aforementioned R^{16} , R^{17} or R^{18} groups may be
15 optionally substituted by a group selected from cyano, C_1 - C_6 alkoxy, C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl, and any of the aforementioned R^{16} , R^{17} or R^{18} groups groups may be optionally substituted by one or more halogen atoms, and
(b) aryl, heteroaryl, C_1 - C_3 alkylaryl and $-C_1$ - C_3 alkylheteroaryl, said aryl and heteroaryl
20 groups being optionally substituted;
or R^{18} , R^{19} and R^{20} may independently represent hydrogen.

23. A compound according to any one of claims 19 to 22 wherein both of R^{4a} and R^{4b} are independently selected from $-C(O)R^{16}$, $-SO_2NH_2$, $-PO(OR^{19})(OR^{20})$, $-CHR^{26}-OPO(OR^{19})(OR^{20})$
25 where R^{26} is hydrogen or C_1 - C_6 alkyl, and $-C(O)NR^{17}R^{18}$.

24. A compound according to any one of claims 19 to 22 wherein one of R^{4a} and R^{4b} is selected from $-C(O)R^{16}$, $-SO_2NH_2$, $-PO(OR^{19})(OR^{20})$, $-CHR^{26}-OPO(OR^{19})(OR^{20})$ where R^{26} is hydrogen or C_1 - C_6 alkyl, and $-C(O)NR^{17}R^{18}$; and the other of R^{4a} and R^{4b} is hydrogen.
30

25. A compound according to any one of claims 19 to 24 wherein one or both of R^{4a} and R^{4b} are independently selected from $-C(O)R^{16}$.

26. A compound according to claim 25 wherein R^{16} is C_1 - C_6 alkyl or C_3 - C_{10} cycloalkyl in
35 which either of the aforementioned groups may be optionally substituted by a group selected from $-OPO(OR^{19})(OR^{20})$ and $-(O(CH_2)_z)_rOR^{24}$, where each z , which may be the same or different, represents 2 or 3, r represents an integer selected from 1 to 20, and R^{24} is hydrogen, C_1 - C_3 alkyl or $-PO(OR^{19})(OR^{20})$ or R^{16} is phenyl optionally substituted by $-(CHR^{26})_q-OPO(OR^{19})(OR^{20})$ wherein q represents 0 or 1.

40

27. A compound according to claim 18 selected from:

2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl diacetate;
ethyl 5-(dimethylcarbamoyl)-3,4-bis((dimethylcarbamoyl)oxy)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;

45 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-methylpiperazine-1-carboxylate);

- 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis([1,4'-bipiperidine]-1'-carboxylate);
ethyl 5-(dimethylcarbamoyl)-4-((dimethylcarbamoyl)oxy)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
- 5 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2-methylpropanoate);
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethylpropanoate);
ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(sulfamoyloxy)-1*H*-pyrrole-2-
- 10 carboxylate;
ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-(phosphonooxy)-1*H*-pyrrole-2-carboxylate;
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrol-3-yl [1,4'-bipiperidine]-1'-carboxylate;
- 15 ethyl 3,4-bis((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
ethyl 3-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate;
ethyl 4-((diethoxyphosphoryl)oxy)-5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-1*H*-
- 20 pyrrole-2-carboxylate;
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)-1*H*-pyrrole-3,4-diyl bis(2-methylpropanoate);
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-methoxypropanoate);
- 25 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)propanoate);
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-methoxyethoxy)-2,2-dimethylpropanoate);
ethyl 5-(dimethylcarbamoyl)-3-hydroxy-1-(4-methoxyphenyl)-4-((phosphonooxy)methoxy)-1*H*-
- 30 pyrrole-2-carboxylate;
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(3-(2-(2-methoxyethoxy)ethoxy)-2,2-dimethylpropanoate);
2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2-methylpropanoate);
ethyl 5-(dimethylcarbamoyl)-4-hydroxy-1-(4-methoxyphenyl)-3-((phosphonooxy)methoxy)-1*H*-
- 35 pyrrole-2-carboxylate;
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate);
2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(3-(phosphonooxy)propoxy)propanoate);
- 40 2-(dimethylcarbamoyl)-5-(ethoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate);
2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(25,25-dimethyl-2,5,8,11,14,17,20,23-octaoxahexacosan-26-oate);
2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-
- 45 (phosphonooxy)ethoxy)ethoxy)propanoate);

2-(dimethylcarbamoyl)-5-(isopropoxycarbonyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(2,2-dimethyl-3-(2-(2-(phosphonooxy)ethoxy)ethoxy)propanoate);

2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(piperidine-4-carboxylate);

5 2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)benzoate); and

(1*R*,1'*R*,4*R*,4'*R*)-2,5-bis(dimethylcarbamoyl)-1-(4-methoxyphenyl)-1*H*-pyrrole-3,4-diyl bis(4-((phosphonooxy)methyl)cyclohexanecarboxylate);

or a pharmaceutically acceptable salt or solvate of any one thereof.

10

28. A compound according to claim 1 which is ethyl 5-(dimethylcarbamoyl)-3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2-carboxylate, or a pharmaceutically acceptable prodrug derivative, or a pharmaceutically acceptable salt or solvate thereof.

15 29. A pharmaceutical composition comprising a compound according to any one of claims 1 to 28, without provisos a) to i), optionally in combination with one or more pharmaceutically acceptable diluents or carriers.

30. A pharmaceutical composition according to claim 29 comprising one or more other
20 therapeutically active ingredients.

31. A compound according to any one of claims 1 to 28 without proviso a) to i) for use as a medicament.

25 32. A compound according to any one of claims 1 to 28 or 31 without proviso a) to i) for use in combination with one or more other therapeutically active ingredients.

33. A compound according to claim 31 or 32 for use as a medicament which is diethyl 3,4-dihydroxy-1-(4-methoxyphenyl)-1*H*-pyrrole-2,5-dicarboxylate or a pharmaceutically acceptable
30 prodrug derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

34. A compound according to any one of claims 1 to 28, or 31 to 33 without provisos a) to i) for use in the treatment of bacterial infections caused by bacteria producing pore-forming toxins, such as cholesterol dependent cytolysins.

35

35. A compound for use according to claim 34 wherein the bacterial infection is caused by *Streptococcus* spp. (e.g. *Streptococcus pneumoniae*, Group A Streptococci or *Streptococcus suis*), *Clostridium* spp. (e.g. *Clostridium perfringens*), *Listeria* spp. (e.g. *Listeria monocytogenes*) or *Bacillus* spp. (e.g. *Bacillus anthracis*).

40

36. A compound for use according to claim 35 for the treatment of bacterial infection which is caused by *Streptococcus pneumoniae*.

37. A compound for use according to claim 36 for the treatment of pneumococcal
45 pneumonia, pneumococcal meningitis, pneumococcal septicaemia/bacteraemia, pneumococcal keratitis or pneumococcal otitis media.

38. A compound for use according to claim 35 for the treatment of conditions selected from gas gangrene, gastrointestinal anthrax, inhalational anthrax, porcine meningitis, encephalitis, septicaemia/bacteraemia and pneumonia which are caused by bacteria other than

5 pneumococcus.


39. A compound for use according to any one of claims 31 to 38 wherein the compound is administered in combination with one or more other therapeutically active ingredients (e.g. one or more antimicrobial or immunomodulatory agents).

10

40. A method of treatment of bacterial infections caused by bacteria producing pore-forming toxins, such as cholesterol dependent cytolysins which comprises administering to a subject in need thereof an effective amount of a compound according to any one of claims 1 to 28, or 31 to 33 without provisos a) to i).

15

41. A compound of formula (II):



(II)


20 wherein R^1 and R^2 are as defined in claim 1 for the compounds of formula (I), and R^3 is phenyl substituted by 1 or more substituents independently selected from halo, cyano, hydroxyl, C_1 - C_6 alkoxy, C_1 - C_6 hydroxyalkoxy, C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl, C_1 - C_6 fluoroalkyl, $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl; $-O-R^{15}$ wherein R^{15} is $-(CH_2)_x-P(O)(OR^{23})_2$, where x is 0, 1, 2, 3 or 4 and R^{23} is independently selected from
 25 hydrogen and C_1 - C_3 alkyl, $-(CH_2)_y-S(O)_2Me$ where y is 1, 2, 3 or 4, $-C_1$ - C_6 alkylheterocyclyl which heterocyclyl group may be optionally substituted by C_1 - C_3 alkyl, $-C_1$ - C_6 alkylphenyl which phenyl group may be optionally substituted by C_1 - C_3 alkoxy, or phenyl or 5- or 6-membered heteroaryl which phenyl or heteroaryl group may optionally be substituted by a group selected from C_1 - C_4 alkyl and halo; or $-(O(CH_2)_z)_pOR^{24}$, where each z , which may be the same or
 30 different, represents 2 or 3, p represents 1, 2, 3, 4 or 5 and R^{24} is hydrogen or C_1 - C_3 alkyl; or two adjacent carbon atoms within R^3 may be linked by $-O-CH_2-O-$, or a salt or protected derivative thereof;
 provided that when R^5 or R^6 is optionally substituted aryl, said aryl is optionally substituted by 1, 2 or 3 groups selected from hydroxyl, halo, cyano, C_1 - C_6 alkoxy or C_1 - C_6 fluoroalkoxy, C_1 - C_6
 35 alkyl or C_1 - C_6 fluoroalkyl, and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl; or when two adjacent hydroxyl substituents are present they may optionally be connected by a methylene group to form an acetal;
 and provided that the compound is not:

- a) methyl 2-((2-oxo-2-(phenylamino)ethyl)(phenyl)amino)acetate;
- 40 b) methyl 2-((4-methoxyphenyl)(2-oxo-2-(phenylamino)ethyl)amino)acetate;
- c) ethyl 2-(phenyl(tosylmethyl)amino)acetate;
- d) ethyl 2-((cyanomethyl)(3,4-dichlorophenyl)amino)acetate;
- e) methyl 2-((cyanomethyl)(p-tolyl)amino)acetate;

- f) ethyl 2-(mesityl(2-oxopropyl)amino)acetate;
- g) dimethyl 2,2'-((3-bromophenyl)azanediyl)diacetate; or
- h) dimethyl 2,2'-((4-iodophenyl)azanediyl)diacetate.

5 42. A compound of formula (II) according to claim 41 wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)NR^5R^6$ or wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)OR^7$.

43. A compound of formula (II):



10

(II)


wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)NR^5R^6$ or wherein R^1 is $-C(O)NR^5R^6$ and R^2 is $-C(O)OR^7$, and R^3 , R^5 and R^6 are as defined in claim 1 for the compounds of formula (I), or a salt or protected derivative thereof;

15 provided that when R^5 or R^6 is optionally substituted aryl, said aryl is optionally substituted by 1, 2 or 3 groups selected from hydroxyl, halo, cyano, C_1 - C_6 alkoxy or C_1 - C_6 fluoroalkoxy, C_1 - C_6 alkyl or C_1 - C_6 fluoroalkyl, and $-C(O)NR^aR^b$, where R^a and R^b are independently selected from hydrogen and C_1 - C_6 alkyl; or when two adjacent hydroxyl substituents are present they may optionally be connected by a methylene group to form an acetal;

20 and provided that the compound is not:

- a) methyl 2-((2-oxo-2-(phenylamino)ethyl)(phenyl)amino)acetate; or
- b) methyl 2-((4-methoxyphenyl)(2-oxo-2-(phenylamino)ethyl)amino)acetate.

44. A process for preparing compounds of formula (I) as defined in any one of claims 1 to 28
25 in which R^{4a} and R^{4b} represent H which comprises reacting a compound of formula (II):



(II)

wherein R^1 , R^2 and R^3 are as defined in claim 1 for the compounds of formula (I), with a
30 compound of formula $R^xOCOCOR^x$ in which R^x represents C_1 - C_6 alkyl.

Figure 1




Figure 2A




Figure 2B




Figure 3




Figure 4




Figure 5




Figure 6




Figure 8






Figure 9





(I)